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ABSTRACT 
Endotoxin (LPS, lipopolysaccharide) forms an integral part of the outer 
cellular membrane of gram negative bacteria (GNB). The canines' 
intestine always contains large amounts of GNB, and hence LPS. If these 
GNB with their LPS, remain within the intestinal lumen, they are not 
harmful to the host. When GNB do gain entry into a hosts' circulation a 
bacteraemia will occur with a concurrent endotoxaemia. 
In the past, it had been accepted that GNB were, themselves, primarily 
responsible for the mortality and morbidity of bacteraemic and 
septicaemic patients. Evidence has emerged to indicate that this is not 
altogether true as isolated LPS, without the presence of GNB, can also 
lead to fatalities. 
Circulating LPS is exceptionally chemically stable and highly toxic to 
host cells. Antimicrobial chemotherapy can destroy GNB, but this therapy 
does not reduce the toxicity of LPS, nor does it clear LPS from the 
circulation. Destruction of the GNB by certain antibiotics can, in fact, 
increase the concentration of circulating plasma LPS in a host. 
The functional integrity of the intestinal wall is highly dependent upon 
an adequate blood supply, and the mucosal cells acts as the primary 
defence against the potentially pathogenic, endogenous and exogenous GNB 
and LPS. Once these pathogens become intravascular then the liver is the 
next most important organ of defence. 
(iv) 
Shock, irrespective of its aetiology, without adequate therapy, leads to 
reduced micro-vascular circulation, and thus a state of either localised 
or generalised hypoxia occurs. 
Partial or complete intestinal vascular ischaemia will produce a state 
of regional hypoxia, and lead to damage of the intestinal wall allowing 
GNB, with their LPS, or LPS by itself, to enter into the hosts' blood 
circulation. Therefore, an aetiology that gives rise to any type of 
"classified shock," may eventually give rise to concurrent endotoxaemia. 
In clinical practice there are numerous different diseases, physical 
onslaughts, and either acquired or congenital anatomical defects, that 
can give rise to intestinal vascular ischaemia, and hence, endotoxaemia. 
Many treatment regimens to combat the effects of an endotoxaemia have 
been advocated over the years, but this problem still has an 
unacceptably high mortality and morbidity index, probably because almost 
all such therapeutic regimens fail to destroy the LPS molecule. 
Recent clinical studies have shown that immunotherapy is effective in 
combating gram negative bacteraemia and septicaemia in humans and 
animals. Research workers have been able to produce a "broad-spectrum" 
or "polyvalent" equine, hyperimmune, anti-endotoxir, antibody-enriched 
plasma (ANTI-LPS), with favourab"^ responses recorded when this plasma 
was used to treat a variety of experimentally-induced endotoxin-shocked 
subjects. ANTI-LPS significantly reduced the mortality in experimentally 
produced superior mesenteric arterial occlusion endotoxaemia in rabbits, 
presumably by neutralizing and opsonizing the circulating plasma LPS. 
(v) 
Equine practitioners have reported successful results when ANTI-LPS was 
incorporated into the treatment of certain medical and surgical equine 
endotoxic related problems. 
A ^/ery recent, independent, Canadian study showed the effectivness of 
ANTI-LPS, where this preparation was tested against other anti-LPS 
products, to treat experimentally-induced sepsis in rats. The polyvalent 
equine ANTI-LPS was the most effective, in that its use resulted in the 
longest survival. 
In order to establish the generality of the use of equine ANTI-LPS 
plasma, I have extended these studies to the canine, since an abdominal 
vascular ischaemia carries a serious, high-risk, surgical emergency with 
unsatisfactorily high mortality rates, despite successful surgical 
intervention with concurrent supportive medical therapy. 
Twenty healthy dogs were divided into four groups; a control group (n=5) 
and three experimentally treated groups (n=5 in each group). All twenty 
dogs were subjected to the well-documented cranial (superior) mesenteric 
arterial occlusion (CMAO) shock model. The three experimental groups 
received the polyvalent equine, ANTI-LPS at different times and by two 
different routes, with no side effects being observed in any of these 
dogs. One group (n=5) received ANTI-LPS s.c. before CMAO was performed, 
a second group (n=5) received their dosage of ANTI-LPS i.v. during the 
three-hour occlusion period, and a third group (n=5) received their dose 
s.c, within three minutes after the CMAO was released. Survival was 
recorded when any dog lived for a minimum of 14 days after the occluded 
(vi) 
vessel was released. All 5/5 (100%) controls died within 17 hours after 
the release of the occluded vessel, whereas only one of the 15 (6,5%) 
experimentally ANTI-LPS treated dogs died (P<^0,001) during a fourteen-
day period following the release of the vessel. It was concluded that 
the polyvalent equine ANTI-LPS produced the significant difference in 
the survival rate that was recorded in this research. 
The experimental therapeutic importance of this immunotherapy was then 
applied to the clinical environment of routine veterinary practice. 
Patients with Canine Parvovirus Disease (CPV) are known to die from the 
combined effects of the viraemia, a septicaemia, and an endotoxaemia. In 
this study, CPV patients admitted to a private veterinary hospital were 
randomly divided into two groups, where one group (n= 89) received 
ANTI-LPS whilst the control group (n=36) did not. The ANTI-LPS-treated 
group had a significantly greater survival rate (83% vs 16% :p <"0,001). 
In summary, in this work I found that equine ANTI-LPS hyperimmune plasma 
significantly reduced mortality in endotoxin shock caused by both 
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'Errors have a way of becoming established 
by a kind of law of mass action. If some-
thing is said or written often enough, 
regardless of whether it is wrong to start 
with, it becomes accepted. As far as I know 
nothing can be done about it. Thus a 
reasonable error, soon mimicked and often 
repeated, may lead to the establishment 
of the error in acceptable form Thus 
we have the interesting phenomenon of an 
infinite number of wrongs making a right." 
William B. Bean. (1975).* 
-000-
W.B.Bean : Medical Writing : Discrepancies between theory and 
practice; in S.B.Day (ed) Communications of Scientific Information, 
Barsel S. Karger, 1975, Chapter 1. 
Shock can be likened to a mysterious footprint on the early morning 
beach, after the high tide has receded. Who made it? It does not really 
matter, as, at the next high tide, a wave will rise to wipe it out, as 
easily as shock will claim its next victim. 
Shock is a serious medical crisis, so often a prelude to death, and a 
recurring problem in every-day emergencies. 
Shock is a mysterious malady which has no respect for breed, age, sex, 
weight, colour, general health status, or medical speciality. 
Shock is usually recognised from behind, while the clinician surveys the 
widespread destruction in its wake. Attempts are being made to recognise 
shock as it approaches, and to try and divert its often fatal course. 
Shock has many and varied aetiological agents. It is a syndrome of 
responses to cellular injury, and at some point these responses lead to 
a common pathway, which is recognised as the patient in shock. 
Shock, whatever its initiating cause, eventually leads to a generally 
agreed-upon common pathophysiological injury, namely, a reduced 
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1.1. HISTORY OF ENDOTOXIN SHOCK 
Endotoxin shock is a pathophysiological phenomenon resulting from the 
release of LPS from dead GNB, or following experimental parenteral and 
2-4 
per os adminstration of LPS. The pathophysiology of endotoxin shock 
has been a major subject of research for many years, and has resulted in 
5 6 
enormous bibliographies in reviews of this vast subject. ' 
It has been said that the history of endotoxin shock research goes back 
many years, and could have begun with observations by physicians who 
were attending patients ill with the manifestations of fever, 
observations as old as the study of medicine itself. This universal 
interest in LPS could possibly have been due to the fact that: 
1. bacterial endotoxins evoke a variety of biological responses which 
are reported to have adverse effects on almost all host organ 
systems, 
2. GNB infections, sepsis and endotoxaemia are important medical and 
surgical problems, because patients with this type of infection may 
be life-threatened, despite the use of antibiotics in conjunction 
with other life-supporting therapy. ' 
Brill and Libman, cited by Hinshaw, described the first case of gram 
5 
negative bacteraemia in 1899. In the same year Crile, cited by Agawal, 
pointed out that the maintenance of an adequate blood volume and central 
venous pressure, with an i.v. infusion of warm saline, led to reduced 
mortality in experimental haemorrhagic shock. However, Westphal states 
that it was left to Richard Pfeiffer who, in 1904, introduced the term 
"endotoxin", a heat-stabile and toxic chemical released from 
page 3 
disintegrating bacteria. He used this term to distinguish the chemical 
from "exotoxin", which is a heat-labile chemical released from living 
bacteria. 
The modern understanding of shock was reported by Thai to have been 
based on field studies conducted behind the fighting lines during the 
First World War by several workers including Cannon, Bayliss and 
12 
Mclean. Cannon pointed out that acute circulatory failure was 
produced by hypovolemia and from this work stemmed the belief that 
shock was the result of tissue hypoxia. 
Spink and co-workers gave one of the first indications that LPS 
13 participates in the genesis of shock. This arose from their clinical 
observations following the use of an antibiotic, aureomycin, to treat 
patients with Brucella melitensis. In 1951, Waisbren described how 
patients with a bacteraemia exhibited the "typical shock picture" of 
14 
peripheral vascular collapse. During the same year, Borden and Hall 
described a fatal case of shock as the result of bacteria-contaminated 
15 blood transfusions. In 1953, Braude and co-workers experienced and 
lfi 
described the same condition by using blood contaminated with GNB. 
Three years later, Studdiford and Douglas described shock as a sequel to 
septic abortion. 
These early, and extremely important observations and recordings opened 
the door to a vastly expanded, and still expanding, area of medical and 
veterinary research, in mans1 endeavour to gain knowledge that will be 
beneficial to humans and animals alike. 
Initially, endotoxin shock was thought to be due to GNB with its LPS, 
page 4 
where the two pathogens were exerting their effects in combination with 
one another. The combination of live GNB and LPS was shown to elicit an 
accelerated Schwartzman reaction or an acute allergic reaction, either 
18 
of which could lead to shock. This supported the concept that the GNB 
and LPS were acting together to produce their fatal consequences. Later, 
researchers were able to isolate LPS and administer it into experimental 
19 
animals where fatalities were recorded. This work was to form the 
basis of futher in-depth projects, which showed that LPS is the mediator 
of the endotoxin-shocked patient. It was then recorded that LPS alone 
could cause shock, and that a concurrent bacterial infection produced 
20 21 
other toxic problems in the same patient. ' Irrespective of whether 
the GNB and LPS are producing their effects singularly or in combination 
with each other, it has been reported that these GNB account for the 
19 
majority of "septic" shock cases. 
22 
The source of the GNB now came into being and in 1974 Goldstein 
recorded that dogs always have GNB present in their gut in health and in 
23 
sickness, which supported the work of earlier researchers. Therefore 
these intestinal commensuals should be described as the endogenous 
source of GNB and LPS. However, GNB and LPS, singularly or together, may 
gain entry into a host via a variety of sources (through the skin, 
27 28 29 
respiratory system, per os ' , etc) and these sources of infection 
must therefore be exogenous. 
Initially the toxic effects of bacterial LPS under experimental 
conditions could only be demonstrated when they were given 
30 31 
parenterally. ' However, researchers were able to demonstrate the 
effects of transmural migration of the LPS by itself, and the lethal 
28 
effects produced by this migration of LPS in the host. 
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The symptoms of various types of shock generally resemble endotoxin-
induced experimental shock. Because of this fact, it was suggested that 
LPS played an important role in the pathogenesis of shock. In this 
respect, endotoxin shock has become a popular model in shock 
31 32 
research. ' It has also been recorded that the limulus amoebocyte 
lysate test with its various modifications, had become popular for the 
33-37 
demonstration of LPS in a host's circulating plasma. 
Further research has shown that the endotoxin shock process appeared to 
have an immunological basis which involved the release of vasoactive 
substances, and neuro-endocrine agents, with the activation of the 
6 38-40 
coagulation and complement pathways. ' " It has also been documented 
41 
that LPS is a potent immunosuppressor even though they are known to be 
11 42 
immunogenic. ' 
Current research on the problem of shock is no longer concerned with the 
initiation of a shock syndrome, but with the mechanisms responsible for 
the progressive, and seemingly inevitable, decompensatory deterioration 
during profound and protracted shock. There are from 15 to 20 different 
ways of producing circulatory collapse in as many as 8 to 10 different 
animal species, and in 1982 Hinshaw said " We are now able to produce 
shock, but we are still a long way from recognising its development in 
5 
the natural case, as well as in the prevention of it." The therapy of 
the shock syndrome has advanced, and the research towards its 
elimination in practice has gained momentum world-wide. Our ultimate 
goal must be to recognise endotoxin shock in its developmental stages, 
and then to eliminate its often fatal course. 
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1.2. MEDICAL SIGNIFICANCE OF ENDOTOXIN SHOCK 
In American surveys, it was reported that approximately 300,000 persons 
develop GNB-sepsis in hospitals annually, and about 100,000 of them 
13 43 
die. ' Another survey estimated that out of 333,000 bacteraemic 
44 
patients in the United States, 132,000 deaths occured. Yet another 
report, this time from Japan, stated, "despite the judicious use of 
antibiotics, mortality due to endotoxin shock is still very high, and 
this type of shock produces substantial mortality in hospitalized 
patients." It has been estimated that between 1 and 5% of all 
hospitalised patients develop secondary GNB infections and, in a 
significant number of these cases, bacteraemic sequelae are the primary 
44 45 
cause of morbidity and mortality. ' 
The extent to which modern health care practices or nosocomial agents 
contribute to an incidence of secondary infections remains conjectural. 
Mortality associated with established gram negative bacterial sepsis 
remains distressingly high, and current evidence indicates that the 
46 frequency of bacteraemic complications are on the rise. 
During a ten-year period from 1972 to 1982, surgical patients were 
47 assayed for the presence or absence of circulating plasma LPS. Of 487 
patients tested for the presence of LPS, 222 were shown to be positive. 
The mortality rate in these 222 patients was 52.2% and the authors 
stated that circulating plasma LPS was the lethal factor. Hinshaw, in 
his address at the annual congress of the Physiology Society of South 
Africa in Pretoria (1984), stated that the mortality rate in endotoxin 
page 7 
shock was 30 to 80% world-wide. 
Despite aggressive surgical treatment, specific antibiotic therapy and 
other pharmacological support, the mortality rate of human endotoxaemia 
48 
is still between 30 to 70%. These percentages differ from each other, 
which is possibly due to the fact that the work was undertaken at 
different centres in different countries. Absolute figures are generally 
not forthcoming in veterinary literature, but a report did state that 
endotoxin shock is often an unrecognised clinical entity that is 
49 
associated with a high rate of mortality. A recent report has recorded 
that during a ten-year period from January 1974 to December 1983, the 
overall mortality rate of dogs treated at a veterinary faculty, for 
50 
sepsis, was 71%. 
There has been a tendency for the veterinarian to record the death of a 
patient by the anatomical aetiology, or by the disease aetiological 
diagnosis. For example, Canine Parvovirus Disease has had reports of up 
to 80% mortality yet death in these patients is actually due to 
51-55 
secondary endotoxaemia. Similarly, gastro-splenic torsion is 
56 associated with over a 50% mortality in spite of successful surgery. 
It has, however, been established that the latter cases have high 
57 concentrations of plasma LPS just prior to death. With all the above 
facts in mind, the overall mortality rate of the veterinary endotoxin 
shock patient orobably has similar percentages to those recorded for the 
human, or even higher. 
GNB and LPS are known to exert profound multiple biological effects in 
the host. Thomas, in 1974, made the following very significant comment, 
"Our arsenal for fighting off bacteria are so powerful, and involve so 
page 8 
many different defence mechanisms, that we are in more danger from them 
than from the invaders. These macromolecules (LPS), are read by our 
tissues as the yery worst of bad news. When we sense lipopolysaccharide 
5 
(LPS), we are likely to turn on eyery defence at our disposal." It is 
known that the LPS have serious adverse effects on coagulation and 
complement pathways, on the platelets and the leucocytes, on endothelial 
cells, and a wide variety of other host cells which are doing their best 
to preserve life. ' These reactions will be discussed in a section to 
follow (see Chapter 2). Body defence mechanisms usually destroy or 
reduce the accumulation of circulating plasma LPS slowly, thus LPS is 
capable of remaining in circulation for a long time after the parent GNB 
have been destroyed by antibiotics or by the host's natural defence 
13,59,60 processes. ' ' 
Lethal dosages of live E.coli have been administered to different 
species of experimental animals with resultant death being reported as 
C I C O 
being due to the E.col 1. " In the practise of medicine this is an 
important statement, as theoretically, if the bacteria are destroyed, 
then survival should improve. These statements may not be entirely true, 
as recent ongoing research has demonstrated that when primates were 
given a LD-|Q0 dose of live E.coli i.v., no bacteria were cultured from 
64 
the systemic circulation at the time of the death. On the other hand, 
circulating LPS concentrations at death were extremely high when 
compared to baseline concentrations in the same animal. This could 
indicate that although the bacteria were destroyed by host defence 
mechanisms, the LPS released from such destroyed bacteria was not 
eliminated or neutralized. Another explanation could be that the E.coli 
could have produced intestinal hypoxia, with a resultant entry of 
page 9 
endogenous LPS into the vascular system, resulting in mortality. 
Endotoxaemia is now considered to be an important contributory factor 
towards the mortality and morbidity associated with septic and non-
19 20 49 
septic shock in man and animals. ' ' There is a critical need for 
research in clinical endotoxin shock to circumvent the unacceptably high 
mortality and morbidity rates that are still recorded. There is also a 
serious need for research regarding the basic mechanisms responsible for 
the all too often fatal consequences of the circulating plasma LPS. 
1.3. ANIMAL MODEL FOR ENDOTOXIN SHOCK RESEARCH 
Many questions have arisen concerning the adequacy of animal shock 
models with regard to their application in human endotoxin shock. 
However, as these questions were being raised, our knowledge of 
14 endotoxaemia increased in veterinary medicine. In 1964, Waisbren, made 
what was then a very important statement, "in the last analysis, the 
true explanation of the pathophysiology of gram-negative shock will come 
from more intensive studies of patients while they are suffering from 
the condition and, perhaps more practically, from intensive study of an 
animal model These further studies may prove that endotoxin 
65 
has a role in gram-negative shock." Later, Weil commented, "the extent 
to which the reactions to endotoxin in one type of experimental animal 
serves as an applicable model of bacterial shoc!v in another type of 
animal is controversial." 
In order to develop more realistic animal models, recent emphasis has 
been placed on the administration of live organisms rather than 
page 10 
endotoxin, and results from these two means of eliciting experimental 
19 
septic shock have been compared. The use of live E.coli organisms 
introduced into the normal animal seems to possess the more clinically 
relevent characteristics of a slow release of endotoxin within the 
host's circulation following endogenous destruction of the E.coli. 
Other models include: 
fifi 
1. the canine "septic leg" procedure, 
2. the injection of live E.coli into the canine gallbladder following 
fi7 
division of the cystic artery and duct, 
3. the placing of human faecal material within gelatin capsules which 
are then introduced into the abdominal cavity of the experimental 
CO 
subject, 
4. the performing of an appendectomy in dogs without suturing the caecal 
stump to allow the contents of the caecum to escape directly into the 
69 peritoneal cavity, and, 
5. caecal ligation in the dog. 
Researchers showed that occluding the CMA in dogs produced endotoxaemic 
death. What was more fascinating was that they recorded the fact that 
in those dogs where the occlusion was not released, these dogs took 
longer to die compared to those who had the occlusion released. This is 
a yery typical and recorded observation in the clinically presented case 
of the gastric-dilatation-volvulus syndrome with or without splenic 
and/or intestinal involvement. Similar personal observations have been 
made with regards to the traumatically produced diaphramatic hernia with 
herniation of the small intestine into the thoracic cavity. The 
occlusion of the CMA has been found to be a very reliable method of 
72 73 producing endotoxaemia in the dog. ' 
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Papa et al were able to demonstrate that LPS from intra-intestinal 
bacteria were capable of entering the general circulation transrnurally 
28 
from the caecum. This mode of entero-endotoxaemia is further supported 
by researchers who found that patients with liver cirrhosis showed 
74 positive endotoxaemia especially if an ascites was present. 
1.4. DEFINITION OF SHOCK 
Three common misconceptions about shock are perpetuated in most 
textbooks and have obscured the understanding of its essential nature. 
These are: 
1. that shock is a single disease entity, 
2. that the physiologic defect of shock is hypotension and low cardiac 
output, with high peripheral resistance, and, 
3. that this physiologic picture characterises all stages of all 
aetiologic types of shock. 
These misconceptions most probably arose because of a failure to 
recognise that physiologic derangements start with the onset of the 
precipitating aetiological event, and not when the patient is first 
recognised as being in shock, nor at the terminal stage when they become 
refractory to therapy. 
A definition of shock which is satisfactory to all researchers and 
clinicians is difficult to produce . However, based on present day 
knowledge it should include the facts that: 
1. it is more of an acute process than a chronic one, 
2. it is not a single entity but a syndrome of manifested problems, 
page 12 
3. the hallmark of all types of shock is the altered micro-vascular 
circulation, so that whether the total blood flow is low, normal or 
high, critical organs in the patient are inadequately perfused. 
Therefore, shock may be defined as an acute syndrome of cardiovascular 
failure, in which many vital organs are inadequately provided with 
nutrients and oxygen, which in turn leads to their inadequate function 
and prolonged recovery or possible death. 
Inadequate blood perfusion indicates not only inadequate nourishment to, 
but also inadequate waste removal from cells, organs and tissues. This 
inadequate perfusion is capable of leading to a state of localised or 
generalised hypoxaemia with resultant ischaemia. In 1976, Dr.Leena 
75 
Mela cited two researchers by stating that "an adult mammal can 
withstand total lack of oxygen for only a couple of minutes, before 
vital intracellular functions are destroyed, resulting in the ultimate 
loss of organ function." 
1.5. AETIOLOGICAL CLASSIFICATION OF SHOCK 
Aetiological classification has contributed to the apparent confusion 
encountered when shock is discussed. Terminology such as "surgical" 
"cardiogenic", "neurogenic", "traumatic", "ice pick", "Chevrolet", 
"anaphylactic", "oligaemic1, "haemorrhagic", "hypovolemic", "septic", 
"bacteraemic" "septicaemic" and "toxic", should be removed from the 
vocabulary of shock as they unfortunately cloud the happenings during an 
episode of shock. 
* 
Four general forms of shock, according to a recent classification, are 
page 13 
hypovolemic, cardiogenic, distributive, and obstructive shock. 
Endotoxin shock has been placed in the category of distributive shock by 
this author, who terms it "bacterial shock". As such, it possesses a 
defect in blood volume distribution in as much as alterations in 
capacitance account for sequestration of blood in the venous circuit. 
1.6. CLASSIFICATION OF ENDOTOXAEMIAS 
The liver has been shown to be the main organ of defence in the 
37 59 77 
endotoxaemic patient. ' ' A recent study has suggested a means of 
actually classifying endotoxaemic patients according to the presence or 
47 
absence of circulating LPS in various blood vessels. Of 237 patients 
with digestive disorders, 83 (35%) were positive for circulating plasma 
LPS. Oesophageal varices comprised 59 of these 237 patients, and of 
these 59 cases, 29 (49.2%) were positive for LPS. Blood was collected 
from the portal and hepatic veins and from a systemic artery in 23 of 
these 29 cases. These 23 cases were then classified according to where 
the LPS was found (see table 1, page 14). 
It is interesting to note that these researchers did not record a value 
for the normal concentration of circulating plasma LPS. Therefore are 
these determinats of value, in as much as they could be "normal"? 
However this type of classification could be a means of obtaining a 
prognostic evaluation of the endotoxaemic patient and assist in the type 
and intensity of therapy, where and when it is practically possible to 
catheterise the hepatic-portal blood vessel. 
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Only the portal vein had detectable LPS concentrations. 
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1.7. THE STRUCTURE OF THE GRAM NEGATIVE BACTERIAL CELL WALL 
Bacteria are divided into two major groups, gram positive and gram 
78 
negative, depending on their reaction to a Gram staining procedure. 
The reaction of the bacterium to the stain, which differentiates these 
two groups, will depend upon the chemistry of the relevent bacteria's 
outer cell membranes. 
Gram negative bacteria have a thin peptidoglycan layer adjacent to the 
outer cell membrane surface. ' Lipoprotein serves to cross-link this 
substance with the outer cell membrane. Lipopolysaccharide is associated 
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with the outer cellular membrane, and it is this biochemical molecule 
which contributes most of the uniqueness to the GNB outer cellular 
membrane. A diagramatic representation of the GNB outer membrane is 
78 
shown in figure 1. 
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Lipoprotein 
- Peptidoglycan 
Cytoplasmic membrane (inner) 
Fig. 1. Diagrammatic illustration of the structure of the outer cell 
membrane of gram negative bacteria. 
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1.8. BIOCHEMICAL STRUCTURE OF ENDOTOXIN 
Lipopolysaccharides (endotoxin,LPS) are pathogenic agents of GNB, 
responsible for many pathological alterations seen during gram-negative 
c c p 
infections. ' ' Robert Pfeiffer (1904) introduced the term endotoxin 
to distinguish this heat-stabile and toxic chemical from exotoxin, which 
is the heat-labile chemical that is released from living bacteria during 
an infection. Endotoxin is mainly released when the bacteria 
49 59 81 82 
disintegrate, by lysis ' or by chemotherapeutic agents, ' and 
49 
possibly when they undergo active replication. 
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LPS is not an exogenous product of GNB. After their biosynthesis in the 
cytoplasmic membrane, they are transported to the surface where they are 
retained as a vital constituent of the outer membrane of the cell. In 
this exposed location they also function as the characteristic "0" 
antigens of these bacteria. 
LPS conform to a common biochemical structural principle, consisting of 
a polysaccharide, an oligosaccharide and a covalently bound lipid 
component. The oligosaccharide consists of two sub-components which are 
under separate genetic control. ' The molecular weights of LPS from 
different GNB species vary from between 400 000 to about 4 000 000 
daltons, and these can be further modified by varying the nature of the 
solvent. In summary, figure 2 schematically shows the structure of 
83 
a typical Salmonella LPS. 
O-specific chain — — l l cor e IL_Lipid A — ' 
Polysaccharide 
O * Monosaccharide •-Phosphate <^«Ethanolamine 
«»/w». »Long chain (Hydroxy) fatty acid 
Fig.2 : Schematic structure of the Salmonella LPS. 
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1.8.1. POLYSACCHARIDE COMPONENT 
The "0" antigen specific side chain is the hydrophillic portion of LPS 
and is a polymer of saccharide molecules, designated the "repeating 
unit". Many types of sugars have been found as constituents of the 0-
chain and include neutral sugars with 5 - 7 carbon atoms, deoxy and 
amino sugars, uronic and aminuronic acids, 0-methyl, 0-acetyl, and 
phosphate substituted sugars. This variability of constituents and 
their linkages produces an immense diversity of 0-specific chains. The 
nature, sequence, and type of linkage of the 0-chain, is characteristic 
and unique for a given LPS from a given parental GNB strain. Serological 
and biological investigations revealed that the 0-chain produces the 0-
84-ftfi 
antigenicity which is used to classify GNB. 
The 0-antigenic groups may affect the expressed pathogenicity which is 
contained totally in the toxic lipid-A region. These 0-chain groups do 
not possess any toxic effects themselves, and are thought to be engaged 
in the protection of the bacteria from host enzymes and phagocytic 
87 
cells. Anti-"0" antibodies are relatively specific for the GNB 
serotype and are protective against homologous bacterial strains only, 
84 
cross protection in the host being limited. 
1.8.2. OLIGOSACCHARIDE COMPONENT 
The oligosaccharide component covalently binds the lipid-A to the "0" 
polysaccharide. It is composed of branched hetero-oligosaccharides which 
87 
show some structural variability. The oligosaccharide and lipid-A, 
together, are known as "core glycolipid". At least six individual 
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oligosaccharide types have been identified and they show only minor 
differences in their composition. In general, two core types are now 
recognised, an inner core of 3-deoxy-D-manno-octulosonic acid (KDO), and 
an outer core made up of different glucose molecules. The core is 
immunogenic but it does not express as much diversity as the 0-antigen. 
It has been shown that anti-core antibodies bind to a variety of LPS, 
88-90 
since there are few core types. 
1.8.3. LIPID-A COMPONENT 
Lipid-A is the hydrophobic portion of LPS and consists of a 
phosphorylated hexosamine disaccharide to which long chain fatty acids 
88-90 
are bound. Isolated Lipid-A has been recorded as being weakly 
immunogenic and some lipid-A specific antibodies may be detected in 
84 
host blood in response to a suitable challenge. In more recent 
studies it would appear that this is not entirely true because when LPS 
was bound to a GNB, then both the GNB and the LPS act as a stronger 
91 
antigen in the host. This lipid-A contains large amounts of beta-
84 
hydroxymyristic acid which is incorporated into its toxic site. In 
this respect, the lipid-A demonstrates a wide diversity of biological 
activity, as has been shown by researchers using soluble forms of free 
91 
lipid-A. Table 2 (page 19) summarizes the various activities that have 
92 
so far been demonstrated with soluble forms of lipid-A. 
A synthetic analogue of lipid-A has been prepared which is almost fully 
93 
active in all lipid-A toxic properties. Investigations have shown 
that the lipid-A's of many, but not all, GNB strains are structurally 
OC Q7 QO 
closely related. ' ' and the lipid-A represents the least variable 
part of the LPS molecule. 
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TABLE 2. BIOLOGICAL ACTIVITIES OF FREE LIPID-A. 
Pyrogenicity 
Leukopaenia 
Local Schwartzman reaction 
Embryonic bone reabsorption 
Depression of blood pressure 
Hageman factor activation 
Lethal toxicity in mice 
Leukocytosis 
Bone marrow necrosis 
Complement activation 
Platelet aggregation 
Limulus lysate gelation 
Induction of plasminogen activator Toxicity enhanced by BCG 
Toxicity enhanced by adrenalectomy 
Mitogenic activity for cells 
Hypothermia in mice 
Tumor necrotic activity 
Adjuvance activity 
Macrophage activation 
Induction of non-specific resistance to infection 
Induction of early refractory state to temperature change 
Enhanced dermal reactivity to epinephrine 
Induction of IgG synthesis in newborn mice 
Induction of prostaglandin and interferon synthesis 
Induction of mouse liver pyruvate kinase 
Anti-lipid-A immunoglobulins occur naturally in the serum of normal 
animals and humans, and significantly more frequently in sera of 
91 patients with chronic urinary tract infections. Anti-lipid-A IgG's 
exhibit biological activities that may be protective or damaging. Under 
defined experimental conditions, anti-lipid-A antisera supressed the 
94 
pyrogenic activity of LPS, it protected mice from the abortive effect 
95 96 
of LPS and from infection with Salmonella typhimurium. On the other 
hand, anti-lipid-A antibodies were shown to mediate the development of 
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kidney damage induced by lipid-A. 
1.9. AETIOLOGY OF CIRCULATING PLASMA ENDOTOXIN 
LPS may gain access into the host's circulation as the result of very 
wide and diversified aetiological onslaughts from both physical and 
biological conditions. Once in the host, this LPS will interact with 
numerous host-defence mechanisms, which in turn will activate other 
harmful pathways, causing cellular injury and possible depletion of 
essential elements which are needed to sustain life . These interactions 
are discussed in more detail in a later chapter (refer chapter 2). 
When GNB gain access to the host's circulation, LPS in the outer 
membrane is accessible to the blood where it will begin to exert its 
toxic effects. There are numerous GNB infectious and contageous diseases 
of man and animals, which are therefore essentially endotoxaemias. 
Zoonotic GNB infections may also be an important source of a potential 
endotoxaemia which is often overlooked. Traumatic wounds that become 
contaminated with faecal GNB or from the external environment, may also 
provide aetiology. All these causes are possible exogenous sources of an 
eventual endotoxaemia. 
As mentioned earlier in this work, the gastro-intestinal tract plays 
host to a myriad of different GNB. Normally these GNB with their LPS are 
not harmful to the host if they remain within the lumen of the gut. The 
gut wall acts as the prime defence against the invasion of these 
29 
potential pathogens. Therefore, almost any damage to the gut mucosa 
will allow the entry of these bacteria and LPS into the general 
circulation of the host. These represent the possible endogenous source 
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of endotoxaemia. 
It has been shown that pathological events within and outside the gut 
lumen are capable of producing an often irreversible damage to the 
defence mechanism of the gut mucosa. For example, peritoneal dialysis 
for kidney disease can produce a transmural migration of intestinal 
31 
bacteria into the host's circulation. In fact, early studies on 
pathology caused by various dialysing fluids, led Jacob Fine and others 
to postulate that intestinal damage was probably the most important 
31 98 
cause of irreversible shock. ' Later it was shown that CMAO, when 
released produced fatality, but the actual pathogen was not isolated. 
In addition, it was demonstrated that transmural migration of intestinal 
endotoxin occured after a period of colonic ischaemia without the 
28 
migration of their gram negative bacteria. 
Non-infected or aseptic wounds are also known to evoke an uptake of 
endogenous LPS. A study was undertaken in rats which had been subjected 
24 to dermal burning, using hot water. An endotoxaemia was detected 
within 30-40 mins in venous blood draining the burnt area and at 90-120 
mins in arterial blood after the experimental hyperthermia had been 
completed. E.coli and Klebsiella were recovered from the plasma and 
livers of these experimental animals, but not in sufficient amounts to 
produce detectable LPS. When blood draining the burnt area without any 
detectable LPS was injected i.v. into other normal rabbits, a fatal 
endotoxaemia was produced in such recipients within 12-18 hours. On the 
other hand if the second rabbit's intestine had been sterilised with a 
non-absorbable antibiotic then the animal survived the subsequent 
challenge with the "burnt" blood. On this basis it appeared that a 
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vasoactive substance was released from the burn into the circulation, 
producing a generalised increase in vascular permeability. This in turn 
allowed the transmural migration of endotoxin from the intestinal lumen. 
Catecholamines and/or other vasoactive agents are released from damaged 
tissues. These chemicals circulate and are capable of producing regions 
of localised intestinal ischaemia. Thus, secondary intestinal mucosal 
damage results, causing an elevated escape of LPS from the gut to the 
24 
hepatic-portal circulation. 
Once LPS has entered the circulation from the gut, its accumulation in 
the blood and tissues is in part largely due to the failure of the 
host's hepatic or systemic antibacterial and detoxifying defences, as 
well as the concentration of circulating plasma high-density 
59 99 100 lipoproteins. ' ' Futhermore, experiments have shown that the 
prolonged infusion of epinephrine, norepinephrine, bradykinin or 
serotonin can lead to fatal endotoxaemia. 
1.10. MEASUREMENT OF CIRCULATING PLASMA ENDOTOXIN 
Limulus polyphemus is commonly known as the horseshoe crab. This crab 
has amoebocytes contained in its haemolymph, which can lyse to form a 
protein solution. This limulus amoebocyte lysate (LAL) is particularly 
sensitive to the presence of LPS and forms a firm gel or clot in the 
-9 
presence of less than 10 g/ml LPS. This finding created a new horizon 
with regard to the diagnosis of the endotoxaemic patient. ' 
The crab's haemolymph is collected by inserting a needle into a joint 
between the cephalothorax and the abdominal region. About 50 to 250 ml 
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haemolymph can be collected from each crab and this haemolymph is then 
102 
centrifuged to separate the amoebocytes. Normally, these amoebocytes 
have a coagulation system which participates in both haemostasis and 
defence against invading micro-organisms in the crab. This coagulation 
system consists of several protein components, some of which are highly 
sensitive to LPS.1 0 1' 1 0 2 
The LAL-gel test is used to detect the presence of circulating plasma 
LPS qualitatively, because the test lacks a degree of reliability and 
reproducability, with both false positives and false negatives 
oc If)*? 
reported, ' for example, synthetic dextran derivatives can produce 
104 positive LAL assays. These and more recent findings question whether 
a positive LAL test proves that a plasma sample actually contains 
LPS. ' However this test has been used for the diagnosis of 
endotoxaemias and meningitis and for the detection of LPS in blood 
, 107 samples. 
To date several modifications of the conventional LAL gel test have been 
108 
reported to improve the sensitivity and accuracy of the test. These 
tests have been based on, for example: 
109 
1. nephelometry, 
2. spectro-photometric assay for use with seawater, 
3. a turbidometric method, and, 
4. the measurement of the amount of protein gelled during the clot 
112 reaction. 
The recent introduction of the chromogenic substrate method provides 
the greatest sensitivity and reproducibility required for the 
quantitation of circulating plasma LPS. ' These newer methods 
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incorporate a chromogenic substrate (Boc-Leu-Gly-Arg-p-nitroanilide) or 
fluorogenic substrate (Boc-Leu-Gly-Arg-4-methylcoumarin-7-amide) for the 
amoebocyte clotting enzyme, which had been activated by LPS. In these 
techniques the activated LAL enzyme splits a peptide bond, resulting in 
a marked increase in the absorbance quantum yield of terminal 
chromophore or fluorophore. The chromogenic substrate method allows 
determination of LPS concentrations in circulating plasma as low as 20 
37 
pg/ml, with accurate and replicable results. 
1.11. NORMAL CONCENTRATION OF CIRCULATING PLASMA ENDOTOXIN 
A study has recently been completed wherein it was established that the 
circulating blood of normal healthy dogs contains LPS at a concentration 
of 0.053-0.004 ng/ml. These circulating plasma LPS molecules, could 
have either beneficial or no effects, or continuous harmful effects, as 
yet unknown in the normal healthy individual. Certain experiments in man 
have been performed, in which beneficial effects of LPS were recorded, 
and it may be possible to extrapolate these findings to the canine. 
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2.1. MITOCHONDRIAL ENERGY-LINKED FUNCTIONS 
Mitochondrial energy-linked transfer reactions fulfill almost 95% of the 
75 
body's energy needs . To support these vital activities these 
organelles utilise over 90% of the available cellular oxygen under 
normal circumstances. Therefore adequate cellular oxygenation is 
essential for the continuation of mitochondrial metabolism. 
Intracellular oxidative glucose metabolism proceeds through the citric 
acid cycle (Krebs cycle) for adenosine triphosphate (ATP) production. In 
this process the energy provided by the oxidation of one molecule of 
75 
glucose is used to form 36 ATP molecules. ATP synthesis is not 
possible without the correct function of the adenine nucleotide 
translocase and the phosphate carriers. For these mitochondrial 
electron-transfer reactions to proceed uninhibited, adequate amounts of 
oxygen are necessary for the essential oxidative phosphorylation. 
Given substrates and oxygen, in the presence or absence of adenosine 
diphosphate (ADP), the mitochondria is capable of assuming four states 
114 
of respiratory activity. State 3, which is the active state of 
respiration, is achieved during the synthesis of ATP when adequate 
amounts of ADP are available. State 4 is said to be a resting state when 
no ATP is synthesised, due to a high ATP : ADP ratio. This ratio, 
expressing the phosphorylation potential, controls the mitochondrial 
respiratory activity in the cell, that is, respiration is determined by 
115 
the cell energy demand. 
An equally important function of the mitochondrion, in addition to 
oxidative phosphorylation, is its capacity to transport or "pump" 
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calcium internally from the cytoplasm. By doing so, mitochondria are 
partly responsible for the control of the concentration of intracellular 
unbound calcium. Therefore it is significant that this mechanism is 
energy dependent, is sensitive to ischaemia, and is more sensitive than 
the respiratory activity. ' The processes by which the mitochondria 
regulate intracellular calcium consist of two separate pathways; one is 
responsible for the uptake of calcium from the intracellular fluid, 
whilst the other is for the release of the cation back into the 
intracellular fluid. The uptake pathway transports calcium inside the 
organelle, utilising ATP. The release pathway returns the calcium to 
the environment by simple diffusion. Consequently, calcium ions become 
available again to the uptake pathway, thus establishing the "calcium 
cycle".118 
A lack of oxygen transport to a cell is a most damaging insult to its 
mitochondria. After a long-term cessation of blood, and hence oxygen 
perfusion to an organ, the mitochondrial membranes become irreversibly 
damaged. Mitochondrial enzyme reactions involved in oxidative 
phosphorylation are inhibited concurrently with an increase in anaerobic 
119 
respiratory activity. However, hypoxia in vital organs does not fully 
explain mitochondrial damage in shock. Possibly, the reduction of 
blood flow to, and hence nutrients into, and waste products out of 
cells, may also constitute a key factor in mitochondrial injury. 
In a shocked patient, it has been shown that anaerobic glycolysis plays 
an important role in providing the energy requirements. However, in this 
process a nett of only two ATP molecules are formed from the oxidation 
of one glucose molecule, which is only 5.6% of the total of 36 molecules 
of ATP synthesized during oxidative glucose metabolism 
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75 
In rats, cats and dogs in shock, at the same time that hypoxaemia causes 
a fall in ATP concentrations, tissue lactate concentrations and 
120 
lactate/pyruvate ratios increase, and tissue pH falls. Similar 
metabolic alterations have been demonstrated in experimental animals as 
121 
a result of endotoxin shock. Significantly, lowered tissue ATP 
concentrations and increased lactate concentrations are found after 
several hours of endotoxaemia in the brain, liver and kidney, but not in 
121 122 
the cardiac or skeletal muscle of the animals studied. ' 
These alterations in tissue metabolite levels indicate metabolic failure 
in the vital organs of animals in endotoxin shock. In the liver, brain 
and kidney, mitochondria have been shown to become functionally damaged 
123 
during an episode of endotoxaemia. Dog's brain mitochondria are 
particularly sensitive to the presence of live E.coli in the blood, and 
at the time of the dog's death 60% of brain mitochondrial ATP synthetic 
capacity is inhibited, compared to only 30% in the kidney of the same 
124 
dog. It has been demonstrated that cerebral, hepatic, and renal 
blood flows are significantly diminished in endotoxin shock whereas, 
only slight alterations occur in the coronary flow of dogs and sub-human 
123 primates. 
Within the cell itself, there is a 60-70% reduction of mitochondrial ATP 
content during the late stages of an endotoxaemia. At the same time, 
adenine nucleotide translocase can no longer transport ADP or ATP across 
123 mitochondrial membranes, thereby further inhibiting ATP synthesis. 
This can result in a reduction in the activity of membrane ionic pumps, 
+ 2+ which in turn causes reductions in intracellular K and Mg and an 
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increase in Na ,C1 and free Ca . 
2.2. THE CLEARANCE OF CIRCULATING PLASMA ENDOTOXIN 
The rate of LPS uptake into the vascular circulation would appear to be 
partly dependent on the site and the source of aetiological entry, the 
degree of concurrent tissue injury and the health status of host defence 
mechanisms. The uptake from secondary wound infection depends upon the 
size of the wound, the degree of contamination, and the speed of 
bacterial replication. The latter is in turn influenced by the type of 
organism involved and the medical attention that the infected area has 
or has not received. 
Experimental administration of either LPS or live E.coli has produced 
elevated concentrations of plasma LPS. ' ' In these experiments 
blood samples were taken simultaneously from the hepatic-portal and a 
systemic vein. In view of the fact that the hepatic-portal vein usually 
had the greater LPS concentration, this suggested that the liver was 
mainly responsible for the primary clearance of circulating LPS. A 
number of other researchers hypothesized the same thoughts. 
Later research indicated that the rate of clearance of LPS from the 
59 14 
vascular circulation appeared to be fairly slow. C-labelled LPS, 
prepared from a smooth and rough variety of Salmonella abortus equi and 
Salmonella minnesota respectively, were administered i.v. into 
experimental subjects, and their respective rates of removal from the 
vascular circulation was then determined. It was demonstrated that the 
rate of removal of the rough mutant form of LPS was incomplete compared 
to the smooth wild type, and that their respective rates were slow. 
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Furthermore, it was reported that the rate of clearance was not dose-
dependent. 
Other investigators' observations on the fate of the LPS molecule after 
i.v. administration into experimental animals, contradicts some of the 
earlier observations made on the speed with which LPS is cleared from 
the circulating plasma. ' In the latter studies, general agreement 
seems to have been reached in that the LPS leaves the plasma in two 
phases. The initial phase is very rapid (within a few minutes) where 
unbound LPS appears to be taken up mainly by the liver and spleen, and, 
127 to a lesser extent the lungs. This' appears to represent the removal 
of LPS which is not complexed to high-density lipoproteins (HDL). During 
this rapid phase of LPS removal from the plasma, some LPS becomes 
attached to platelets which is then removed by tissue blood vessels 
(liver sinusoids) or phagocytosed by fixed tissue macrophages (kupffer 
cells).10 0'1 2 8 
More recent research has reported that the rate of removal of 
circulating LPS depends on, firstly, the concentration of circulating 
99 
HDL, and secondly, factors affecting the binding of LPS to HDL. One 
third of LPS in circulation rapidly binds to circulating HDL to form a 
complex. This interaction prevents some LPS from attaching to platelets 
and decreases its uptake by macrophages because LPS is sterically 
125 unavailable in this complex. The LPS-HDL complex is cleared slowly 
from the plasma compared to the LPS which remains unbound, the process 
takes up to a few hours and the LPS is mainly taken up by the liver, 
adrenals and ovaries. These workers also demonstrated that the presence 
99 
of antibodies to LPS inhibited the binding of LPS to the HDL. 
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Therefore, the presence of specific circulating anti-LPS antibodies 
would speed the clearance of LPS which was not bound to HDL from the 
circulation. 
Two thirds of the injected LPS remains unbound and is removed very 
99 
rapidly from the plasma by the liver and spleen. It is of great 
interest to note that pre-treatment of the experimental animals with an 
adrenoglucocorticoid, dexamethasone, decreased the uptake of LPS-HDL 
complex by the adrenals, but at the same time increased the uptake of 
"free" LPS by the same glands, thus allowing bound LPS to continue to 
circulate for much longer. Other research workers reported that anti-LPS 
antibodies circulating in the plasma were able to modify the binding of 
LPS to HDL. Firstly, in vitro experiments suggest that homologous 
antibodies inhibit LPS-HDL binding, presumably by blocking LPS binding 
sites. A similar mechanism has been proposed for an acute-phase protein 
129 
that may also inhibit the LPS-HDL binding. Secondly, homologous IgG 
antibodies to LPS were able to opsinize both LPS and preformed LPS-HDL 
complexes and increase their uptake by tissues rich in phagocytic 
cells.130 
2.3. FATE OF ENDOTOXIN IN TISSUES 
Shock was induced by injecting experimental animals with radio-labelled 
14 
LPS and the fate of this C-LPS was followed with immunohisto-
59 
chemistry. The removal of the circulating LPS was primarily dependent 
upon the amount of circulating plasma HDL and this elimination was 
primarily the responsibility of the cells of the macrophage-phagocytic 
system, and to a lesser extent, the granulocytes. Some LPS is also 
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99 
taken up by epithelial cells of the adrenal cortical cells, and some 
endothelial cells of the pulmonary capillaries and alveolar 
59 
epithelium. If the LPS is derived from a rough mutant GNB, then this 
131 
LPS can be readily phagocytosed by the hepatocytes. 
The immunohistochemical detectability of LPS in most tissues increased 
continuously during the first 48 hours after the administration of the 
14 59 
C-LPS, showing the strongest LPS staining in the liver and adrenals. 
Macrophages were found to be the most important cellular site of primary 
LPS uptake in all organs except the adrenals, where LPS was mainly 
99 
present in phagocytic vacuoles of the cortical epithelium. In all the 
organs studied it was found that maximal detectable levels of LPS was 
14 noted four to five hours after the C-LPS was injected. These high 
levels persisted for three to four days, with detectable levels still 
present fourteen days after the initial challenge. 
Immunoperoxidase methodology and radioactivity measurements for LPS 
14 
revealed that 14 days after the administration of the C-LPS, the 
persisting LPS in the liver and spleen had lost its antigenic 
59 
properties. However the loss of LPS toxicity was not reported. 
2.4. EXCRETION OF ENDOTOXIN FROM THE HOST 
Experimental animals were injected with a dose of biosynthetically 
radiolabeled LPS from Salmonella abortus equi and the route of 
132 
excretion of this LPS was observed. It was found that excretion was 
slow and that a large part of the radioactivity was still present in the 
liver fourteen days after the initial injection. Further to this, it was 
established that the excretion of the radioactivity occured mainly in 
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the faeces and to a smaller extent, in the urine. 
It is interesting to note that the rate of excretion of LPS appeared to 
be dependent on the route of administration of the LPS, and on whether 
or not the subject had been given an anaesthetic. Under an anaesthetic, 
when LPS was administered by either the i.v. or i.p. route, its 
subsequent excretion from a host was slow. In contrast, i.p. 
administration of LPS without an anaesthetic led to the rapid excretion 
132 
of the radioactivity. 
2.5. BIOLOGICAL ACTIVITY OF ENDOTOXIN 
LPS is known to be an exceptionally potent toxin which is capable of 
producing clinical symptoms at plasma concentrations as low as 
_g 
1,10 g/ml, which, due to its high molecular weight, results in a molar 
-12 133 
concentration of about 10 M. The potent nerve poison tetrodotoxin, 
found in the Japanese puffer fish and said to be responsible for 150-200 
gourmets' deaths per year, is not active at concentrations less than 
_g 
10 M. Therefore LPS is at least 1,000 times more potent than 
133 
tetrodotoxin. Another clinically important feature of LPS is the 
fact that it is extremely chemically stable and it does not lose its 
134 
potency even when boiled. Further to this, LPS is not destroyed by 
135 
antibiotics, except possibily by polymyxin B, or other known 
antimicrobial chemotherapeutic agents. 
When the bacteria which produced it have been destroyed either by 
13 81 
antibiotics ' or by some of the host's normal defence mechanisms, the 
LPS may continue to circulate or may remain fixed in host tissues for up 
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59 131 
to 14 days, ' presumably continuing its toxic effects. Furthermore, 
a recent report has demonstrated that gentamicin destroyed GNB so 
rapidly in experimental E.coli sepsis, that there was a 2000-fold 
82 
increase in plasma LPS concentrations. 
2.5.1. INTRACELLULAR CHEMICAL MEDIATION BY ENDOTOXIN 
LPS interacts with numerous host-defence components which in turn have 
the ability to either activate or inhibit endogenous inflammatory 
mechanisms, that themselves are capable of causing host injury. These 
interactions are also capable of depleting the host of essential 
elements required by the various defence systems. 
2.5.1.1. LYSOSOMAL ENZYMES have been identified in virtually all animal 
cells that have been studied. They are described as an intracellular 
membrane-delimited body consisting of acid-hydrolase activity, and they 
are capable of digesting most biological macromolecules by unknown 
mechanisms. LPS causes the release of these lysosomal enzymes from most 
cells, but especially from those in the the liver, kidney, spleen and 
pancreas. Subsequently, these enzymes may disrupt the cellular 
membranes of nearby normal cells which in turn release their lysosomal 
enzymes. When they enter the circulation the lysosomal enzymes may 
cleave proteins, and cause a depression of heart contractility with 
coronary vasoconstriction. 
2.5.1.2. KININS are normally formed by the action of certain proteolytic 
enzymes on kallikreins and kininogens. LPS produces an increase in 
kinins as a result of the action of lysomsomal enzyme action on alpha-2-
globulin. Bradykinin, a nonapeptide, is then produced in the plasma, 
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137 whilst decapeptide lysylbradykinin forms in the tissues. These kinins 
are thought to play a major role in causing damage to the micro-vascular 
circulatory system, producing vasodilation with an increase in capillary 
permeability leading to hypotension. They may also initiate disseminated 
intravascular coagulopathy (DIC) by their interaction with the 
fin 
haemostatic coagulation factor XII (Hageman factor). 
2.5.1.3. HISTAMINE normally behaves as a co-transmitter in the 
regulation of the micro-vascular circulation when hypoxaemic conditions 
138 
are prevalent in the host. Histamine is released from a variety of 
damaged cells and is able to produce a local increase in capillary 
permeability and vasodilation. Since some of the histamine released by 
the presence of LPS may be produced by the disruptions of cells other 
than endogenous mast cells, all the histamine is not effectively 
139 
blocked by antihistamines. Histamine produces local dilatation of the 
140 141 
gastric mucosal blood vessels and oedema in rats and dogs. This, 
in turn, increases gastric mucosal blood flow, mainly to the body of the 
stomach and to a lesser extent, the antrum. Mast cells from canine 
fundic mucosa can synthesise histamine which will increase the 
142 
production of cyclic-AMP and acid secretion. In dogs, auto-regulation 
occurs as an adjustment of vascular resistance, to maintain a constant 
perfusion. Gastric blood flow during hypoxia shows this phenomenon where 
an increased flow occurs with decreased resistance and an increased 
143 oxygen uptake during histamine stimulation. 
2.5.1.4. SEROTONIN (5-hydroxytryptamine) normally occurs in a high 
concentration in platelets. An equally high concentration is normally 
present in the chromaffin cells of the gut. When these cells are damaged 
by LPS, serotonin is released and exerts a potent, local and sustained 
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vasoconstrictor effect on arteries and arterioles. In large doses 
these chemicals are capable of producing renal vasoconstriction which 
will reduce the renal blood flow and glomerular filtration rate. 
2.5.1.5. FIBRONECTIN is an important adhesive glycoprotein, and an 
organiser of tissue topography in the interstitium. It binds avidly to 
24 
denatured collagen, and to fibrin at an inflammatory site. Through 
surface receptors this fibronectin is capable of binding to monocytes 
and macrophages and by so doing, enhances the activity of these cells. 
This increases their phagocytotic activity and induces the secretion of 
proteases and plasminogen activator into the blood which is necessary 
for the scavenger function of the macrophages. Fibronectin becomes 
depleted during an episode of sepsis and DIC, thus allowing the fibrin 
degradation products to accumulate and circulate for prolonged 
144 
periods. 
2.5.1.6. LACTIC ACID increases intracellular^ with increased anaerobic 
75 glycolysis. This may lead to a ten-fold increase in the concentration 
of circulating lactate which, in turn, could reduce cardiac performance 
and reduce receptor sensitivity to catacholamines which are also 
145 elevated in concentration. 
2.5.1.7. PEROXISOMES are a group of intracellular membrane-delimited 
bodies involved in peroxide metabolism. These peroxisomes contain 
enzymes which both produce and destroy peroxide, namely, D-amino acid 
oxidase and urate oxidase. Peroxisomes are always present in kidney and 
liver cells, and most other cells of the body. LPS is capable of 
producing hyperpolarization of the mitochondrial membrane with an 
o 
increase in calcium ion concentration in the cytosol. When LPS is 
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phagocytosed, reactions involving membrane phospholipids cause the 
release and oxidation of arachidonic acid as well as a burst in cellular 
respiration together with the generation of the super-oxide anion. 
Furthermore, free oxygen radicals and super-oxides are released by 
aggregating cells into the vascular circulation. LPS may initiate this 
aggregation which can give rise to an excess production of free 
radicals. If this occurs in aggregating leukocytes within the lungs, 
pulmonary endothelial cells are damaged and capillary leakage occurs, 
146 
which is so often seen in the terminal endotoxin-shocked patient. 
In intestinal ischaemia, additional significant tissue damage may occur 
after restitution of the intestinal blood flow, and data indicating that 
this additional tissue damage is caused by oxygen-derived free radicals 
147 148 
is accumulating. ' The generation of free radicals takes place 
during the re-oxygenation period of the hypoxic tissues, whereas super-
oxide radicals have been proposed to be generated by the oxygen-
149 
dependent xanthine oxidase. It was suggested that the catabolism of 
hypoxanthine to uric acid, catalysed by xanthine oxidase, produces 
super-oxide radicles in the post-ischaemic intestine. During hypoxia, 
xanthine dehydrogenase is converted to xanthine oxidase, therefore, re-
oxygenation during reperfusion, which allows this enzyme to be active, 
148 generates the super-oxide radicals. 
2.5.1.8. PROTEASES are released from neutrophils accumulating in 
response to the presence of LPS in the pulmonary circulation. These 
proteases can destroy both structural proteins (collagen and elastin) 
and circulating proteins plasma proteins, fibrinogen, fibronectin, 
150 Hageman factor and complement. 
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2.5.1.9. FIBRIN DEGRADATION PRODUCTS (FDP) accumulate as a result of 
LPS mediation. Normally, fibrinolysis is a continuous process and if it 
does not occur, then significant anti-coagulative effects may be 
experienced by the host. Fibrinolysin lyses fibrin and fibrinogen 
forming a degradation product, which, in turn, inhibits thrombin's 
ability to split fibrinogen if it is not removed by the macrophage-
137 
phagocyte system. Excessive accumulation of these FDP's are able to 
block the functions of the reticuloendothelial system, are 
anticoagulant, and are hypotensive in action. 
2.5.1.10. MYOCARDIAL DEPRESSANT SUBSTANCES have been reported to be 
released by fragmentation of cellular proteins. At least nine such 
substances are suggested to be formed with molecular weights between 250 
fin 
and 1000 daltons. The depressant effect on the myocardium has been 
demonstrated in both in vitro and in vivo experiments. This effect is 
independent of electrolyte concentrations and pH, and changes in 
coronary blood flow or preload. Some groups however, do not agree that 
such factors are present in significant amounts (L.B.Hinshaw, personal 
communication, 1985). 
2.5.1.11. PASSIVE TRANSFERABLE LETHAL FACTOR has a molecular weight of 
16,000 daltons and is found in the circulation following increased LPS 
fin 
concentrations and after cardiopulmonary bypass. It acts by producing 
myocardial depression via the rnacrophage-phagocyte system (RES). 
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2.5.2. H0ME0STATIC RESPONSES TO CIRCULATING PLASMA ENDOTOXIN 
2.5.2.1. SYMPATHETIC ACTIVITY is mediated by baro- and chemoreceptors 
which results in an increased rate and force of myocardial contraction. 
Widespread arteriolar and venoconstriction occurs which diverts 
151 
available blood to the heart and brain. 
2.5.2.2. CIRCULATING CATECHOLAMINES are increased between ten- and 
forty-fold ( adrenaline = up to 3 ug/ml; noradrenaline = up to 7 ug/ml). 
Noradrenaline arises from the synaptic clefts, whereas adrenaline is 
152 released from the adrenal medulla. These increased concentrations of 
circulating catecholamines increase the effects of the sympathetic 
activity, but the specific effects of these hormones on any particular 
end-organ is modulated locally by at least 20 different mechanisms. 
These effects vary from species to species, from individual to 
individual and from organ to organ. 
2.5.2.3. RENIN-ANGIOTENSIN The reduction in the glomerular blood flow 
increases renin secretion by the juxta-glomerular apparatus. 
Consequential decrease of sodium delivery to the macula densa of the 
distal tubule occurs with a reduced afferent arteriolar pressure. The 
resultant increase in circulating angiotensin will lead to 
153 vasoconstriction which also produces the release of aldosterone. 
2.5.2.4. ANTIDIURETIC HORMONE Increased blood fluid osmolarity 
stimulates the osmoreceptors situated near the supra-optic nucleus of 
the hypothalamus. Antidiuretic hormone is released into the 
neurohypophysis from where it will be rapidly dispensed into the 
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vascular system. This hormone is thought to play a role in the 
maintainence of blood pressure by contributing to splanchnic 
137 vasoconstriction. Intestinal hypoxia results, which will add to the 
insult of vascular ischaemia causing extensive damage to the intestinal 
defence mechanisms. This will allow the escape of more endogenous LPS 
into the host's circulation. 
2.5.2.5. ALDOSTERONE secretion is increased during an episode of 
endotoxaemia with a resultant increase in the distal tubular resorption 
of sodium in the kidney. This was brought about by increased renin-
angiotensin production. Water is also resorbed with the sodium, whilst 
137 there is an increased potassium excretion by the kidney tubules. 
2.5.2.6. PROSTAGLANDINS are normally present in the cellular membrane 
of all mammalian tissues. Their production is increased as a result of 
the activation of the phospholipase A~ enzyme. This enzyme is activated 
154 when cellular membranes are damaged by LPS. When this insult occurs, 
arachidonic acid (AA) is released from the cell with its subsequent 
metabolism to unstable prostaglandins. Inter-reactions between 
prostaglandin and platelets have been the subject of intense and recent 
154-156 research. In addition to the mediation of various inflammatory 
responses, these metabolic end-products are the mediators of the 
interaction between platelets and the vascular endothelium during normal 
coagulative homeostasis. Thromboxane A~ (TxA~) and prostacyclin (PGIp) 
have received a great deal of attention and it is rr.cognised that they 
are the most important physiological products of AA metabolism in the 
155 157 
pathogenesis of septic and endotoxin-mediated shock. ' 
Metabolism to intermediate unstable endoperoxides is mediated through 
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cyclo-oxygenase, an enzyme present in all cells. These products are 
converted to PGI? and TxA~ by prostacyclin synthetase and thromboxane 
synthetase or they may undergo spontaneous degeneration to PGE2, PGF^ 
or PGD?. Another pathway of AA metabolism is via an enzyme, lipo-
oxygenase to produce leukotrienes which have pathologic effects. PGI? 
is an arterial smooth muscle relaxant and a potent inhibitor of platelet 
aggregation. TxA? is a potent vasoconstrictor and it has been suggested 
that PGIp and TxA? are normally present in low "balanced" quantities. 
During shock TxA? accumulates which leads to some of the 
vasoconstriction observed. 
159 LPS produces direct endothelial damage by as yet unknown mechanisms. 
The endothelial damage allows the metabolism of AA to be dominated by 
155-159 
the production of TXA~. The overall nett effect is that 
widespread platelet aggregation and adhesion occurs with vaso-
constriction. These reactions will add to micro-vascular circulatory 
stagnation, ischaemia, and DIC, and eventual organ failure may result. 
2.5.2.7. COMPLEMENT ACTIVATION The complement system consists of a 
series of circulating inactive plasma proteins which are activated in a 
sequential manner to bring about the destruction of micro-organisms and 
I en 
various toxins. This cascade of events can be triggered at two 
different levels. "Classical" activation involves IgG and IgM 
immunoglobulins and occurs at the first complement component (C-.) and 
the "alternative" pathway can be activated without involving any 
immunoglobulins. This second pathway is triggered at the third level 
161 
(Co) of the cascade by various substances including, LPS. It would 
appear that cell membranes are the primary target of the complement 
102 
enzymes, which are then irreversibly damaged. 
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When C-, is activated by LPS, the circulating and previously inactive 
plasma complement proteins, will culminate in histamine release, 
cellular lysis, leukocytic chemotaxis and opsonization, among other 
functions. Excessive complement is capable of producing disordered 
144 
leukocytic function. It has been established that the activation of 
complement results in the generation of a factor that can stimulate 
polymorphonuclear leukocytes to selectively release lysosomal 
16? 
enzymes. This lysosomal enzyme-releasing factor shares many of the 
properties of complement C5 which displays chemotactic and 
anaphylatoxin activities. Evidence suggests that some of the lethal 
effects of LPS are related to the presence of polymorphonuclear 
leukocytes. When these circulating cells were depleted in experimental 
animals, then the animal's response to an i.v. dose of LPS was 
144 profoundly detrimentally, altered. 
CO lCf) 
Complement activation is not always beneficial to the host. ' 
Experiments have been conducted in dogs to suggest that the complement 
65 components may be involved in the lethal effects of LPS. When dogs 
received transfusions of decomplemented blood (56°C, 30 mins), they were 
protected against the lethal effects of experimentally administered LPS. 
In many cases of GNB infections, there appears to be an overproduction 
of circulating complement. Consequently, there is an exaggerated 
inflammatory response, producing increased endothelial permeability. 
This permits blood leakage into the interstitial spaces and the release 
of lysosomes from the leukocytes. Lethal dosages of LPS injected into 
rabbits produced a rapid and sustained fall in circulating plasma 
163 
concentrations of complement. In a similar study it was found that 
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serum complement activity declined after adjuvant amounts of LPS was 
164 
introduced into rabbits. 
Alterations in complement concentrations in gram negative bacteraemic 
165 patients were studied. Patients with uncomplicated gram negative 
bacteraemia had mean C3 values similar to those of the controls, whereas 
there was a significant decrease in the C3 values in those patients who 
were in shock and in those who died. 
2.5.2.8. VASCULAR CELLULAR ELEMENTS can be altered during a homeostatic 
response to circulating plasma LPS. These responses include: 
a. Erythrocyte response -- when increased concentrations of plasma LPS 
are present in the vascular circulation, the erythrocytes may undergo 
stagnation and margination, with concurrent separation of the plasma and 
lfifi 
the vascular elements in small blood vessels. Decreased blood flow 
through the micro-vascular circulation occurs producing the local 
hypoxia which is damaging to the mitochondria. In addition, 
consequential haemoconcentration occurs resulting in increased blood 
viscosity, and the stagnation of erythrocytes will increase the 
incidence of DIC during an episode of endotoxaemia. 
b. Platelet response -- a thrombocytopenia occurs at the onset of LPS 
administration to rabbits, dogs and guinea pigs as well as at the 
onset of induced sepsis. The drop in the platelet count is ascribed 
to their widespread destruction, adhesion and aggregation. It has also 
been suggested that this thrombocytopenia may be an aid to the positive 
diagnosis of an endotoxaemia, if other aetiology of thrombocytopenias 
1 fift 
can be excluded. 
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The aggregation of blood cells in the presence of antigen, antibody and 
the first four complement components has been termed immune adherence. 
Receptor mediated immune adherence is present on the platelets of non-
Ififi 
primate species. One of the mechanisms of the platelet-endotoxin 
interaction depends on the presence or absence of immune adherence 
CO 
receptor sites on the platelet membrane. 
c. Neutrophils -- also show a response after the administration of LPS. 
An initial neutropenia has been observed which is then followed by a 
neutrophilia within a few hours. This is usually a regenerative response 
49 
with a shift to the left. There is a relocation of the neutrophils 
from the circulation to the marginal pools, especially in the pulmonary 
capillary bed, where they degenerate and produce lysosomal-induced 
micro-vascular damage. 
LPS exposure causes an increase in both the consumption of oxygen and 
the production of carbon dioxide by the neutrophils. LPS destruction of 
the neutrophils will bring about a release of kininase, lysozome and 
other enzymes, mimicking the changes occuring in the process of 
CO 
phagocytosis. These events indicate that LPS causes toxic damage to 
circulating neutrophils and fewer neutrophils are available to migrate 
to inflamed tissue sites. Both neutrophils and the cells of the 
macrophage-phagocyte system have the ability to detoxify LPS. 
d. Monocytes and macrophages -- these will also show a response to 
circulating plasma LPS. Circulating monocytes and tissue macrophages 
provide defence against microbial invaders because of their phagocytic 
properties. At the same time, they are stimulated to release 
CO 
prostaglandins and collagenase. It has been reported that LPS can 
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actually stimulate the monocyte to increase its ability to phagocytose 
105 bacteria and produce lysosomal hydrolases. 
Peritoneal macrophages are activated, particularly by the lipid-A 
169 
component of LPS to produce collagenase. This collagenase production 
was significantly inhibited by indomethacin, an anti-prostaglandin, 
83 
suggesting that prostaglandins mediate this effect. Macrophages are 
stimulated to produce a plasminogen activator when exposed to LPS. 
Purified populations of peripheral blood monocytes and peritoneal 
macrophages have been shown to synthesise and release prostaglandin-E 
which is enhanced when these cells are exposed to LPS and supressed by 
169 
the anti-prostaglandin, indomethacin. 
e. Lymphocytes -- will show their response when LPS stimulates the 
proliferation of large populations of lymphoreticular cells. It is 
thought that the lipid-A, and to a lesser extent, the "0"-antigen 
component of the LPS evokes this mitogenic effect, which was shown to be 
93 thymus cell independent. 
2.5.2.9. COAGULATIVE ACTIVITY Endotoxin-shocked patients exhibit DIC 
which is thought to be brought about by the activation of the intrinsic 
pathway of the haemostatic system, as it is known that factor XII is 
activated by LPS. Extrinsic activation is also thought to be involved 
since leukocytes are required to produce both the local and generalised 
Schwartzman reactions. In addition, monocytes produce a tissue factor 
CO 
which can initiate clotting via the extrinsic pathway. Furthermore, 
activated factor XII is capable of activating plasma prekallikrein to 
form kallikrein, which can generate bradykinin to activate plasminogen. 
Two injections of culture filtrates from GNB demonstrated the ability of 
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this filtrate to produce tissue injury via coagulation changes. These 
observations were extended and resulted in two widely used test models, 
namely, the local and the generalised Schwartzman reactions. It is now 
known that the culture filtrates contained LPS and that LPS by itself 
can produce these reactions. In the local reaction, dermal necrosis is 
seen after the second dose of LPS is administered, whilst in the 
generalised reaction, bilateral cortical necrosis of the kidneys is 
observed. 
DIC eventually leads to a depletion of the clotting factors and enhanced 
fibrinolysis. This will also result in the accumulation of FDP in the 
blood where they act as anticoagulants. These factors contribute to the 
extremely serious bleeding disorders associated with GNB infections and 
endotoxaemia. 
2.5.3. ENDOTOXIN EFFECTS ON METABOLIC PRODUCTS 
2.5.3.1. EFFECT ON CARBOHYDRATE METABOLISM. In muscle tissues, LPS 
disturbs the carbohydrate metabolism and decreases the utilisation of 
glucose and ketone bodies, with increased catabolism of branched chain 
172 
amino acids. Different severities of endotoxaemia are capable of 
173 
affecting the glucose and insulin concentrations in circulation. With 
early endotoxaemia the cardiac output is still high, the blood glucose 
and plasma insulin concentration are elevated. As the cardiac output 
decreases and blood lactate rises, a progressive hypoglycaemia occurs 
with insulin concentrations dropping rapidly. This hypoglycaemia results 
from the depletion of glycogen stores and depressed gluconeogenesis with 
172 174 
increased tissue usage of glucose. ' LPS is also known to increase 
page 48 
172,173 adrenalin secretions which, in turn, inhibits insulin secretions 
2.5.3.2. EFFECT ON LIPID METABOLISM. Marked increases in the serum 
concentrations of either or both free fatty acids and triglycerides, 
175 occur in patients that have a gram negative bacteraemia. LPS can 
significantly elevate the serum triglyceride concentration leading to 
impairment of lipid disposal mechanisms and it can enhance lipolysis due 
to the release of adrenaline and noradrenaline. It can also increase the 
adenylate activity in fat cells as a direct effect of the lipid-A 
176 
component of the LPS 
2.5.3.3. OTHER METABOLIC EFFECTS. Serum iron concentrations decrease 
as a result of LPS and the drop in the concentration is so replicable 
that it has been suggested that serum iron concentrations could be used 
as a diagnostic screen for an endotoxaemia. ' LPS depresses cellular 
119 174 respiration producing irreversible mitochondrial damage, ' it can 
172 
produce damage to the surface phospholipids of lung alveoli cells, 
cause a cholestasis, and produce hypophosphataemia. 
2.6. SUMMARY OF CIRCULATING PLASMA ENDOTOXIN EFFECTS 
It has been demonstrated that high concentrations of circulating plasma 
LPS produces a series of haemodynamic changes which in turn will lead to 
hypotension. These changes can be summarised as follows: 
a. Vasoactive substances are released by LPS, these include 
catecholamines, histamine, kinin, prostaglandin and serotonin. ' 
b. These vasoactive agents produce a local "contraction" away from each 
neighbouring endothelial cell, and damage each cell, thus increasing 
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capillary permeability. 
c. Oedema and hypovolaemia result from this increased permeability of 
the capillaries. In the thoracic cavity this phenomenon gives rise to 
18? 183 
the well described "shocked lung syndrome". ' Similarly, this 
endothelial damage gives rise to the intra-intestinal haemorrhage so 
often described as a post mortem finding or as a clinical symptom of the 
184 endotoxin shock patient. 
d. The plasma loss that occurs with circulating plasma LPS, leads to 
133 
heamoconcentration and increased blood viscosity. 
e. LPS evoke mechanisms which give rise to vasoconstriction of the 
central and hepatic veins allowing the blood to "pool" in the splanchnic 
133 
region. This vasoconstriction together with the above described 
hypovolaemia, will lead to a reduced venous return to the heart. 
The above described events will allow a reduced cardiac output and 
sequential hypotension. This will in turn give rise to a reduced oxygen 
delivery to the tissues (localised ischaemia) and a reduced removal of 
waste from these tissues. The hypoxia so produced will give rise to an 
increased plasma lactate concentration and acidosis. 
The total effect of the hypotension is to instigate and contribute to 
the deterioration of lysosomal membranes with subsequent release of 
proteinases and many other hydrolytic enzymes and harmful chemicals. 
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The patient in shock, irrespective of the aetiology, is diagnosed when 
life-threatening changes to the micro-vascular circulation have already 
occurred. A reduced flow of the micro-vascular circulation gives rise 
to either a generalised or localised hypoxia. It is known that 
intestinal defences are adversely affected by a reduced blood flow to 
and from itself, and this event occurs during hypoxia or ischaemia. As 
a result LPS leaks into the vasculature from the intestinal lumen, which 
adds to the pathology of the patient in shock, even if the aetiology has 
a non-septic origin. 
Many treatment regimens have been advocated, with varying success, where 
the objectives have centred around the: 
1. Restoration of the reduced micro-vascular circulation. 
2. Counteracting pathologic disturbances which have occured to homeo-
stasis. 
3. Destruction of any bacteria that are concurrently present. 
Unfortunately, the neutralization and elimination of circulating plasma 
LPS has not been well recognised until fairly recently. Therefore, a 
fourth objective should be the elimination of these pathogens as early 
as possible. 
Whilst a patient is being treated for endotoxin shock, physiological 
monitoring should provide a continuous assessment of fundamental 
defects, to guide the therapeutic management of the patient. 
Unfortunately, this monitoring requires extremely expensive equipment, 
which is often beyond the realms of the private veterinary practitioner. 
Futhermore, the variables that are most often measured are those that 
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are easiest to monitor, rather than those that are relevant to the 
crucial question of survival or death. 
3.1. RESTORATION OF REDUCED MICRO-VASCULAR CIRCULATION 
The haemodynamic and metabolic effects of treatment with various types 
of fluids have been reported extensively, however the micro-vascular 
circulatory effects are not known in detail. Most indirect studies 
indicate that disturbances in tissue perfusion may persist in tissues 
186 
for prolonged periods of time following treatment. 
Infusion of hypertonic solutions prevented tissue damage during shock 
and ischaeinia. Recovery from haemorrhagic shock occured more rapidly in 
dogs treated with 1.8% saline, 2.74% sodium bicarbonate, or 10% glucose, 
than in dogs treated with isotonic solutions. In this report it was 
postulated that the hypertonicity reduced post-ischaemic cellular 
swelling. Since then, the use of hypertonic solutions for situations 
187 
such as tissue preservation has become commonly accepted. 
Reduced micro-vascular circulation may be restored by using any of the 
agents described below, either singularly or in combination. 
3.1.1. VOLUME REPLACEMENT 
Volume replacement is standard therapy for hypovolemic and traumatic 
shock, but it is not as well recognized as being beneficial for septic 
or cardiogenic shock. In septic shock, large volumes of blood are 
sequestered in the rnicro-vascular circulation of the viscero-cutaneous 
areas, and further volume is lost through damaged vascular membranes. 
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Therefore, this fluid is lost from the effective circulating volume. 
Large volumes of plasma, plasma substitutes and electrolyte solutions 
loo 
are often required by a patient in endotoxin shock. Unless there is 
pre-existing anaemia or intravascular haemolysis, the need for 
erythrocyte transfusions is not urgent. The goal in the therapy for 
endotoxin shock, specifically with regards to fluid volume, is to 
restore blood pressure by an increase in cardiac output, rather than by 
an increase in peripheral resistance where central venous pressure can 
be used to monitor blood pressure. Fluids which may be used include; 
3.1.1.1. BLOOD TRANSFUSIONS This is instituted only if there has been 
haemorrhage, haemolysis or pre-existing anaemia. Generally, if the 
haematocrit is below 30%, then whole blood is necessary, at a dosage of 
20-40 ml/kg body mass. 
3.1.1.2. PLASMA TRANSFUSIONS Plasma, lyophilized plasma, serum or 
albumin solutions may be used. When plasma is used, it must be 
remembered that antiplasma-antibodies may be present in the recipient 
and the necessary precautions must be taken. Initially, the plasma can 
be administered at a rate of 5 to 10 ml/min, and then more slowly until 
a total dosage of about 20 to 40 ml/kg body mass is given. 
3.1.1.3. PLASMA EXPANDERS Several types have been used with success 
e.g., dextran 6%, low molecular weight dextran and gelatin polymer 3.5%. 
The dosage rate of these substitutes is in the region of 10 to 20 ml/kg 
body mass. 
3.1.1.4. ELECTROLYTE SOLUTIONS Lactated Ringer's solution is a balanced 
electrolyte solution which replaces extracellular fluid. If energy is 
required, then 5% dextrose or 5% levulose can be added. Plasmalyte B, a 
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bicarbonated solution, can also be used with satisfaction. 
3.1.2. DIRECT CARDIAC STIMULANTS 
When volume replacement alone fails to increase cardiac output, 
additional therapy is required in the treatment of some shocked 
patients, in order to reduce vasoconstriction and improve tissue 
perfusion. Cardiac stimulants that are inotropic agents, would be an 
extremely helpful form of therapy, but there are only a few available in 
veterinary medicine and these have not yet proved to be successful when 
used alone. 
3.1.2.1. DIGITALIS This pharmacological agent can increase cardiac tone 
and' may be benificial in the sub-acute or chronic patient, but in the 
acute situation it will often fail. 
3.1.2.2 ISOPRENALINE. This is a beta stimulating drug which increases 
the rate and force of myocardial contractions. It has the added 
advantage of being a peripheral vasodilator and can increase cardiac 
output and reduce vasoconstriction in beta beds, principally in the 
voluntary muscles. 
3.1.2.3. HEPTAMINOL This drug can be used, because it is an indirect-
acting sympathomimetic, which will thus augment the force of myocardial 
contractions. 
3.1.3. VASODILATORS 
In shock, cardiac performance can be increased through reduction of 
peripheral resistance and stagnation. There are three general types of 
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drugs that induce vasodilatation. These are; i. those that produce 
direct vasodilatation, such as isoprenaline, ii. those that produce 
vasodilatation by blocking the vasoconstrictive effects of adrenaline 
and noradrenaline on alpha receptors, thereby reducing vasoconstriction 
produced by increased sympathetic tone. An example being the alpha 
adrenergic blocking agents, and iii. those that produce vasodilatation 
by unknown mechanisms, such as the corticosteroids. 
3.1.4. BETA ADRENERGIC BLOCKERS 
It has been suggested that excessive beta adrenergic stimulation with 
the opening of multiple arterio-venous shunts in the pulmonary and 
splanchnic areas is of primary importance in the pathogenesis of late 
shock. °' Propranolol administration significantly increases the 
survival rate of dogs in states of haemorrhagic and endotoxin shock. 
3.1.5. ANTICOAGULANT THERAPY 
The complication of DIC which often accompanies endotoxin shock is 
particularly evident in the dog. Anticoagulant agents may play an 
important role in the survival of the dog. Their mechanism of action is 
simply based on the clearing of sludged blood clots and thrombi from 
damaged peripheral vessels. 
3.1.6. OXYGEN THERAPY 
The patient in shock has either a generalized or localized hypoxaemia 
due to an altered micro-vascular circulation. An adequate oxygen supply 
should be administered to the patient in shock, especially that produced 
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189 by haemorrhage or endotoxaemia. 
3.2. COUNTERACTION OF PATHOLOGIC DISTURBANCES 
3.2.1. ANTI-PROSTAGLANDIN THERAPY 
Some phospholipids in cell membranes are prostaglandin precursors and 
convert to active prostaglandins prior to their release by a variety of 
190 191 physiological, pharmacological and pathological stimuli. ' It now 
appears that prostaglandins have been implicated in the pathogenesis of 
192 the symptomatology associated with an endotoxaemia. These 
prostaglandins released by the LPS participate in a variety of 
pathophysiological processes including inflammation, thermal injury, 
hypertension, peptic ulcer disease, diarrhoea, skin conditions, 
vasomotor regulation, derangement in platelet function, gynaecological 
A- A A * 130,190,193-196 
disorders, and fever. ' ' 
The use of anti-prostaglandin therapy could therefore be beneficial to a 
patient with endotoxin shock. Non-steroidal anti-inflammatory drugs have 
been shown to attenuate the haemodynamic events in canine endotoxin 
"1 on 
shock, but results have been conflicting. 
Pre- and post-treatment with aspirin or indomethacin were employed in 
197 experimentally-induced canine shock models. Both of these drugs were 
equally effective in improving survival without any apparent alteration 
to coagulation pathways. However, indomethacin, whether used 
prophylacticaly or therapeutically, in pharmacological or physiological 
doses, did not improve survival in an overwhelmingly lethal model of 
endotoxin-induced shock.'30 
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Studies in a number of species, including dog , calves and sub-
199 
human primates have demonstrated a relationship between the 
concentrations of prostaglandins in the blood and the severity of LPS 
shock. The pulmonary vasculature has been shown to be quite sensitive 
to the vasoconstrictive properties of sublethal doses of aJminisiiered 
LPS, and this response was associated with significant changes in the 
196 
levels of prostaglandin in the blood . Inhibitors of prostaglandin 
synthetase prevented this undesirable response. 
It would appear that foetuses do not produce large amounts of 
196 
prostaglandins in response to circulating LPS. Prostaglandin blood 
concentrations in maternal and foetal circulations were measured after 
each individual had received a separate experimental infusion of E.coli 
LPS. Five hours after LPS administration, the concentration of 
prostaglandin in maternal blood rose. In contrast, prostaglandin in 
foetal blood showed no significant change even after foetal 
administration of LPS, at ten times the dose required for maternal 
response. In the same study, indomethacin was administered to a group 
of maternal subjects after the experimental infusion of LPS. 
Prostaglandin blood values were decreased by one third, presumably by 
the indomethacin. 
3.2.2. OPIATE ANTAGONISTS 
The discovery of enkephalins as natural opiates within the central 
nervous system led to the discovery of other endogenous opiate 
49 
substances, for example, beta-endorphin. This chemical is produced by 
the anterior pituitary gland in response to stress and it is released 
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systetnically in conjunction with ACTH. Target cells for beta-endorphin 
are situated both centrally and in the peripheral tissues. 
Endogenous opioid peptides have been shown to participate in the 
pathophysiology of experimentally-induced LPS shock and is accompanied 
by a rise of enkephalins in the cerebrospinal fluid. Experimental use 
of a pure opiate antagonist, naloxone, has shown beneficial effects in 
the reversal of degenerative haernodynamic changes seen in septic 
201 
shock. Naloxone attenuates the decrease in cardiac output seen with 
experimentally-induced endotoxaemia and it reverses the myocardial 
depression by unknown mechanisms. A direct positive inotropic effect of 
naloxone is thought to be responsible for these changes. 
The anti-opiate effects appear to last for only 2-10 minutes and 
therefore, its therapeutic benefit is questionable. Futhermore, high 
doses of naloxone must be administered frequently, and the high cost of 
this chemical probably excludes its usage in most settings. 
3.2.3. SUPER-OXIDE ANTAGONISTS 
Various experimental shock protocols produce intestinal ischaemia, 
resulting in haemorrhagic mucosal lesions in the small intestine. These 
mucosal lesions cause the release of cardio-depressive substances, from 
damaged cells, into the vascula • circulation which further compounds the 
202 damage that has already occurred. 
* lode 1s of localized intestinal ischaemia have been reported to produce 
additional tissue damage after the restoration of the intestinal blood 
147 202 203 
flow. ' ' Data indicating that this additional damage is caused 
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by oxygen-derived free radicals, and that the generation of these free 
radicals takes place during the re-oxygenation of the ischaemic and 
147 148 204 
hypoxic tissues is accumulating. ' ' Recently, it was suggested 
that the catabolism of hypoxanthine to uric acid, catalysed by oxygen-
147 149 dependent xanthine oxidase, produced the super-oxide radicals, ' 
which in turn causes peroxidation of lipid components of the cellular 
148 
membranes. During hypoxaemia, xanthine dehydrogenase is converted to 
xanthine oxidase and consequently, re-oxygenation during reperfusion 
allows this enzyme to become active, and to generate more super-oxide 
148 
radicals. 
Competitive inhibition of xanthine oxidase might provide protection to 
the body during a shock phase. Allopurinol is a competetive inhibitor 
of xanthine oxidase. When experimental cats were given allopurinol prior 
to an intestinal ischaemia, then cats were protected. They showed no 
signs of small intestinal mucosal damage at 10 and 60 rnins following 
148 restoration of perfusion pressure to the small intestine. In a 
haemorrhagic shock model in the dog, pre-treatrnent with allopurinol also 
205 increased survival time. 
3.2.4. CORTICOSTEROID THERAPY 
An aspect that should be emphasized, and already has been mentioned, is 
that haemorrhagic shock causes regional nypoxia of the gut which, in 
turn, gives rise to intestinal mucosal damage. This allows endogenous 
GNB with their LPS, or endogenous LPS by itself, to enter the host's 
blood circulation. Therefore, much of the early work performed on 
haemorrhagic shock models in different species of experimental animals, 
can be interpreted as work performed on special cases of endotoxin 
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shock. 
Scientific investigations into the effects of corticosteroid (CTS) 
therapy in canine haemorrhagic shock began in 1942 when researchers 
concluded that the administration of CTS alone, did not produce 
significant favourable effects on homeostatic mechanisms in the 
experimental animals. However, the combination of blood transfusions or 
i.v. fluids with CTS did produce beneficial effects. 
Howard et al., combined CTS and vitamin B-,? treatment for 
207 
experimentally-induced haemorrhagic shock in dogs and reported that 
this therapy had no beneficial effect. However, upon closer examination 
of their data, it was reported that it was necessary to withdraw 25% 
more blood from the treated animals than from the control group, to 
produce the same degree of shock. 
Prior to the gradual withdrawal of 50% of adrenalectomised rats' blood 
volume, they were treated with either cortisone or desoxy-
209 
corticosterone. Rats receiving desoxycorticosterone maintained a 
higher blood pressure than the control rats, but not as high as those 
that received cortisone. It was concluded that the former steroid 
provided better protection in this experimental model. Researchers were 
later to report on a successful regimen of using a "cocktail" of 11 
adrenal cortical hormones in patients with post-operative shock, where 
the shock had not been reversed by large amounts of blood or i.v. 
fluids. All 24 human patients showed a definite response to this 
"cocktail".210 
The effects of administered CTS during an endotoxic episode varied from 
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negligible to nearly complete protection. Therefore, the value of 
212 213 
CTS alone in these shock states still remained controversial. ' 
Facts that did emerge from these conflicting conclusions were, firstly, 
that once haemorrhagic hypotension in the dog had persisted for longer 
than 45 minutes, administration of hydrocortisone would not affect the 
eventual outcome of the shock process. Secondly, for hydrocortisone to 
be effective it had to be administered i.v., and finally, although the 
hypertensive effect of hydrocortisone occurred in the absence of fluid 
administration, blood transfusion was still the most appropriate initial 
response in clinical haemorrhagic shock. 
Later it was postulated that beneficial effects following hydrocortisone 
administration were due to modifications by CTS on the vascular response 
214 to endogenous catecholamines. These workers showed a different 
response in experimental subjects to cortisone, a glucocorticoid, and 
desoxycorticosterone, a potent mineralocorticoid. In view of these 
differences, the effects of several adrenal cortical compounds on the 
215 course of haemorrhagic shock in the dog were studied. It was 
concluded that CTS, with predominantly glucocorticoid activity, were the 
more effective agents than were the CTS, which were primarily 
mineralocorticoid in their action. 
It appeared that the dosage of CTS administered to the shocked 
experimental subject was of importance. Normal physiologic doses of CTS 
indicated that experimentally-induced shock mortality decreased. When 
high physiologic doses of CTS were employed in similar experimental 
models, an improved survival rate was recorded in the latter animals 
compared to those animals which received the normal physiological dose 
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of CTS. Ultra-physiologic (pharmacologic) doses demonstrated the 
greatest improvement in the survival rates of experimentally-induced 
217 endotoxaemia in the same type of experimental shock. These 
pharmacologic doses then became accepted by those treating these shock 
cases, however the actual timing of the administered CTS appeared to be 
of paramount clinical significance. 
A 100% lethal model of canine haemorrhagic shock was used to investigate 
the effects of a prophylactic dose of 60 mg/kg body mass of 
niethylprednisolone sodium succinate (MPSS), administered 1 hour prior to 
on o 
the onset of bleeding. Despite a significant reduction in the total 
peripheral resistance and a transient improvement in the cardiac output 
in the MPSS treated dogs, there was no significant improvement in the 
mean survival time. It thus appeared that neither physiologic nor 
pharmacologic doses of CTS could improve survival in models of 
haemorrhagic shock that are severe enough to cause 100% mortality in 
dogs receiving only fluid supportive therapy. 
This work was modified by other researchers who evaluated the influence 
of the timing of the administration of the glucocorticoid on the course 
219 
of canine haemorrhagic shock. It was found that the haemodynamic and 
oxygenation indices in dogs receiving CTS at the beginning of 
hypotension or 1 hour later, were significantly better than in those of 
untreated controls. When CTS administration was delayed until the end 
of the nypotensive phase, then haemodynamic indices were identical to 
those of the untreated dogs. Also, CTS treated dogs required less fluid 
during the recovery phase to achieve normovolaemia. In addition, 
following restoration to normovolaemia, the haemodynamic indices 
remained closer to pre-shock values in the CTS treated group of dogs. 
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Pre-treatment using rlPSS in E.coli LPS-induced porcine shock was 
22Q 
studied. This preparation was administered 25 minutes before the 
infusion of E.coli LPS. Control pigs received the LPS alone. Within 210 
minutes of the i.v. infusion of LPS, all 17 controls were dead. In 
contrast, of 7 pigs which received a pre-LPS infusion dosage of MPSS, 6 
were still alive 210 minutes after the LPS infusion. These results were 
221 
consistent with those recorded in similar experiments in dogs , 
000 00*\ /jo 
rats , cats and monkeys. 
The ability of MPSS to protect gut mucosa during a regional hypotensive 
224 
phase was investigated. Cats given MPSS at the conclusion of a 2-
hour abdominal vascular ischaemic period, demonstrated significantly 
fewer small intestinal mucosal lesions one hour later, than did the 
untreated controls. In addition, it was reported that in the presence of 
MPSS there was a reduction of cardiotoxic enzymes released from the 
ischaemic small intestine into the general vascular circulation. 
Furthermore, the MPSS-treated cats did not manifest systemic hypotension 
following release of the occluded intestinal artery, as occured in the 
control cats. 
In another study, experimental animals were given MPSS with and without 
an infusion of E.coli LPS, and the effectiveness of MPSS in preventing 
or reversing tissue damage caused by the administered LpS was 
225 
studied. It was concluded that the early administration of CTS to 
LPS-treated animals prevented deleterious effects of LPS in the lungs, 
kidneys, haematological system and lysosomal enzyme liberation, but not 
in the liver. However, late treatment with MPSS did not prevent LPS-
induced changes in the kidneys, and detrimental effects on lung 
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metabolism were observed. The administration of CTS to patients in the 
pre-terminal stages of endotoxin shock may therefore be dangerous. 
Several mechanisms resulting in beneficial changes in haemodynamic and 
metabolic parameters by glucocorticoid therapy for endotoxin shock have 
been proposed. ' ' Corticosteroids have been suggested to 
function by: 
00 f\ 
a. Elevating the cardiac output, 
221 
b. Augmenting venous return by diminishing peripheral pooling, 
c. Increasing the coronary blood flow and elevating regional blood 
flow,221 
227 
d. Preventing aggregation of platelets, 
227 
e. Protecting against activation of the coagulation pathway, 
227 
f. Inhibiting the activation of complement, 
5 
g. i'laintaining the RES function, 
h. Inhibiting the generation and release of vasoactive substances such 
5 
as kinins, prostaglandins, histamine and beta-endorphin, 
i. Stimulating hepatic gluconeogenesis and maintenance of oxidative 
poo 
phosphorylation, 
229 j. Supporting liver carbohydrate metabolism, 
230 k. Stabilizing hepatic lysosomal membranes, 
227 1. Protecting endothelial integrity, particularly of the capillaries. 
3.2.5. CQRTICOSTEROID-ANTIBIQTIC COMBINATION THERAPY 
Several animal models have shown that the early administration of CTS in 
combination with an antibiotic for the treatment of a lethal infusion of 
GNB, markedly reduced the mortality seen in the antibiotic-only treated 
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controls. ' It has also been reported that CTS alone protected 
against lethality during the first 15 hours better than did gentamicin 
227 alone, although ultimately, both displayed the same mortality rate. 
ilore recently, it has been shown that CTS plus antibiotic treatment of 
the same animal had a lower mortality rate than mortality after 
232 
treatment with either of the two drugs individually. 
Different steroids have been employed in combination with certain 
231 antibiotics to treat experimentally-induced endotoxin shock animals. 
Experimental dogs were i.v. infused with live E.coli organisms (1.1 x 
10 organisms/kg body mass) over an one-hour period. These dogs were 
divided into various groups and received either a combination of a 
steroid and an antibiotic or an antibiotic by itself. An 80% mortality 
was observed in the groups that received dexamethasone and gentamicin 
together or gentamicin alone. In contrast, the group that received 
combined MPSS and gentamicin therapy had a 100% survival. However, it 
should be stressed that the treatments were always administered prior to 
or with the infusion of the pathogenic organisms. 
This combined CTS-antibiotic therapy holds promise, but unfortunately 
the time lapse from GNB infusion to the beginning of the combined 
treatment does not coincide with the typically presented clinical case 
of endotoxin shock. 
3.2.6. ANTIBIOTIC THERAPY 
During an episode of shock the eradication of exogenous and endogenous 
GNB are important aspects, and the early administration of non-
absorbable antibiotics to destroy endogenous GN8 in the gut has been 
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advocated. When circulating GAB are destroyed by antibiotics, 
increased circulating plasma levels of LPS can occur and thus the 
administration of antibiotics should be carried out with caution in late 
81 8? 
endotoxin shock. ' Antibiotics with broad spectra should preferably 
234 
be administered, orally and parenterally. If the patient in shock 
has concurrent wounds then basic traumatic wound therapy is essential to 
eliminate septic foci. 
Basic wound treatment is absolutely necessary if this was part of the 
aetiology or if concurrent wounds are present. Sterile gauze sponges 
should be placed into the wound to protect it while hair is shaved from 
a generous area around the wound. The shaved area should then be 
prepared with surgical soap and warm saline. Surgical debridement is 
necessary to remove dirt, necrotic tissues, and to make the contaminated 
wound as aseptic as possible. Atraumatic handling of tissues must be 
performed since additional trauma will increase the likelihood of 
bacterial invasion. Bleeding blood vessels must be closed and care 
taken to preserve nerves. Suturing of open wounds is mandatory and is 
determined by the physiological status of the patient in shock. It is 
not unreasonable to leave wounds unsutured initially, but then adequate 
coverage and use of local antibacterial chemotherapeutic agents must be 
incorporated into the regimen of secondary wound closure. 
For most GNB, gentamicin has been reported to be effective at a dose 
rate of 4 mg/kg body mass, eyery 12 hours. Clindamycin, 4 mg/kg body 
mass eyery 6 hours or chloramphenicol, 20 to 30 mg/kg body mass eyery 3 
235 
hours have also been suggested as initial therapeutics. Specific 
treatment will depend upon the results of wound culture and 
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antimicrobial susceptibility testing. 
The outcome of septic shock appears to be more dependent upon factors 
involved in host prognosis, than whether appropriate antibiotics were 
used. Antibiotic therapeutic regimens have been focused on those 
patients with the worst prognosis and in whom many attempts have been 
made to improve their outcome. A summary of such antibiotic treatment 
is as follows; 
a. Empiric therapy - therapy is started when the first signs of 
infection is appreciated. Combinations should be used that have a broad 
spectrum of activity designed to be effective against the bacteria 
TOO 
likely to be aetiologically implicated. 
b. Synergistic combinations of antibiotics - the combinations of two 
drugs often displays more activity against a bacteria than can be 
expected from the sum of the activities of each individual 
235 antibiotic. 
c. Development of new antibiotics - determinations of which antibiotics 
234 
are more effective because of increasing antibiotic resistance. 
d. Prophylactic use of antibiotics - reduction of the opportunites for 
nosocomial infection and for resistance to develop by the bacteria 
against the antibiotic being used. 
The combination of carbenicillin and gentamicin has been reported to 
give better overall results (83%) than either drug used alone (50% and 
234 
57% respectively). When a combination of cephalosporin plus 
carbenicillin or ticarcillin were used together, then this treatment was 
equally as successful as an aminoglycoside plus carbenicillin or 
.•,,. 188 cicarcillin. 
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Polymyxin B is a cyclic peptide antibiotic which is bactericidal for 
most GMB species. In addition, it is known to bind avidly to the lipid A 
region of LPS ° and this reduces some of the biological activities of 
LPS. However, these researchers had to use polymyxin B at 100-fold 
excess concentrations and then only 30-50% inhibition of LPS binding to 
the amoembocyte of the horseshoe crab was demonstrated. Also, polymyxin 
B should not be used as a systemic antibiotic because of its known toxic 
effects within the host. 
A yery important consequence of antibiotic therapy against GNB infection 
op 
was recently described. The rapid destruction of E.coli by gentamicin 
lead to a 2000-fold increase in circulating plasma LPS concentration, 
from their "sloughing off" killed bacteria. Therefore it must always be 
remembered that although the antibiotics may destroy bacteria, they 
appear to have no harmful effects on circulating LPS, and in fact, are 
liable to increase LPS concentration. 
3.2.7. ENDOTOXIN SHOCK IMMUNOTHERAPY 
LPS can stimulate host defence mechanisms to produce specific antibodies 
which in turn will eventually destroy the circulating plasma LPS. 
Immunotherapy directed specifically against LPS has recently received 
133 
increased attention as this form of treatment reduced the mortality 
associated with septic shock in several experimental animals, clinical 
veterinary patients and human studies.3 7' 0 1' 7 7' 1 1 3' 1 3 4' 2 3 7' 2 3 8 
Serum obtained from persons who had recently recovered from various 
Dacterial infections was used successfully to treat Pseudomonas 
infections. j ^ e p r e s e n c e 0f high titres of antibodies specific to 
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LPS or other gram negative bacterial antigens in the host's circulating 
plasma, was protective in patients with gram negative septicaemia and 
reduced their mortality rate from 64% to less than 10%. Specific 
antibody-rich plasma fractions are already used therapeutically in 
suspected exposure to Varicella and tetanus. 
Success was obtained when anti-Pseudomonas antibodies were used for the 
239 treatment of pseudomonas-induced sepsis in burn patients. The 
effectiveness of this therapy was limited mainly to Pseudomonas spp. 
This work was followed by a complicated process of actively immunizing 
healthy human volunteers with a boiled E.coli mutant to obtain 
133 antiserum. This preparation reduced morbidity in patients suffering 
from neutropenia following treatment for leukaemia or lymphoma. 
Another study identified an important immunological marker, which 
correlates with protective immunity in a common form of gram negative 
septicaemia, by studying the relationship between serum antibody to the 
cross-reactive LPS "core" of E.coli, and survival following Pseudomonas 
241 aeruginosa septicaemia. A total of 43 patients with Pseudomonas 
septicaemia, among whom there was a mortality of 42%, were evaluated. 
"Core"-specific antibodies of both isotypes were higher in patients who 
survived compared with those who succumbed to their septicaemias. 
Stepwise linear discriminant analysis indicated that type-specific 
antibody levels were the best predictor of outcome, among those 
antibodies examined. It was also noted that prior steroid therapy was 
associated with low levels of both "core"-specific IgG and Igi'l. These 
data suggested a heterologous protection against Pseudomonas aeruginosa 
septicaemia by naturally occuring antibodies to tne "core" of E.coli. 
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Until 1975 it appeared that only mono- or bivalent sera were 
investigated. At this point Gaffin and co-workers in Israel produced a 
242 polyvalent anti-LPS serum from human blood. Units of human blood 
that had been donated to blood banks were screened for high 
concentrations of LPS-specific antibodies. The naturally occuring IgG 
antibodies to LPS which were found in this donated blood, had high 
affinities to bind LPS prepared from E.coli, Klebsiella, Salmonella, 
Shigella and Pseudomonas. Also, these IgG's had a longer in vivo half-
life than did the Igi'I preparation of previous workers. 
Commencing 2 hours after the onset of an experimental haemorrhagic 
shock, a group of cats were experimentally treated with a polyvalent 
human hyperimmune plasma rich in anti-LPS antibodies, whilst control 
242 group received normal plasma. Survival was improved in the treated 
group compared to the controls. These workers thus showed that 
antibodies specific to LPS may be therapeutically useful in "non-septic" 
shock aetiology. This polyvalent anti-LPS was found to bind to and, 
presumably, opsonize the LPS released from antibiotic-killed GNB. 
Another ^ery important biological activity of this polyvalent anti-LPS 
is that, in the presence of complement, the anti-LPS antibodies can 
243-245 
destroy a range of GNB themselves. Since several antibodies 
could bind to a single LPS molecule, the likelihood of developing 
resistant strains cr GiJB is lower with anti-LPS, than with conventional 
antibiotic therapy acting at one site. 
Human patients in septic shock were treated with conventional therapy 
and they also received an intramuscular gamma globulin preparation of 
246 
anti-LPS. Twenty of twenty-two patients responded by either 
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recovering completely or showing a temporary improvement in their 
clinical signs. 
In another clinical trial, patients were admitted to a study after they 
247 
had satisfied certain stringent criteria for shock. Control patients 
received conventional therapy whilst an experimental group received the 
same conventional therapy plus an intravenous human freeze-dried plasma 
rich in anti-LPS IgG. This was also polyvalent in nature as the anti-
L?S contained IgG which bound to a wide range of GNB, including E.co1i, 
Pseudomonas, Klebsiella, Salmonella and Proteus. Mortality in control 
patients was 40% compared with 4.7% in the patients who received the 
anti-LPS. Moreover, the mean hospital stay of survivors was 23,2 days 
in control patients and 14,2 days for those patients who received anti-
LPS. Unfortunately, the excellent results obtained in this clinical 
trial are open to subjective bias, as this was not a double-blind 
study. 
Polyvalent anti-LPS hyperimmune plasma was produced in equines (ANTI-
LPS) and this plasma has been used in experimental animal models of 
endotoxin shock as well as in clinical veterinary 
practice.37'5 1'5 7'1 1 3'1 3 4'2 3 7'2 3 8 Equines with Colitis"X" responded 
yery rapidly to their ailment after they were given the equine anti-LPS 
plasma despite the previous failure of conventional therapy. Equine 
post-operative peritonitis, foals with periacute enteritis and epidemic 
gastroenteritis were found to respond \iery favourably to the addition of 
equine ANTI-LPS into their treatment regimens compared to those that had 
134 
only received the conventional therapy. Flushing GNB infected joints 
244 with ANTI-LPS was also reported to produce beneficial results. 
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ExperiiViental rabbits were subjected to a superior mesenteric artery 
occlusion shock for 60 mins. Twelve animals were pre-treated with a 
single dose of human anti-LPS serum 2 days prior to the arterial 
occlusion shock. Eight animals acted as controls and survival was 
recorded when each animal was still apparently normal 10 days post-
release of the occlusion. One of eight controls survived the 
experimentally-induced shock, compared to 10 out of 12 treated animals. 
In a preliminary report, equine ANTI-LPS antibodies were shown to bind 
with LPS present on the surface of living bacteria (Wells, Gaffin, 
Gregory, et al., 1986, submitted). During this binding process, it was 
shown that complement was activated and the Klebsiella bacteria were 
destroyed. This property of the equine hyperimmune plasma was 
successfully exploited in the treatment of Pseudomonas keratitis in 
245 134 
rabbits, and intra-uterine Klebsiella infection in equines. 
When equine ANTI-LPS was mixed with various GNB for 30 minutes there was 
a \/ery rapid (seconds) reduction in the number of viable organisms 
detected by plate counts of 21 different isolates, including various 
multi-resistant forms (Wells, Gaffin, Gregory, et al., 1986, submitted). 
In the various controls, normal growth of these same 21 bacterial 
isolates were obtained. In this work, it was also shown that various 
Pseudomonas species, as well as Proteus and Providencia were the most 
susceptible to the equine ANTI-LPS. 
In summary, ANTI-LPS nas three effects; 
1. it destroys GNB, 
2. it binds to the LPS released from killed GNB, 
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4.1. SUMMARY 
GNB alone were generally considered to be the cause of the mortality and 
45 240 
morbidity of septic and gram negative bacteraemic patients. ' Later 
it was reported that GNB were also responsible for the death of non-
5 
septic patients. German and other workers showed that GNB possess a 
biochemically structured molecule consistent with that of a 
lipopolysaccharide (LPS) situated in, and forming an integral part of, 
83 84 
the outer cellular membrane of these bacteria. ' These and other 
workers showed that LPS was potently toxic and chemically very 
stable.248 
This work led to the isolation of LPS which was tnen parenterally 
5 
administered into experimental animals. Death occured in these 
experimental animals as a result of the administered LPS, and the 
symptomatology and pathology were described as being identical to those 
of septic, non-septic and gram negative bacteraemic shock. LPS was also 
termed "pyrogen", since it could cause a rapid biphasic increase in body 
temperature, and "endotoxin" because it was not secreted by living 
bacteria. It is now generally accepted, without direct proof, that it 
is the LPS which is primarily responsible for the mortality and 
5 
morbidity associated with septic, non-septic, and endotoxin shock. 
The gastric microflora of most monogastric mammals consist of 
22 
acidophilic gram positive bacteria and yeasts. Likewise, the normal 
bacterial flora of the small bowel includes many genera and dozens to 
23 249 
thousands of species of GNB. ' It is thought that carnivorous 
mammals have more GNB present normally, than do omnivorous mammals. 
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There appears to be variations in tne concentration of different GNB 
species from individual to individual of the same species of mammal. 
Because LPS forms an integral part of the outer cellular membrane of 
GNB, the dog always has LPS present in its gut. 
The LPS molecule of GNB has three distinct regions, wnich are recognised 
as: i. the lipid-A, ii. the core oligosaccharide and iii. the outer 
83 84 
polysaccharide region which contains the "0"-antigen. ' Lipid-A 
displays the least variability from one GNB species to another, but 
contains the exceptionally potent toxic region. In the outer 
polysaccharide region, the "0"-antigens exhibit specificity for a 
particular GNB species, and are thought to be weakly immunogenic in a 
84 
host. Certain mutant GNB lack the "0"-antigen and some core 
oligosaccharides. 
LPS is released or "sloughed off" from the parent bacterium when it dies 
91 
or it is killed by chemotherapy. Others have suggested that LPS may 
49 
also be released when the parent bacteria undergo active replication. 
However, if LPS remains within the intestinal lumen, it does not exert 
72 
any obvious toxic effects within the host. 
GNB with their LPS, or isolated LPS, can gain entrance into a host's 
vascular circulation, and produce the clinical signs of endotoxaemia.0 
These GNB, with their LPS, circulating in the nost's vasculature during 
an episode of bacteraemia and endotoxaemia, can have either an exogenous 
or an endogenous (or both) source. It has also been established that 
endogenous LPS from the intestines, gains entrance to the circulation 
po yn 
without their parent bacteria, and in non-septic conditions. 
Page 77 
The intact intestinal mucosa acts as the host's primary defence against 
29 
endogenous and exogenous LPS which infect the host per os. These 
findings were supported when animals with normal intestinal function, 
were dosed per os with between 500-3000 times the minimal lethal 
parenteral dose of LPS, and they displayed no clinical signs to this 
30 
experimentally administered LPS. In addition, no evidence has emerged 
to indicate that an intestinal enzyme is present to destroy or 
inactivate LPS when it is present in a dog's intestine. Futhermore, 
orally administered LPS can be recovered intact from the normal 
72 
intestine. 
Shock has many and varied aetiology and many reviewers of this subject 
have tunnelled their treatment regimens, sometimes with tragic results. 
Today our understanding of shock indicates that irrespective of the 
aetiology of the shock, an altered micro-vascular circulation results, 
wnich will provide inadequate nutrition to, and waste removal from, 
tissues.5,251 
The oxygen-reliant intestinal mucosal cells require an adequately 
perfused vasculature to prevent LPS from escaping into the host's 
75 
vascular circulation. During intestinal ischaemia, LPS with or 
without their GNB, enter the hepatic-portal circulation and wnen 
these toxic molecules are taken up by the liver, they can then be 
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rendered harmless by the macrophage-phagocyte system. ' If the liver 
is overwhelmed or if the liver is itself not functioning adequately, 
LPS can enter the systemic circulation, where it will exert its toxic 
59 
effects for up to two weeks. 
Circulating plasma LPS is removed by various tissues at different times 
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59 99 and in different sequences. ' It has been shown that a reduction in 
total plasma LPS concentration appears to be related to tne 
99 
concentration of circulating plasma HDL. LPS that are not bound to HDL 
are removed rapidly from the plasma by tissues that are rich in 
phagocytic cells, mainly tne liver and spleen. The LPS-HDL bound complex 
has a prolonged half-life in the plasma and accumulates in tissues by a 
mechanism that probably involves receptors for HDL, these tissues being 
primarily the liver, adrenal glands and the ovaries. After the LPS 
(bound and unbound) is taken up by the different organs, it is destroyed 
by the rnacrophage-phagocyte system in those organs and finally excreted 
in the bile and faeces. 
The haemolymph of horseshoe crabs (Limulus polyphemus) contain 
amoebocytes that are particularly sensitive to LPS, and combine with it 
to form a firm gel. ' This discovery brought about the limulus 
ainoebocyte lysate (LAL) gel test for LPS. Unfortunately, this test was 
found to be not entirely reliable, and today it is mainly used to detect 
34 35 
LPS in pharmaceutical products. ' Later work established that the 
chromogenic substrate modification of the LAL gel test was both a 
reliable and reproducable method to measure, quantitatively, circulating 
LPS in plasma.36,37 
In order to determine whether there is an abnormal concentration of LPS 
in the circulating plasma of the dog, it is necessary to first establish 
normal values. This value has been recorded and in view of this 
achievement it should now be possible to accurately diagnose a 
113 
developing endotoxaernia, and a developed endotoxin shock status. 
idhen LPS gains entry to various host tissues it can exert fatal effects 
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on the cells within these tissues. Tnese include the activation of 
certain host systems whose end products can exert futher serious and 
5 
life-threatening effects. LPS is capable of stimulating host 
homeostatic systems, and once these pathways have been activated, the 
toxic end products of their pathways may add to the destruction of more 
253 
cells and tissues . Eventual organ collapse will occur, resulting in 
the possible death of the host. 
yl 
"Free" LPS has been reported to be immunogenic, albeit weakly. Given 
sufficient time, anti-LPS antibodies can be synthesised by a host, which 
could then render the circulating plasma LPS harmless. If the host has 
not succumbed to the initial effects of circulating LPS, the recovery 
period is invariably prolonged, compared to the patient who has adequate 
antibodies to negate circulating plasma LPS. During the recovery phase 
from endotoxaemia, a patient must be fully supported with treatment 
aimed at neutralizing the harmful effects of the different toxic 
metabolites that were produced by damaged host cells and LPS circulating 
in the plasma. In addition, corrective surgery, if the aetiology 
indicated this approach, must be performed on the high-risk, emergency 
patient. Yet, in spite of successful surgical intervention, mortality 
49 
due to the effects of circulating plasma LPS remains high. 
It is known that the surgical correction of a partially or completely 
obstructed intestinal vascular bed produces a further rise in 
circulating plasma LPS. ' Rapid, passive immunotherapy, using 
antibody-enriched serum or plasma, prior to removal of the obstructing 
anatomical feature, should be able to improve the patient's chances of 
survival. Preferably, a broad-spectrum or polyvalent anti-LPS antibody 
enriched plasma would be of greatest value, as invariably, several 
Page 80 
species and strains of GNB are involved during an endotoxaemic episode. 
Endotoxin shock can occur in any patient as a result of septic or non-
septic aetiological onslaughts.24'28'37'51'113'134'237'238'254 In the 
United States, the frequency of gram negative bacteraemia has been 
estimated to be as high as 1 per 100 hospital patients, with fatality 
44 
rates as high as 30-80%. This figure may be even higher in cases of 
"pure" endotoxaemia, since endogenous LPS is able to enter the 
circulation without GNB during an onslaught of exogenous GNB septacaeinia 
or endotoxaemia. This high mortality is confirmed by other studies in 
5 47 
America and Japan. ' In veterinary medicine mortality rates due to 
49 50 
endotoxin shock are known to be the same or possibly even higher. ' 
Despite the advancements made in the development and use of broad-
spectrum antimicrobial chemotherapeutic agents, the judicious use of the 
corticosteroids, anti-prostaglandin chemicals, adjuvant supportive 
electrolyte and nutritional fluids, other supportive therapy to combat 
released activated metabolites, and expensive and elaborate life-
supporting and monitoring equipment, the incidence of gram negative 
bacteraemia, and hence endotoxaemia, continues to increase with 
133 
sustained high mortality rates. The treatment for endotoxin shock 
has focused on the killing of the GNB, and supporting the patient until 
there was recovery, whilst, little or no attention was given to the 
neutralization or abrogation of the concurrent endotoxaemia. 
Antibiotics can destroy GNB which are sensitive to the antibiotic 
187 188 
used. ' Once killed, GNB will release their potent, toxic LPS which 
are known to be refractory to these antimicrobial chemotherapeutic 
agents.<51 Recent studies have shown that the concentration of 
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circulating plasma LPS can increase up to 2000-fold after an antibiotic 
was used to destroy the GNB that produced them. 
Tolerance to LPS can be induced by vaccinating animals with ^jery small 
4.3 4fi 055 
doses of either LPS or Killed GNB. ' 0 , t The harvesting of the plasma 
from sensitised human donors, and the subsequent administration of this 
harvested plasma into human recipients, is known to protect tne 
256 257 
recipient against the lethal effects of LPS. ' It was thought that 
specific anti-LPS antibodies in the donor's plasma provided this 
protection. Braude reviewed most of this work and in 1973, he and co-
workers demonstrated that human antiserum to an incompletely synthesized 
18 
form of LPS conferred passive immunity to LPS effects in animals. 
Later, Gaffin et a!., produced the first "broad-spectrum" or 
242 
"polyvalent" anti-LPS plasma from human blood donors. This anti-LPS 
improved the survival rate of cats subjected to endotoxin shock, 
secondary to an experimentally-induced haemorrhagic shock. 
A polyvalent, anti-LPS, antibody-enriched, plasma (ANTI-LPS) is now made 
in equines by immunizing horses with an undisclosed vaccine. Successful 
treatment of a wide variety of equine endotoxin-mediated disorders have 
been reported, when this equine ANTI-LPS was incorporated into the 
134 
treatment regimens of these conditions. Similar successes have been 
achieved wnen this ANTI-LPS was used in conjunction with routine therapy 
for diagnosed endotoxaemic conditions in the cat and dog. ' ' 
"Atoxin", Atox Pharmaceuticals, Gillitts, Rep.So.Afr. 
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The success of this particular ANTI-LPS antibody preparation probably 
lies in the fact that it is broad-spectrum in activity against a wide 
range of LPS structures, as well as the parent bacterium. ' ' ' 
It is therefore unnecessary for the clinician to isolate and identify 
either the species of GNB or the LPS when gram negative bacteraemia or 
endotoxaemia have been diagnosed. 
Values for the concentration of circulating plasma LPS in healthy dogs 
113 
have been established. With this knowledge the clinician is now able 
to positively diagnose a developing endotoxaemia. The administration of 
tnis equine polyvalent ANTI-LPS will lead to the early administration of 
an LPS specific therapy with safety, as to date, no side effects of this 
equine origin ANTI-LPS have been reported in dogs. 
Dogs are popular household pets throughout most of the Western world and 
they have also been used as experimental subjects in veterinary medical, 
and surgical research, in the investigation of the problems associated 
with abdominal iscnaemia. Partial and complete abdominal vascular 
ischaemic problems are encountered in clinical veterinary practice and 
when diagnosed, these patients represent immediate surgical intervention 
on a high-risk emergency. 
4.2. PURPOSE OF INVESTIGATION 
Zanotti and Gaffin (1983) were able to reduce the mortality and 
morbidity of rabbits subjected to an experimental superior mesenteric 
arterial occlusion shock for one hour, when they used equine origin 
ANTI-LPS plasma. Rabbits are omnivorous animals and therefore it is 
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possible that the concentration of circulating endogenous plasma LPS 
would not be as high as that which could arise in a carnivorous animal 
experiencing the same type of experimental endotoxin shock. 
The purpose of this study was, first, to investigate whether the 
polyvalent equine ANTI-LPS hyperimmune plasma was capable of reducing 
the mortality rate of experimental, abdominal vascular obstruction in a 
carnivorous species, the dog. This model would simulate similar 
intestinal vascular ischaemic canine problems which are frequently 
diagnosed in veterinary practice. In order to establish which were the 
most representative canine subjects to use as the experimental subjects, 
the hospitalisation records of all hospitalised patients admitted to a 
private veterinary hospital over a two-year period were examined. 
Secondly, I investigated whether the polyvalent equine ANTI-LPS plasma 
could be beneficial in the treatment regimen of Canine Parvovirus 
Disease patients. This recently described canine disease has been well 
documented, is known to occur epidemically, and produce an endotoxaemia 
with exceptionally high mortality rates and prolonged morbidity 
. , 51-55 periods. 
Highway Veterinary Hospital, Pinetown, Rep.of So. Afr. 
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5.1. MATERIALS FOR CRANIAL MESENTERIC ARTERIAL OCCLUSION SHOCK MODEL 
5.1.1. SELECTION OF SUBJECTS 
The aetiology of partial and/or complete abdominal vascular occlusions 
may be congenital or acquired. When diagnosed, these patients are 
invariably high-risk, surgical emergencies. Yet, despite successful 
surgical intervention, the mortality and morbidity rate in these cases, 
remains high. 
Standardisation of animal species, and biological subjects for 
experimental work should always be attempted. Because I was to evaluate 
the validity of a specific anti-endotoxin immunotherapy for dogs, only 
canine subjects were used in this study. In this respect all the donated 
dogs were subjected to definite standardised selection criteria. 
Initially the records of all patients admitted to a private veterinary 
hospital (refer page 83) were scrutinised under strict confidence in an 
attempt to find the "type" of dog most frequently hospitalised, with 
regards to age, sex, breed, body mass, and colour. After these records 
were examined it was decided to select donated healthy dogs based on 
body mass and sex. These potential subjects then had to fulfill other 
criteria based on their vaccinational status and clinical examination. 
5.1.1.1. VACCINATION STATUS Certain highly infectious and contageous 
canine diseases are known to produce endotoxaemia and some of these 
diseases can De prevented by vaccination. The first criterion applied to 
each potential subject, was to ensure that it was accompanied by a valid 
vaccination certificate, indicating that the vaccinational status was up 
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to date against ; 
a. Canine Distemper Virus b. Leptospirosis 
c. Infectious Canine Hepatitis d. Canine Parvovirus Disease 
e. Parainfluenza f. Rabies 
5.1.1.2. CLINICAL EXAMINATION Once the validity of the vaccination 
status was satisfied, each potential subject was provisionally admitted 
to this study. Each dog was kenneled separately at the private 
veterinary hospital where it was kept under observation for a forty-
eight hour period. Food and water were provided, and where undesirable 
behavioural patterns (e.g., viciousness, timidness ) emerged, the dog 
was excluded from the study. When this initial observation period had 
lapsed, each potential subject underwent a clinical examination, 
performed by myself, to ensure that a standardised procedure was 
followed. This examination included ; 
a. The visible mucous membranes of the eyes, mouth, anus and where 
applicable, either the penis sheath or the vulva, were examined 
macroscopically. Attention to their colour, vascular network and 
capillary refill time was noted. 
b. Abdominal palpation of the organs was undertaken to detect 
abnormalities of the liver, spleen, kidneys, urinary bladder, the small 
and large intestines, and where applicable, the prostate gland. 
c. Thoracic oscultation of the heart and lung sounds were performed 
using a clinical stethoscope. 
d. The integumentum was examined to exclude pruritic conditions which 
may have been been treated with corticosteroids or steroid sex hormones 
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during the three months prior to this initial examination. 
e. The superficial lymph glands, prescapular, popliteal, inguinal and 
maxillary, were examined for abnormalities in size and shape. 
f. The locomotory system was scrutinised by carefully examining the dog 
at rest and during exercise. Any condition that may have been under 
treatment with corticosteroids excluded the dog from the study. 
If each potential subject fell within the normal parameters of each of 
the systems described it was then subjected to further laboratory 
examinations as follows; 
g. Urine examination, an examination of the urine from each potential 
subject was undertaken for quantitative evaluation of pH, protein, 
glucose, ketones, biliribin, urobilinogen and blood. A sterile catheter 
of appropiate size was used to collect a sterile urine sample which was 
then examined using a reagent strip. If the specimen fell within the 
accepted canine normals then the next examination was performed. 
h. Faecal examination, a fresh faecal sample was collected from each 
dog and a microscopic examination was performed on tnis collected 
material, for the presence of helminths and coccidia. Appropriate 
treatment was instigated where necessary after which routine follow-up 
faecal examinations were performed to ensure that the potential subject 
remained free of helminths and coccidia. 
When each potential subject passed the above described clinical and 
laboratory examinations, they were then admitted to the final stages of 
their selection. 
"I'lultistix", Ames Division, Miles Labs., England. 
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5.1.1.3. KENNELING OF POTENTIAL SUBJECTS Potential subjects that 
passed the above described criteria were transferred to the animal 
colony of the University of Natal's Medical School. Pre-experimental 
acclimatisation kenneling followed for a minimum of two weeks, where 
each dog was housed separately and observed at least four times e^ery 
day. During this period they were given a commercial dry and wet dog 
food, and water was provided ad lib. 
Between 08.00h and 09.00h on the day prior to the operation each 
potential subject was again subjected to the same examinations as 
previously described above. Those dogs that passed this examination were 
then fed and left with water. During the course of this day each dog had 
its ventral abdominal area electrically shaved and then washed with a 
povidone-iodine solution. All food was removed at 18.00h. but each dog 
was left with water overnight. 
5.1.1.4. FINAL SELECTION CRITERIA At 06.30h on the experimental day, 
each dog had its water dish removed. Temperatures were recorded after 
the thermometer had been in the rectum for one minute and those dogs 
that were within the normal range (38,0 C to 38,4 C ) were weighed. 
These dogs had now satisfied all the requirements and they were the 
finally selected subjects. Each dog was randomly designated to a 
specific group as will be discussed in the methods. 
"Vitagen" and "Chow", Epol Pty.Ltd., Johannesburg, Rep.So.Afr. 
"Betadine", Adock-Ingram Labs., Industria, Rep.So.Afr. 
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5.1.2. EQUINE ANTI-ENDOTOXIN HYPERIMMUNE PLASMA (ANTI-LPS) 
A commercially prepared product was used to treat some of the 
experimental dogs (see methods). Certain details of procedures of 
production are confidential. Healthy horses were suitably immunized to 
produce a plasma containing high concentrations of LPS specific IgG's. 
Each horse was plasmapheresed into sterile, apyrogen, plastic bottles, 
which contained sodium citrate as the preservative. After centrifugation 
this plasma was bottled in a laminar flow nood, and then stored at -
20°C until used. Just before administration the plasma was thawed in a 
container of cold tap water at room temperature. 
The concentration of antibodies specific to LPS was determined in the 
pooled, sterile equine plasma. The final product contained anti-LPS IgG 
at a concentration of 1200 ug/ml according to an ELISA calibrated by an 
242 immunoprecipitation procedure. This anti-LPS plasma contained IgG 
that could bind to 26 strains of E.coli, Shigella flexneri, Salmonella, 
Klebsiella pneumoniae, Pseudomonas, Proteus and Enterobacter (Wells, 
Gaffin, Gregory et al., 1986, submitted). 
5.2. MATERIALS FOR CANINE PARVOVIRUS DISEASE CLINICAL STUDY 
CPi/ is a very recently described, highly infectious, canine disease, 
52-55 
which can assume epidemic proportions. It is known to have high 
mortality, indicies, and death of the patient is due to the combined 
effects of a rapidly developing viraemia, bacteraernia and endotoxaemia. 
"Atoxin", Atox Pharmaceutical Co., Gillitts, Rep.So.Afr. 
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During a recent outbreak of CPV, patients were brought to the private 
veterinary hospical and diagnosed by myself as having this disease. Only 
tnose patients that exhibited seven out of eight of the following signs 
were admitted to this study: 
1. A non-vaccinated individual, 
2. Acute onset of vomiting, especially after fluids had been taken, 
3. Acute onset of the characteristic watery, ^ery foetid, grey to 
haemorrhagic diarrhoea, 
4. Rapid onset of lethargy and depression, 
5. Rapid onset of dehydration, 
5. Initial pyrexia or subnormal rectal temperature, 
7. Marked congestion of the visible mucous membranes, which were also 
slightly cyanotic, 
8. A leukopenia. 
Because CPV is a "new" canine disease, the first ten consecutive 
patients that were admitted to this study, based on the above criteria, 
had their diagnosis confirmed by the demonstration of the virus in their 
faeces. A fresh faecal sample of approximately 2 grams, was collected 
from each dog admitted to this study. This was placed into a sterile 
container which held 50 ml of a dextrose saline solution. To this 
mixture, 2 ml of a penicillin-streptomycin antibiotic was added. The 
sample was then sealed, placed on ice and airfreighted to the Veterinary 
Research Institute, Onderstepoort, Pretoria, for electron microscopy 
(Prof.P.Howell, personal communication). 
In addition to the above, patients that succumbed to CPV, underwent a 
post mortem examination and histopathological specimens were collected, 
page 92 
and sent to a private veterinary specialist pathologist for further 
confirmation of diagnosis (Dr.W.Botha, Pretoria, personal 
communication). After ten of ten CPV patients had been correcCly 
diagnosed, and the diagnosis confirmed by either or both of the methods 
described above, the faecal and histopathological examinations were 
terminated. 
These admitted CPV patients were randomly placed into a control group 
(Group 1 dogs, n=36) which received conventional therapy according to 
the attending veterinarian's discretion. A second, experimental group 
(Group 2 dogs, n=89) received the same treatment as the control group 
but in addition they were also administered two doses of equine ANTI-LPS 
plasma. Breed, age, weight and sex of each patient was disregarded. 
After a total of 72 cases had entered this study, a significantly 
increased survival rate was recorded in the group that were receiving 
the ANTI-LPS plasma. At this stage the alternate selection into two 
groups ceased and all subsequent diagnosed CPV patients were allocated 
to the experimental group. 
5.3. METHOD OF CRANIAL MESENTERIC ARTERIAL OCCLUSION SHOCK MODEL 
5.3.1. PREMEDICATION OF SUBJECTS 
* 
The dogs were premedicated with a mixture of 10 mg/ml \tropine and 10 
mg/ml acetylpromazine maleate as is customary in veterinary practice. 
This mixture was injected subcutaneously at a dosage of 1 rnl/lOkg 
--
"Atropine 10", Centaur Lab.Pty.Ltd., Johannesburg, Rep.So.Afr. 
"Panvet ACP", Panvet Pty.Ltd., Kempton Park, Rep.So.Afr. 
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body mass. Each dog received the premedication at 07.30h and was then 
left undisturbed in a kennel until approximately 09.00h. 
5.3.2.ANAESTHETIC OF SUBJECTS 
Each dog was anaesthetised using sterile, pyrogen-free equipment. The 
upper third of the anterior aspect of the right radial area was clipped 
short of hair, and then swabbed with alcohol. Pressure was applied to 
the cephalic vein just below the elbow, and this vein was entered using 
an i/v catheter of appropriate size. Half of the calculated dose of 
pentabarbitone sodium (10 mg/kg) was injected rapidly, using a syringe 
attached to the i.v. catheter. When each dog had lapsed into the first 
stage of anaesthesia it was placed in a left lateral recumbent position. 
An appropiate size endotracheal tube was then positioned in the trachea 
and the cuff inflated. The remainder of the anaesthetic was injected 
slowly to the desired plane of surgical anaesthesia. 
5.3.3. PRE-OPERATIVE PERIOD 
When the syringe which was used to administer the anaesthetic was 
removed and the i.v. catheter suitably stoppered, each dog was then 
placed in a dorsal recumbent position and the endotracheal tube secured 
in the trachea by taping it to the mandible. A Starling pump was set to 
deliver positive respiration at 70 ml/min, and this pump was then 
attached to the end of the endotracheal tube. A sterile, pyrogen-free, 
"Surflow", Terumo Corp., Tokyo, Japan. 
"Sagatal", ilaybaker, Port Elizabeth, Rep.So.Afr. 
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fluid administration set was then attached and secured to the 
i.v.catheter so that a Ringer's lactate solution could be administered 
during the operative period. 
The hind legs were stretched to a comfortable extended position and 
secured to the operating table. Both front legs were extended to a 
position so that the elbow joint was just straight enough to ensure that 
the cephalic vein remained fully patent during the operation. These legs 
were also secured by taping them to the table. 
The shaved ventral abdominal area was thoroughly washed again using a 
hexachlorophene soap. Alcohol soaked swabs were used to remove this 
soap and finally, povidone-iodine was applied to this area and left 
there. A rectal thermometer was inserted and secured to the tail and at 
the same time the heating mechanism of the operating table was switched 
on to maintain a constant body temperature. 
5.3.4. SURGICAL PROCEDURE 
Autoclaved drapes were positioned so that the mid-ventral abdominal area 
was left exposed from the xiphoid region to about 3-5 cm posterior to 
the umbilicus. The left-hand margin of the exposed area was about 2 cm 
lateral to the midline and the right-hand margin 2,5 cm. At this stage 
the Ringer's lactate solution was started and regulated to deliver 
approximately 45 drops/min. The surgeon always operated from the right 
"I/V Adminset", Terumo Corp., Tokyo, Japan. 
"Viaflex", Sabex Pty.Ltd., Aerton, Rep.So.Afr. 
"Sumanol Soap", Lever Bros., Durban, Rep.So.Afr. 
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side of the dog with an assistant standing on tne dog's left. Sterile 
surgical techniques were strictly adhered to throughout the operation. 
The abdominal cavity was entered via a linea alba incision after 
adequate naemostasis had been applied to any small bleeding blood 
vessels. This incision started approxi.nately 3 cm posterior to the 
xiphoid cartilage and ended approximately 2 cm posterior to the 
uiiibi licus. 
The superior or cranial mesenteric artery (CMA) is located in the 
dorsal, anterior abdominal region where it arises posterior to the 
splenic artery. It is the fourth artery of the abdominal aorta and it 
gives off a common trunk for two colic arteries and the ileo-caeco-colic 
artery. These arteries supply arterial blood to the right part of the 
colon, the jejunum, tne ileum, and the caecum. 
The duodenum was deflected to the left side of the abdominal cavity and 
tne origin of the CMA was located by blunt dissection. A sterile, 
pyrogen-free, synthetic, vascular occlusion tape (Vesseloop) was 
applied loosely around the exposed CMA. A stab incision was made through 
the right lateral abdominal musculature approximately 2 cm lateral to 
tne midline incision. The occlusion apparatus (Vesselclude; to take the 
occlusion tape was positioned through this right lateral stab incision. 
A section of jejunum was dislocated out of the abdorirnal cavity so that 
the jejunal arterial pulsations could be observed. The presence of these 
palpations indicated a viable arterial blood supply to the organ. The 
"Vesseloop" around the CMA was then temporarily tightened to ensure that 
"Vesseloop" & "Vesselclude", Neuromedics, Texas, USA. 
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the pulsations of tne jejunal arteries ceased, which indicated that the 
loop was correctly positioned, after which it was then relaxed. The 
jejunum was returned to the abdominal cavity, and the dog allowed to 
acclimatise for 15 rnin. During this short acclimatisation period, nylon 
sutures of appropriate size, were positioned through the lateral stab 
incision and around the "Vesselclude". These sutures were left untied 
and a sterile damp swab was placed over this area. 
After this acclimatisation period had lapsed, the "Vesseloop" was 
positioned through the "Vesselclude", and drawn tight to occlude the 
CMA. The time was noted and recorded as the beginning of the occlusion 
period. A loop of jejunum was again dislocated out of the abdominal 
cavity and observed to ensure that no arterial pulsations were observed 
by the surgeon. Once this factor was satisfied, the jejunal loops were 
immediately returned to the abdominal cavity. This was followed by an 
inspection of the abdominal cavity to ensure that there was no bleeding. 
Abdominal surgical closure was then performed using appropriate size 
surgical catgut in a simple interrupted pattern through the Tinea alba, 
followed by routine closure of the skin using nylon sutures of 
appropriate size in a horizontal mattress pattern. 
The surgical drapes were removed and the surgical site cleaned with an 
alcohol-soaked swab. Povidone-iodine was applied to the sutured areas 
and after the leg ties were removed, each dog was placed in a left 
lateral recumbent position on the operating table. The i.v. dinger's 
lactate solution, which had been maintained throughout the operation 
period, was continued whilst the subject remained in lateral recumbency. 
"Ethicon", Johnson & Johnson, Halfway House, Rep So.Afr. 
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5.3.5. OCCLUSION PERIOD 
The occlusion period began with the tightening of the "Vesseloop" and 
securing it into the "Vesselclude". During this period all the dogs 
(except no.5) remained in the lateral recumbent position on the 
operating table. The Starling pump remained attached to the endotracheal 
tube and the drip was in operation. The dog's rectal temperature was 
still being maintained between 38,0°C and 33,4°C possibly aided by the 
heating mechanism of the operating table. 
After an occlusion period of three hours, the "Vesseloop" was released 
and it, together with the "Vesselclude", was removed from the subject. 
The preplaced nylon sutures were then knotted, the operated area 
cleaned, and swabbed with the povidone-iodine solution. 
In dog no.5 the above-described procedure was varied very slightly. In 
this dog the abdominal cavity was not closed until 10 min after the 
release of the "Vesseloop". During the three hour occlusion period, the 
abdominal cavity was entered and very gently, a loop of jejunum was 
handled so that photographs could be taken every thirty minutes. Other 
than this variation, the procedure was as described. 
5.3.6. POST-OCCLUSION PERIOD 
The subjects remained in the lateral recumbent position on the operating 
table, with the Starling pump on. When each dog began to shiver, 
indicating that the effects of the anaesthetic was becoming less, the 
Starling pump was gradually withdrawn until respiratory activity was 
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voluntary. At this stage of the procedure the i.v. drip was usually 
finished, and it was then removed from the catheter. Each dog then 
received a 10 mg/kg i.v. dose of tetracycline, and then the i.v. 
catheter was withdrawn. When each subject displayed mouth, tongue or 
swallowing movements, the endotracheal tube was removed, after the cuff 
had been deflated. Each dog was then transferred from the operating 
table to a recovery kennel until it could stand unassisted. At this 
stage each dog was then returned to a kennel where food and water was 
made available. 
5.3.7. CONTROL DOGS 
The procedures described above were performed on 5 dogs which were then 
known as the controls ( no. 1 - 5 ). 
5.3.8. EXPERIMENTAL DOGS 
A further 15 dogs (no. 5 - 20 ) were subjected to the identical 
procedure as the controls. However, in addition, each of the 
experimental subjects received a dosage of equine anti-endotoxin 
hyperimmune plasma (ANTI-LPS) at different times as set out below; 
GROUP A (n=5); This group received a dose ANTI-LPS s.c. during the 
pre-occlusion acclimatisation period. 
GROUP B (n=5); In this group the dogs received their ANTI-LPS during the 
three-hour occlusion period incorporating it into the i.v. Ringer's 
drip. 
"Liquamycin", Pfizer Labs., Pietermaritzburg, Rep.So.Afr. 
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GROUP C (n=5); In these dogs, ANTI-LPS was administered s.c. within 3 
minutes after the release of the occluded CMA. 
Each dog in each of group A, B, and C, received a total dose of 1 ml/kg 
ANTI-LPS equivalent to 1200 ug/ml of LPS precipitable IgG. 
5.3.9. RECOVERY EVALUATION 
Subjects that were alive 14 days after the release of the cranial 
mesenteric arterial occlusion (CMAO) were considered recovered. 
5.4. METHOD OF CANINE PARVOVIRUS DISEASE CLINICAL STUDY 
As previously stated, CPV patients were randomly allocated to a control 
and an experimental group. Individuals in both of these groups received 
the same conventional treatment as set out below. 
5.4.1. CONVENTIONAL THERAPY 
CPV is a virus disease of dogs and, as such, no specific virocidal 
chemotherapeutic agent is available to combat this disease. Treatment of 
these patients is based on the severity of day to day symptoms and all 
therapeutic regimens are therefore symptomatic. In this study patients 
received the following daily therapy based on presenting symptoms and 
the veterinarian's discretion. Dosages and frequency of administration 
of the different drugs varied according to the severity of prevailing 
symptoms, the progress of each patient, and the manufacturers' 
instructions. 
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5.4.1.1. CONTROL GROUP This group received; 
1. Anti-emetics and anti-spasmodics; "Maxolon" (metoclopramide mono-
hydrochloride, Beechams), "Valoid" (cyclizine lactate, Coopers). 
2. Anti-diarrhoea mixtures; "Kantrexil" (kanamycin, Bristol). 
3. Appropriate cardiovascular therapy when necessary which included; 
"Frecardyl" (heptaminol and dihydroxyphenyl theophyllin, Panvet). 
4. Prednisolone sodium succinate; "Solu-Delta-Cortef", Upjohn. 
5. Broad spectrum antimicrobial agents, including; "Clamoxyl" 
(amoxycillin, Beechams), "Genta-50" (gentamicin, Phenix), "Synulox" 
(amoxycillin with clavulanic acid, Beechams). 
o. A non-narcotic analgesic with anti-inflammatory and anti-
prostaglandin activity; "Finadyne" (flunixin meglumine, Schering). 
7. Electrolyte and nutritional supportive therapy consisting of; 
Ringer's lactate, dextrose saline, "Haemo-15" (multivitamins, 
Sterivet), "Tioctan" (thioctic acid, Panvet), "Catasol" (metabolic 
stimulant with vitamins, Bayer). 
5.4.2.2. EXPERIMENTAL GROUPS These three groups of dogs received the 
same conventional therapy as set out for the control group. However, 
these dogs also received two dosages of equine ANTI-LPS either 
subcutaneously or mixed with their intravenous fluid therapy. The 
calculated dosage of ANTI-LPS (0,5 ml/kg body mass) was always 
administered at the same time as the initial conventional therapy. The 
second dose was always administered 24 hours after the first. 
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5.4.3. RECOVERY EVALUATION 
CPV patients were considered recovered when they had not vomited for a 
consecutive 24 hour period after they had voluntarily eaten or had taken 
fluids. At this stage their stools were porridge-like and they were then 
discharged from the hospital. Futhermore, none of the dogs in either the 
control or experimentally treated groups were re-admitted for the same 
problem. 
5.5. STATISTICS 
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6.1. DEMOGRAPHIC DATA 
6.1.1. SEX SELECTION 
The medical hospitalisation records of all patients (n = 1405) which 
were admitted to and hospitalised at the private veterinary hospital 
were examined for their recorded sex. During the period 01/01/1983 to 
31/12/1983, 612 patients were admitted for treatment and for the 
corresponding period during 1984 a total of 793 patients were attended 
to. There were 815 (58%) male dogs, 590 (42%) females. 
The practising South African veterinarian is requested to perform 
sterilizing operations on dogs. In the case of males, a bilateral 
orchidectomy is performed whilst bitches receive a panhysterectomy, with 
or without an ovarian autograph. Sex records at this hospital were 
subdivided as shown in table 3. 
TABLE 3: THE RECORD OF STERILIZED CANINE PATIENTS 
Total number of male dogs 815 
Number of entire male dogs 704 (36.4%) 
Number of orchidectomised dogs 111 (13.6%) 
Entire to sterilized males P^0,0001 
Total number of female dogs 590 
Number of entire female dogs 48 (3.1%) 
Number of panhysterectomised dogs 542 (91.9%) 
Entire to sterilized females P\0,0Q01 
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These statistics show that in this practice, more entire male and 
sterilized female dogs were hospitalised than their individual 
corresponding sex type. Because of the predominances seen at this 
private veterinary hospital, only donated, healthy, entire males or 
healthy, panhysterectomised females were used as subjects in this study. 
6.1.2. WEIGHT SELECTION 
The body weight of e\/ery hospitalized patient was not recorded However, 
the following facts do show significance: 
Total number of dogs admitted for hospitalisation 1405 
Total number of patient's weights recorded 934 
Group 1,total number of patients weights 15Kg 193 (21.2%) 
Group 2,total number of patients weights 15Kg to 35Kg - 535 (58.0%) 
Group 3,total number of patients weights 35Kg 101 (10.81%) 
* X2 (1 - 2) = 413,75; P<0,0001 
+ X2 (2 - 3) = 539,74; P<0,0001 
As a result of these findings, only donated, healthy dogs, that were 
either entire males or panhysterectomised females, and which weighed 
between 15 and 35 Kg were admitted to this study. 
0.1.'. AGE SELECTION 
Patients ages ranged from birth date to 21 years of age. However, ages 
were not substantiated by birth certificates and frequently only an 
approximate age was recorded. Table 4 below shows the number of 
patients in different age groups where the age of the dog was recorded 
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by a single figure. 
TABLE 4: RECORDED AGE GROUPS OF HOSPITALIZED PATIENTS 
Age (years) Number Percentage 
1 — 38 5,0 
2 44 7,0 
3 - 47 7,5 
4 46 7,3 
5 49 7,3 
6 — 45 7,2 
7 — 37 - 5,9 
8 47 7,1 
9 - 52 8,3 
10 44 7,0 
11 33 6,0 
12 - 41 5,5 
13 35 5,5 
14 33 — 5,3 
15 — 17 - 2,7 
15 15 2,4 
Vascular ischaemic conditions were recorded as early as day old 
(congenital diaphragmatic hernia with herniation of the abdominal organs 
into the thoracic cavity) to 21 years ( splenic haernangioma witn splenic 
torsion and rupture). In this study no selection was made with regards 
to the age of the healthy donated subject. 
5.2. CRANIAL MESENTERIC ARTERIAL OCCLUSION SHOCK MODEL RESULTS 
6.2.1. ANTE-MORTAL OBSERVATIONS 
5.2.1.1. CONTROL GROUP The description set out below refers to the 
control dogs collectively. Slight variations would naturally have 
occurred as the subjects were alive and biological, and natural 
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differences would have existed. These slight variations are not 
mentioned, but where obvious variations occurred, these are noted. 
Each dog was considered recovered from the operation and general 
anaesthetic when it could stand and balance unassisted. This occurred 
between 1 to 1 1/2 hours after the release of the occluded CMA. At this 
stage each dog was in a separate kennel where it remained subdued and 
lethargic for up to 3 hours. Dogs no. 2 and 3 drank small quantities of 
water but no control dog attempted to eat during this 3-hour period. 
Rectal temperatures were recorded and averaged 40 C (range= 39,6 C to 
40,2°C; normal = 38,4°C ) as each dog was returned to its kennel. At 6 
hours post-CMAO release (post-CMAO-r) all these dogs were exhibiting 
subnormal rectal temperatures with a mean of 37,0 C and a range of 
36,3°C to 37,4 C. Palpation of the abdominal cavity was accompanied by a 
tensing of the abdominal musculature. A sterile abdominal paracentesis 
was performed and a watery, bloody-coloured fluid was withdrawn. All 
visible mucous membranes were congested and slightly cyanotic. 
Oscultation of the thoracic cavity revealed a tachycardia and normal 
lung sounds. One dog (no.3) had urinated a small quantity of yellow 
urine. 
During the third to fifth hour post-CMAO-r each dog showed varying 
degrees of diarrhoea. The faeces were large in quantity, had an 
offensive smell, were watery to porridge-like in consistency and 
appeared to be arising mainly from the small intestine because of the 
lack of mucus with the faeces and the absence of straining when they 
voided the diarrhoea. At first the faeces were normal in colour but they 
then changed to a dark purple-red colour. Dogs 3, 4, and 5 began passing 
page 103 
a bloody-coloured, watery fluid shortly before each of them succumbed. 
The first control dog died at 6h30min, and the last one succumbed at 
15h05min post-CMAO-r. Just prior to the eventual death of each dog, 
rectal temperatures remained subnormal (mean=37,2°C). Bloody-watery 
faeces and abdominal discomfort were noted and their visible mucous 
membranes had become exceptionally congested and cyanosed. Two dogs 
(no.2 and 4) vomited an offensive smelling, almost black, tar-like 
vomitus about one hour prior to their individual deaths. 
Each dog exhibited an increasing tachycardia and one dog (no.2) 
developed a heart murmur. Lung sounds remained fairly normal although 
each dog showed an increase in its respiratory rate. Post mortem 
examinations were performed on the abdominal and thoracic cavities of 
these control dogs. 
5.2.1.2. EXPERIMENTAL GROUPS Although the experimental group of dogs 
were divided into three groups (see page 98), their symptomatology and 
recovery followed similar patterns, except that dog number 16 died. This 
dog will be dealt with separately (see page 110). When each dog 
recovered from the anaesthetic and operation it remained quiet and 
lethargic for up to 6 hours post-CMAO-r. Twelve of the fifteen dogs 
drank water within 5 hours of being returned to their kennel (dogs 10, 
11 and 16 did not drink water). Their rectal temperatures were subnormal 
upon recovery from the anaesthetic, but gradually rose to become normal. 
At 20 hours post-CMAO-r all the dogs, except number 6, exhibited normal 
rectal temperatures and continued to do so for the next 14 days. Dog 6 
had a rectal temperature of 40 C at 20 hours post-CMAO-r which returned 
to normal 10 hours later. 
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These dogs also exhibited an initial abdominal tension and discomfort 
similar to that described in the control dogs but at 20 hours post-CMAO-
r each dog allowed its abdomen to be palpated without showing 
discomfort. Initially, a sterile paracentesis of tiie abdominal cavity 
revealed the same type of bloody-coloured fluid as that seen in the 
controls. This bloody-coloured fluid was still evident at 20 hours post-
CMAO-r but had cleared 72 hours later. The following subjective 
observations were also noted; 
a. Mucous membranes of the buccal cavity and eye were initially cyanotic 
and congested as was observed in the controls. However, by 20 hours 
post-CciAO-r the mucous membranes of the experimental dogs had returned 
to a normal colour and remained normal for the next 14 days. 
b. Urine. Up to 20 hours post-G1A0-r all the dogs of these groups had 
passed only yery small quantities of urine infrequently. During the next 
24 hours the frequency of urination and the quantity of urine returned 
to normal in all dogs and they were drinking normally. 
c. Appetite. Only one dog (no.7) ate food during the first 12 hours 
after the release of the occluded CHA. After this period, eyery dog in 
the experimental groups ate food, and normal appetites were maintained 
during the next two weeks. Two dogs, 5 and 20, vomited during the first 
5 hours post-Ci'iAO-r which was of the same nature as that seen in the 
control dogs. Only one dog in t.iis group (no. 16) vomited after this 
time had lapsed. 
d. Diarrhoea exhibited by the controls was also present in all 
experimental dogs. However, by 20 hours post-CMAO-r all but dog number 
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12, were voiding melanic, foetid, porridge-like faeces. At this stage 
dog number 12 still showed watery, slightly bloody faeces. During the 
next 24-hour period the faeces of all the dogs of this group returned to 
normal. 
e. Heart and lungs. Tachycardia and increased respiratory rate as seen 
in the control group were also a feature of all of the dogs in this 
group. As with the control group the lung sounds remained normal. When 
these parameters were examined at 20 hours post-CMAO-r they had returned 
to normal pre-operative baseline values in e\/ery dog in this group. 
6.2.1.3. DOG NUVIBER 16 This dog stopped eating approximately 48 hours 
post-CMAO-r. A clinical examination was undertaken and a differential 
diagnosis of either acute pancreatitis or acute peritonitis or both, was 
•k 
made. Symptomatic pain relieving drugs were administered but no 
specific diagnostic treatment was instigated. The dog died the following 
day and a post mortem examination of the abdominal cavity revealed an 
acute pancreatitis. Streptococcal bacteria were isolated from the 
pancreas and it was thought that the bacteria most probably were 
introduced at the time of the experimental operation by either the 
surgeon or his assistant. 
it 
1."Pethidine", Centaur Lab., Johannesburg, Rep.So.Afr. 
2."Buscopan", Boehr. Inge! Janssen. Johannesburg, Rep.So.Afr. 
3."Isaverin", Bayer, Isando, Rep.So.Afr. 
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o.2.2. POST MORTEM EXAMINATIONS 
Post mortems were performed within one hour of the death of each of the 
control individuals and the experimental dog no. 16. It must be 
emphasised that only the abdominal and thoracic cavities were examined 
in an attempt to establish a diagnosis of fatal endotoxaemia. Except for 
minor macroscopic variations, all these dogs exhibited the same post 
mortal changes. Dog number 15 has already been described and the 
description that follows concerns the dead control dogs only. 
6.2.2.1. ABDOMINAL CAVITY 
a. General signs of hyperaemia, vascular congestion and cyanosis of all 
abdominal organs and parietal pleura was yery evident. These changes 
were noticed by the increased filling of vascular networks with a deep 
red to almost purple-coloured blood. The intestinal regions supplied by 
the CMA were the most severely affected organs. The area where the 
"Vesseloop" was placed around the CMA did not show any evidence of a 
thrombosis nor were thrombo-emboli detected in any of the blood vessels 
leading to or coming from the small intestine or first third of the 
colon. 
Ascites was a positive feature in all the post mortems. On average some 
500 ml (range = 375 to 900 ml) of a watery, bloody-coloured fluid 
containing red clots, was present. 
Haemorrhages were present throughout the cavity, which ranged from small 
petechial areas to frank extravasations. 
b. Individual organs such as the intestines were flaccid and the 
contents consisted of a foul-smelling, watery, oloody fluid. 
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Hepatomegaly was marked, and the livers were deep port wine in colour 
and \/ery friable. Vascular and bile stasis was evident as seen by the 
slow escape of these fluids from the cut surfaces. Each gall bladder 
was \/ery distended and contained a thick, dark olive-green bile. 
The spleens were friable, and slightly shrunken with sharp edges. Each 
spleen was paler than normal in colour and the pulp was not prominent. 
The kidneys were enlarged with the cortex and medulla well-demarcated. 
Urinary bladders contained a small quantity (average = 2 ml, range 0,5 
to 5,0 ml) of concentrated urine, and the bladder walls were of normal 
thickness. 
The pancreas glands were involved with the general signs of hyperaernia 
and congestion. Two dogs (1 and 5) had evidence of pancreatitis in that 
the surrounding tissues were showing evidence of autodigestion. 
The adrenal glands were enlarged and exhibited haemorrhagic necrosis of 
the medulla. 
6.2.2.2. THE THORACIC CAVITY 
Each heart had a flaccid musculature which showed extensive petechial 
haemorrhages. In one dog (no. 2), a hydropericardium of 30 ml of a 
bloody-coloured fluid was present. 
The lungs were all slightly oedematous and when cut into, a small 
quantity of a bloody-coloured froth exuded from the cut surfaces. 
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6.2.3. MORTALITY AND RECOVERY RESULTS 
6.2.3.1. CONTROL GROUP All (5/5) the control dogs died within the 
first 24 hours after the CMAO had been released. 
6.2.3.2. EXPERIMENTAL GROUPS One dog (no.16) died 72 hours after the 
release of the CMAO. The remaining 14 dogs recovered and remained alive 
for the next fourteen days. 
Table 5 (page 114) records the results of the control and experimental 
groups. 
5.3. CANINE PARVOVIRUS DISEASE CLINICAL STUDY RESULTS 
5.3.1. DURING ALLOCATION PERIOD 
During the period when patients were randomly allocated to either of the 
control or experimental group, it became apparent that the the ANTI-LPS 
treated group were experiencing a better survival rate than the 
controls. At this stage a total of 72 CPV patients had been entered into 
the study, 35 in each of the two groups. In the control group the 
mortality was 56,5% (24 dogs) whilst that of the experimental group was 
only 19,4% (7 dogs; p<r0,02). 
5.3.2. AFTER THE ALLOCATION PERIOD 
The ANTI-LPS treated dogs showed a significant reduction in their 
overall mortality rate, and therefore the random allocation into the two 
groups ceased, for ethical reasons. All further admitted cases were 
allocated only into the experimental group and were given ANTI-LPS with 
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GSD = German Shepherd 
xGSD = crossbred GSD 
Dobe = Doberman 
Mix = mixed breed 
Lab = Labrador 
xLao 
Mast = Bull Mastiff 
xCol = crossored Collie 
Box = Boxer 
xBox = crossbred Boxer 
Rott = Rottweiller 
crossbred Lao 
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their conventional therapy as has already been described. During this 
stage of the study, a total of 53 patients was allocated to this ANTI-
LPS group. Of the 53 dogs admitted to this second part of the study, the 
mortality rate was 15% (8 dogs), which was an improvement on the first 
results obtained during the allocation period. 
6.3.3. OVERALL RESULTS 
A total of 125 CPV patients was admitted to this study. The control 
group receiving conventional therapy experienced an overall mortality 
rate of 66,5% (24/36). Those patients that received equine ANTI-LPS in 
addition to conventional therapy had a substantially elevated survival 
rate of 83,1% (74/89; P<0,001). 
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7.1. DISCUSSION 
The potential for developing an endotoxaemia is always present in the 
22 23 249 canine gut, ' ' (endogenous source) and in its total environment 
(exogenous source). LPS is known to be a potent, chemically stable 
toxin, consisting of three biochemically active components, which form 
an integral part of the outer cellular membrane of GNB. ' ' The LPS 
components, which possess immunogenic activity in a host, remain 
harmless to a host until released from dying and dead GNB, and it 
becomes intravascular.0 ' 
Non-specific defence barriers include intact skin and mucous membranes, 
and the intact mucosal linings of the respiratory, urogenital and 
gastro-enteric systems. These are the host's initial defences against 
the invasion of either or both exogenous and endogenous LPS, with or 
without their parent bacteria. An extremely wide diversification of 
aetiology, both septic and non-septic, are capable of producing the 
necessary pathological changes which can damage and disrupt these 
natural defences. Once this undesirable phenomenon has occurred and LPS 
becomes intravascular, various life-threatening pathophysiological 
processes are set in motion. These morbid effects are instigated either 
by the damaged cells themselves, or by LPS, or by the combined effects 
5 6 
of both. ' Besides being a cause of early cellular death, LPS can 
itself initiate the activation of different defence cascades which are 
themselves capable of adding to the already developed pathological 
5,5 processes. ' 
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Damaged cells release vasoactive chemicals and neuro-endocrine 
substances into the vascular circulation where they are capable of 
producing both cellular and systemic pathological disarray. ' In this 
manner more host cells are irreparably damaged, thus adding to the 
pathology of the patient. The continuation of this chain of events are 
capable of producing the necessary changes seen in the shocked patient. 
A patient is diagnosed as being in shock when serious, potentially 
fatal, decompensatory, reductions to the micro-vascular circulation have 
already occurred by the cycle described above. It is now recognised that 
a patient in shock has an extremely high potential of becoming endotoxic 
if the diagnosed shock is not immediately reversed, irrespective of 
whether the original onslaught had a septic or non-septic origin. 
Decreased oxygen supply to cells will adversely affect mitochondrial 
energy-linked membrane transport systems. In addition, decreased 
nutritional delivery to, and waste metabolite removal from these oxygen-
deprived cells, adds to the intracellular pathological processes. If the 
75 hypoxic state persists then premature death of cells will occur. When 
this happens, organ failure may take place which can result in either a 
protracted recovery or death of the patient. 
As a compensatory mechanism to this shock-induced ischaemia, it would 
appear that the intestinal region is among the first to be affected by 
-?r T O O 
the reduced micro-vascular perfusion. ' Thus, cellular functions of 
the more vital areas (brain, heart and skeletal muscles), are maintained 
during the early stages of a shock episode. Intestinal mucosal cells, 
however, experience premature death during the same shock onslaught. 
During this ischaemic period vital oxygen-reliant intestinal mucosal 
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defences, which act against endogenous LPS and GNB, are damaged. As a 
result of the breakdown of these defences, intestinal LPS, with or 
without GNB, enter the host's hepatic-portal vascular network. These 
intravascular LPS molecules can either be rendered harmless by both the 
host's macrophage-pnagocyte system and naturally-occurring specific 
77 97 immunoglobulins, or it will continue to circulate in the plasma. ' 
The persistence of circulating plasma LPS will depend upon the host's 
concentration of circulating plasma HDL and the total efficiency of the 
99 
immune mediated defence processes. If these vital fighting mechanisms 
are malfunctioning or if they have been overwhelmed, then LPS is capable 
of circulating for up to two weeks, and will still maintain its 
131 
destructive nature on host cells. At the end of two weeks, LPS has 
lost its immunogenicity but no reports mention if its toxicity has 
59 125 
either decreased or has been lost altogether. ' If the host has not 
succumbed to the effects of LPS, then LPS will eventually be excreted 
59 99 
via the bile into the faeces. ' Therefore, a therapeutic regimen that 
incorporates a specific anti-LPS substance should be of benefit to these 
patients. 
Antimicrobial chemotherapeutic agents can destroy GNB, but they do not 
133 reduce the toxicity of LPS. Research has shown that certain broad 
spectrum antibiotics, either by themselves or in combination with 
certain corticosteroids, do not improve survival rates when given to 
dogs that have received a severe experimentally-induced endotoxin 
231 shock. Furthermore, antibiotics are known to produce an increase in 
the concentration of circulating plasma LPS of up to 2000 times that 
82 
present prior to these agents being administered. Worse, alarm is 
spreading due to the fact that more and more GNB are becoming resistant 
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234 to the widely used antimicrobial agents. Therefore, in addition to 
conventional antimicrobial chemotherapeutics, it would appear that a 
specific anti-endotoxin treatment is indicated in all developing and 
developed shocked states. 
LPS is known to instigate a potentially fatal chain of events through 
5 6 
chemical mediation once it enters the plasma. ' To be able to 
recognise shock and to successfully treat the endotoxaemia would be an 
achievement for all veterinarians. Our ultimate goal must be to diagnose 
the shock, and hence endotoxaemia, as it develops, and then to 
neutralize the effects of and destroy the circulating plasma LPS. In 
order to achieve this we must appreciate the fact that an endotoxaemia 
occurs with many and varied septic and non-septic conditions. 
In addition, a normal healthy individual could have low concentrations 
of circulating plasma LPS. ' This normal concentration, due to as 
yet unknown factors, but which do not appear to have harmful effects in 
113 a host, has been determined in 50 healthy dogs. Therefore, we are 
now in a position to recognise canine shock (endotoxaemia) in its 
developmental stages. 
Specific anti-LPS antibodies have been harvested from human blood and 
these antibodies protected cats from the effects of an experimentally-
242 
induced endotoxaemia resulting from hremorrhagic shock. Other 
researchers have reported similar results when they used a specific 
anti-LPS against a known specific L ps.
2 3 3 > 2 3 9 ' 2 4 3 > 2 4 7 > 2 5 7 Later, Gaffin 
and co-workers developed a polyvalent equine anti-LPS (ANTI-LPS) which 
successfully reduced the endotoxaemia produced by diversified 
aetiology."I34 
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E.coli septic abortion in experimental animals was reduced when they 
were given ANTI-LPS. Whole body ionizing radiation is known to 
produce an endotoxaemia in animals and when ANTI-LPS was administered to 
259 these experimental animals, increased survival resulted. 
Experimental rabbits which received a dose of ANTI-LPS prior to a one-
hour occlusion of their CMA, had significantly greater survival than 
controls. Experimentally-induced acute hypoxia in primates was 
37 
reported to be followed by an increase in circulating plasma LPS. 
This increase was prevented when the primates were pre-treated with 
ANTI-LPS. 
In yet another project, anaesthetised cats were subjected to a one-hour 
?38 
occlusion of their CMA. During the occlusion period there was a rise 
in circulating plasma LPS concentration, which increased even further 
after this vessel was released. Shortly thereafter, the concentration 
of LPS dropped. In some cats a second and significantly higher increase 
in plasma LPS occurred, and all these cats died. This work indicated 
that a "biphasic pattern" of increased LPS concentration occurred in 
cats following CMAO. In the same experiment, a group of cats were pre-
treated with ANTI-LPS before CMAO-induced shock. This group of 
experimentally-treated cats showed no rise in their plasma LPS 
concentration during both the occlusion period and the post-occlusion 
phase. It was stated that the ANTI-LPS completely prevented the 
increase in LPS concentrations that was observed in the control group. 
Endotoxin shock has high mortality rates and prolonged morbidity periods 
5 
among survivors. A recent survey conducted over a 10-year period from 
January 1974 reported an overall mortality rate of 71% in canine 
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patients who developed post-surgical septicaemia. In this survey GNB 
made up 50% of all culture isolates and a further 20% were due to a 
mixture of gram positive and GNB. E.coli was the primary organism 
involved and accounted for 38% of all the septicaernic patients. 
Intestinal surgery was responsible for 34% of all these post-surgical 
septicaernic patients and furthermore, in 49% of cases, the source of 
infection originated from the gastrointestinal tract. 45% of the 
patients received antibiotic and steroid therapy prior to or during 
surgery, and yet this high mortality rate was still experienced. 
Peritonitis often accompanies abdominal vascular ischaemic conditions. 
Although an animal may die from a chemical peritonitis without a 
Dacterial component, the most rapidly developing and dangerous form of 
peritonitis involves bacteria, the most common being E.coli. ° This is 
most probably when an adynamic, dilated, irritated and ischaemic 
intestinal tract loses its ability to retain endogenous bacteria and LPS 
within its lumen. 
There are few conditions, other than trauma, which are as acutely 
devastating to the canine patient as the gastric-dilatation-
volvulus/splenic-torsion complex. This condition will produce both 
partial and complete occlusion of intestinal vasculature. These patients 
always represent high-risk, surgical emergencies and regardless of the 
successful outcome of the surgical procedure performed, a high mortality 
rate can be expected due to the severe nature of the disease process and 
associated surgical stress. °' ° The veterinarian's surgical correction 
may well be adequate in these patients but the medical supportive 
therapy is lacking in its entirety. Endotoxin shock is the recorded 
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aetiology of death in these cases. 
Research work has shown that when an occluded intestinal vascular 
network is released in experimental dogs then these dogs die sooner than 
those who did not have the occlusion released. Furthermore, it has 
been demonstrated that circulating plasma LPS concentrations increase 
substantially after the occluded CMA was released. At the same time, 
there is also a significant rise in the concentration of harmful super-
oxides after restoration of the poorly perfused intestinal 
147 148 
vasculature. ' These super-radicals and LPS molecules are now known 
to add to the pathological processes of the patient in shock. 
The observations of many veterinarians coincide with my own experiences 
in canine practice, with regard to the time of death in intestinal 
ischaemic patients. Most cases died after successful surgical 
intervention with what was thought to be adequate supportive medical 
treatment. The experimental and clinical findings of these patients, 
with regard to their time of death, support each other. 
Wisleading information may be extrapolated from the results obtained in 
55 one species, when this data is applied to a different species. Hence, 
it is more reliable to record the findings from one species and then to 
apply this knowledge to the same species. In my research I was 
attempting to find out if ANTI-LPS could be beneficial in the canine 
endotoxin shock case. I therefore chose the canine as my experimental 
subject. 
It has also been noted that differences within a species exists from 
individual to individual. Rats from two different laboratories behaved 
differently after they had been subjected to the same endotoxin shock 
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onslaught. It was thought tnat variations in their respective diets 
and environments could explain these discrepancies. Riser has recorded 
major differences in canine zootechnology, with special reference to 
body mass. In my canine experimental subjects, variables were reduced 
by the standardisation of sex and weight selection (page 104). 
Furthermore, environmental and dietary factors were partly eliminated by 
the choice of the same diet and kenneling for all the subjects, both 
pre- and post experimentally (page 89). The result of my 
standardisation is further supported by the few differences that existed 
in the ante- and post mortal findings in the CMAO shock subjects (page 
106). 
Researchers recorded that the administration of live GNB organisms, 
ratner than LPS, appeared to produce the more relevent clinical 
19 
characteristics of a patient in endotoxin shock. This was thought to 
be due to the slow release of LPS from the administered GNB. These facts 
would hold some truth if one is simulating an exogenous GNB infection 
which is capable of producing endotoxin shock. Ongoing research has 
demonstrated that the experimental administration of live GNB into a 
64 canine will allow endogenous LPS to become intravascular. Other 
researchers have demonstrated that endotoxin shock can occur in the 
absence of a bacteraemia. ' 
It has been demonstrated that although both GNB and LPS have detrimental 
20 21 
effects in a host, their individual actions can be different. ' Since 
I was simulating the non-septic clinical endotoxin shock patient where I 
was to evaluate a specific therapy, I chose to utilize the host's 
endogenous LPS in order to eliminate other possible influences by 
administered GNB. 
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The occlusion of the CMA has been documented to produce reliable 
72 73 77 
clinical characteristics of endotoxin shock, ' ' and this model does 
simulate the diagnosis of many similar canine problems. Traumatic injury 
to sofc tissue will allow the release of vaso-active and neuro-endocrine 
chemicals, which are known to produce intestinal mucosal damage. This in 
turn will allow intestinal LPS to "leak" into the micro-vascular 
circulation thus adding to the pathology. Therefore, the operative 
procedure to occlude, and then release the occluded CMA, must be 
performed with the minimal amount of soft tissue damage in order to 
simulate the clinical case more realistically. 
Previous researchers have used varying techniques to occlude the CMA 
which necessitated either keeping the abdominal cavity open during the 
occlusion period or re-opening the cavity so that the CMA could be 
released. In my surgical technique I made use of a specialised vascular 
clamp (page 94) which enabled me to enter the abdominal cavity once 
only. This minimized handling of soft tissues, thereby decreasing the 
effects of surgical trauma. Therefore, in my surgical technique I 
believe that I did not exacerbate the pathophysiological processes which 
were responsible for the "manufactured" endotoxin shock, thus further 
simulating the clinical entity. 
In rny experimental CMAO study, five dogs acted as control subjects and 
all died within 17 hours after the release of their occluded CMA, death 
being due to endotoxin shock. Fifteen experimentally-treated dogs were 
divided into three groups of five, depending on when they received a 
dose of ANTI-LPS. Group I dogs received their ANTI-LPS just prior to 
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the beginning of the occlusion period, and 100% survived for 14 days 
after the occluded CHA was released. Group II dogs received their dose 
of ANTI-LPS during the occlusion period, and a survival rate of 80% was 
obtained. The non-surviving subject died as a result of the gram-
positive pancreatitis introduced at the time of surgery. Group III dogs 
received their ANTI-LPS dosage within three minutes of the release of 
the CMAG, and 100% survived for a further 14 days. 
The post mortem examinations performed on the non-survival (controls) 
subjects exhibited the general signs consistent with recorded endotoxin 
shock death (page 111). Both the control and experimental groups 
received supportive i.v. fluid, and a single antibiotic injection 
following the experimental procedure. As described above, the 
experimental groups also received a dose of ANTI-LPS. This was the only 
difference in the treatment received by the subjects in this 
experimental study. Therefore, the ANTI-LPS plasma most probably made 
the significant difference (p<fo,Q01) recorded between the survival of 
the experimental subjects and the non-survival of the control group. 
Corticosteroid (CTS) administration in experimentally-induced endotoxin 
shock subjects has received considerable attention amongst researchers 
(page 60). The addition of CTS therapy appears to have achieved, on 
average, the highest recorded survival rates when used in experimental 
endotoxin shock models. Some important deductions that can be made from 
this CTS-endotoxin shock research are: 
1. CTS therapy could not improve survival numbers if canine endotoxin 
shock had persisted for more than 45 minutes, 
2. for CTS to be effective it must be administered i.v., '° ' 
3. pharmacological doses are more effective than physiological doses if 
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administered early during the shock episode, 
4. that CTS, in either pharmacological or physiological doses, could not 
219 improve survival in a LD-,Q0 canine endotoxin shock model, 
5. the i.v. administration of CTS has shown to have detrimental effects 
when utilized in the late stages of experimentally-induced endotoxin 
shock.225 
The canine endotoxin shock model utilized in this study produced a LD-,QQ 
in the control subjects. Yet, when ANTI-LPS was administered to the 
individuals in the experimental groups, either, early (before CMAO was 
performed), during the occlusion period, or late (three hours after the 
induction of endotoxin shock), an overall survival rate of 93,3% (14/15) 
was recorded. This immunotherapy contains naturally occuring IgG's and 
therefore has neither a pharmacological or physiological dose. Also, 
this high survival index was recorded after the administration of ANTI-
LPS by both the i.v. and s.c. routes. The ANTI-LPS was easy to 
administer and it mixed with the i.v. fluid without any detectable 
reaction. Furthermore, no side effects were noted in any of the subjects 
that received the ANTI-LPS (n=104). These results indicate a definite 
improvement on other recorded experimental treatments for an LO-JQQ 
endotoxin shock. 
CPV is a recently described disease of the canine having been recognised 
52-55 only since 1979. It occurs both endemically and epidemically in 
South Africa and many other countries. This virus is thought to be a 
mutation of the virus producing feline panleukopenia and is known to 
produce an endotoxaemia with ^ery high mortality rates world-wide. CPV 
appears to be particularly fatal in young and \iery old dogs, most 
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probably due in part to the immune suppression that accompanies this 
disease. Host CPV fatalities are recorded as being the result of acute 
endotoxin shocK. 
for the clinical study of this research I used naturally infected CPV 
cases that were brought to my veterinary practice. Initially, I randomly 
placed dogs into one of two groups. Both groups received the same 
conventional therapy but only one group received additional treatment 
with ANTI-LPS (page 99). After 72 CPV patients had been treated, the 
results were analysed and it was found that the survival rate of those 
dogs which received ANTI-LPS was significantly greater than those which 
did not get ANTI-LPS (17% vs 57%). At this stage the random selection 
of CPV patients ceased, for ethical reasons, and every patient received 
the ANTI-LPS in addition to their conventional medical support. Survival 
in chis group of dogs (n = 53) was 66%, which supported the findings of 
the original 72 randomly selected cases. The overall survival rate of 
the group that received ANTI-LPS (n = 89) was finally recorded at 83%. 
This significant increase in survival rate can be attributed to the 
addition of ANTI-LPS to the total treatment regimen that was used in 
this clinical study (p ̂ 0,001). 
Researchers are now aole to produce endotoxin shock in many different 
species, and in many and varied ways. Numerous different aspects of 
endotoxin shock have been studied, but we have been a long way f-om 
recognising endotoxin shock in its developmental stages, in the natural 
case, and even more so, from preventing the many paths of destruction 
produced by LPS. Circulating plasma LPS can be detected by using a 
37 reliable method, but even so, normal values have not been recorded for 
all species. Without a normal baseline value, it is almost impossible to 
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recognise an abnormal value. Japanese workers were able to detect 
circulating plasma LPS concentrations in various blood vessels and they 
then attempted to classify endotoxaeinia on these findings. These 
researchers did not establish a normal value in their work and therefore 
the values that they did record could have been normal. 
During the course of my experimental work we established the normal 
113 value for circulating plasma LPS in healthy dogs. Knowing this normal 
value enabled us to recognise a developing endotoxaeinia and instigate a 
anti-LPS specific therapy early in the course of the naturally 
developing endotoxin shock. Furthermore, we were successful in this 
treatment, and were able to eliminate the higher than normal 
113 concentration of circulating plasma LPS. 
In the CPV clinical study it is thought that the main reasons for the 
significantly higher survival in the ANTI-LPS-treated group of dogs as 
compared to those that did not receive this ANTI-LPS was: 
1. a specific, broad-spectrum anti-LPS therapy was used to eliminate the 
greater than normal concentration of circulating plasma LPS, 
2. this specific therapy was administered during the developing 
endotoxin shock stages. 
7.2. CONCLUSIONS 
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A. EXPERIMENTAL STUDY: A LD-jQ0 CHAO-induced endotoxin shock model was 
utilized. The control group which did not receive equine ANTI-LPS had a 
mortality rate of 100%. Three experimentally-treated groups received 
this ANTI-LPS and 80% of these canines survived for a minimum of 2 weeks 
after receiving their dose of ANTI-LPS. Therefore, the significant 
survival rate (pvD,001) in the experimentally-treated groups can be 
attributed to the administration of equine hyperimmune anti-LPS plasma. 
8. CLINICAL STUDY: The addition of equine ANTI-LPS to the conventional 
therapeutic regimen for CPV patients produced a significant survival 
rate during the allocation period (p^0,02) and an even more significant 
survival rate over the entire study period (p<0,001). 
From both the experimental and clinical study the following 
recommendations are made: 
1. A polyvalent, equine ANTI-LPS hyperimmune plasma should be used in 
preference to either a monovalent or bivalent ANTI-LPS plasma. 
2. This equine ANTI-LPS should be incorporated into the surgical and 
medical management of the clinical conditions which are known to 
produce either a partial or complete occlusion of the intestinal 
vasculature. 
3. This ANTI-LPS should be preferably administered prior to or during 
the surgical correction of the underlying anatomical abnormality 
tnat is producing the partial or complete obstruction. 
4. ANTI-LPS immunotherapy should be incorporated into the medical 
management of canine enteric disorders, other than CPV, which are 
capable of damaging the intestinal mucosa. 
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Equine ANTI-LPS can be given with safety to a canine patient because 
no side effects were recorded in any (n=104) of the dogs that 
received this ANTI-LPS. 
Any canine patient that is either developing or has developed shock 
from any aetiological agent, should be treated, in part, and as 
early as possible, with this ANTI-LPS hyperimmune plasma. 
Either the s.c. or i.v. routes should be followed and either one, or 
at the most two, injections of ANTI-LPS need to be administered. 
The use of this equine ANTI-LPS plasma in the therapeutic regimen of 
endotoxin-producing problems in species other than the equine and 
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The morbidity and mortality associated with canine parvovirus disease 
(CPV) is caused, in part, by endotoxin (LPS). Equine anti-endotoxin 
hyperimmune plasma (Anti-LPS) was administered to 39 CPV patients in 
addition to conventional therapy. In Anti-LPS treated CPV patients 
mortality was lower (16.8 per cent, 15/39) than in controls who received 
conventional therapy alone (66.7 per cent, 24/36, p ̂ 0.0005). The 
hospitalization period of survivors was reduced from 3.5 — 4.0 days 
(controls) to 5.2- 2.0 days (Anti-LPS treated group). These results 
suggest that an anti-endotoxin specific therapy should be incorporated 
into the treatment regimen of CPV, and possibly, other canine enteric 
disorders, known to produce endotoxaemia. 
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INTRODUCTION 
Endotoxins (1ipopolysaccharides, LPS) are contained in the outer 
cellular membrane of gram negative bacteria, the latter of which are 
always present in the intestines of dogs (Goldstein, 1974). During an 
episode of canine parvovirus (CPV), the intestinal defense mechanism is 
extensively damaged which allows gram negative bacteria and LPS to enter 
into the general circulation. This produces mortality and morbidity as 
a result of the combined effects of the viraemia, the gram negative 
bacteraemia, and endotoxaemia. Any circulating plasma LPS can remain 
toxic to host cells for as long as 2 weeks after the gram negative 
bacteria which produced them, have been destroyed by host immune systems 
or by chemotherapy (Freudenberg e_t. al., 1985). This endotoxaemia 
itself, is thought to be a major cause of death in gram negative 
bacteraemia (Zinner & McCabe, 1976). Furthermore, in many cases such 
LPS alone may be absorbed from the intestinal tract (Papa £t. aj_., 1933; 
Bertok, 1983). 
Treatment regimes for CPV have been directed towards the symptomatic 
relief of the potentially fatal consequences of vomiting, diarrhoea and 
dehydration (Krakowka e_t _al_., 1982). An LPS-directed therapy would 
appear, in principle, to be of benefit to CPV patients. This study 
investigated whether such an approach could reduce the mortality rate 
and morbidity period associated with clinically presented CPV cases. 
The results showed that a polyvalent, equine anti-endotoxin hyperimmune 
plasma was a successful adjuvant to the total therapy for CPV patients. 
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MATERIALS AND METHODS 
A. ENTRY INTO THE STUDY: 
Patients that were exhibiting seven out of eight of the following signs 
were admitted to this study: 
1. A susceptible (non-vaccinated) individual, 
2. Acute onset of vomiting, and vomiting after food or liquids had 
been taken, 
3. Acute onset of a watery, foetid, grey to haemorrhagic diarrhoea, 
4. Rapid onset of depression, 
5. Rapid onset of dehydration, 
6. Initial pyrexia or subnormal rectal temperature, 
7. Slight cyanosis and marked congestion of the visible mucous 
membranes, with an increased capillary refill time, 
3. A leukopenia. 
Initially, patients admitted to this study had their CPV diagnosis 
confirmed by demonstrating the virus in faecal samples by electron 
microscopy (Veterinary Research Institute, Onderstepoort, Pretoria). In 
addition, patients in both groups that died were autopsied and 
histopathological specimens were examined and the diagnosis again 
confirmed by a specialist veterinary pathologist (Botha, Pretoria). 
After ten of ten dogs had been correctly diagnosed, the faecal and 
histopathological examinations were terminated. 
CPV patients were diagnosed at a veterinary hospital where no selection 
was made with regard to breed, age, sex or body mass. Initially, 
selected dogs were placed alternately into the control or experimental 
group. After a total of 72 cases had entered this study, a 
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significantly increased survival rate and decreased morbidity period 
the Anti-LPS treated group was observed, and the alternate selection 
abandoned. Subsequently, all diagnosed CPV patients were allocated 
the experimental group. 
B. THERAPY 
Control Group. This group received: 
1. Anti-emetics and anti-spasmodics; 'Maxolon" (Metoclopramide 
monohydrochloride, Beechams}; "Valoid" (Cyclizine lactate, 
Coopers). 
2. Anti-diarrhoea mixtures; "KantrexiV (Kanamycin, Bristol1). 
3. Appropriate cardiovascular therapy when necessary; "Frecardyl" 
(Heptaminol and dihydroxyphenyl theophyllin, Panvet). 
4. Prednisolone sodium succinate; "Solu-Delta-Cortef", 
(Upjohn). 30 mg/kg, i.v. as a single injection. 
5. Broad spectrum antimicrobial agents; "Clamoxyl" (Amoxycillin, 
Beechams), "Gen:a-50". (Gentamycin, Phenix), 'Synulox" 
(Amoxycillin with clavulanic acid, Beechams). 
6. A non-narcotic analgesic with anti-inflammatory and anti-
prostaglandin activity; "Finadyne" (flunixin meglumine, 
Schering). 
7. Electrolyte (Ringer's lactate, dextrose saline), nutritional and 
vitamin ("Haemo-15" (Sterivet), "Tioctan" (Panvet), "Catasol" 
(Bayer)), supportive therapy. 
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Dosages and frequency of administration varied according to the severity 
of clinical symptoms,the progress of each patient, and manufacturers' 
instructions. 
Experimental Group. In addition to that treatment which was given to the 
control dogs, this group received two dosages (0.5 ml/kg each) of 
polyvalent, equine anti-endotoxin hyperimmune plasma (Anti-LPS). The 
first injection was given eiiher subcutaneously, undiluted, or 
intravenously diluted with approximately 300 ml electrolyte fluid 
depending upon the severity of the patient's condition when admitted. 
In all the subjects of this group, the second injection was administered 
subcutaneously, 24 hours after the first. 
C. CRITERIA FOR RECOVERY: 
Patiencs were considered recovered when their diarrhoea was reduced to a 
porridge-like stool, chey had taken fluids and food per os and had not 
vomited for a continuous 24 hour period, and they were discharged from 
hospi tal. 
D. AiiTI-ENDOTQXIN HYPERIMMUNE PLASMA (ANTI-LPS) : * 
Healthy horses were suitably immunized with an appropriate proprietary 
vaccine and their plasma was collected under sterile conditions by 
plasmapheresis. The final plasma product contained 1500>ug/ml of LPS-
precipitable IgG antibodies. 
* "DETOXIN" Liga Pharmaceutical Co., Vienna, Austria). 
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These antibodies could bind to LPS prepared from Shigella flexneri, five 
scrams of E. coli, five species of Salmonella, plus Klebsiel la spp., 
Proteus spp., and Pseudomonas spp. (Wells et. aj_. 1986. Submitted). 
This plasma was bottled under a laminar flow hood and stored at -20 C 
until used. The experimentally treated group then received 0.5 ml/kg 
body weight per injection either i.v. or s.c. as described. 
F. STATISTICAL ANALYSES 
The Fisher exact probability test was used to examine significant 
differences in survival rates of the two groups of CPV patients. 
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RESULTS 
After examining the results of 36 patients in each group, those dogs 
which had received Anti-LPS showed a significantly reduced mortality 
compared to those which received only conventional therapy (7/36 vs 
24/36, p^0,02). At this stage of the field trial selection into the 
control group ceased. The results for the entire study are recorded in 
Table 1. Mortality in the group which received Anti-LPS continued to 
be less than those that did not receive Anti-LPS. furthermore, Anti-LPS 
reduced the mean hospitalization (morbidity period) of survivors from 
3.5±4.0 days to 5,2-2.0 days (p<J).05). 
ty 
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LPS present in the outer cellular membranes of normal gram negative 
bacterial gut flora are harmless to the host if they remain within the 
gut lumen. Biologically, LPS is a chemically stable, potent, bacterial 
toxin, whose biological structure and role in sepsis have been described 
(Spink e_t _a_L, 1943; Rietschel et al_., 1982). When LPS enters into the 
circulation of normal individuals, the liver detoxifies and/or 
opsonizes these pathogens, in part, utilizing specific antibodies and 
the macrophage-phagocyte system (Jacob e£ a_h, 1977; Zanotti & Gaffin, 
1935). 
C?V produces massive and rapid destruction of intestinal villi which 
allows virus, gram negative bacteria and their LPS to gain entry into 
the hosts's general circulation (Appel, Scott & Carmichael, 1979; Hayes, 
Russell & Baibur, 1979; Nelson, Eustis & McAdaragh, 1979; Carpenter et 
al., 1930; Evermann et al., 1930; ,'iulvey erz_ a_h, 1930; Janssen et al., 
1S32). Because of the rapid entry of these pathogens, the liver's 
iriinunological defenses become depleted and a viraemia, gram-negative 
bacteraemia and endotoxaemia result. Their combined effects produce the 
symptomatology of CPY. 
To date, no specific anti-endotoxin therapy for the CPV patient has been 
documented. A recent report has shown that in gram negative 
bacteraemia, circulating plasma LPS concentrations can increase 2000 
fold after conventional antibiotic therapy destroyed the parent 
bacteria, thus permitting oound LPS to ''slough off" into the blood. 
There they renain in circulation producing a toxic effect on hosts' 
cells iSheneb & Morgan, 1934;. An anti-LPS specific therapy would appear 
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to be an advancement towards the treatment of a CPV patient. 
Human Anti-LPS was successful in the management of septic shock in 
humans (Lachman, Pitsoe & Gaffin, 1934) as well as in protecting cats 
against endotoxin shock induced by haemorrhage (Gaffin et a!., 1981). 
Similarly, equine Anti-LPS was therapeutic in the management of gastro-
enteritis and endotoxaemia in equines (Gaffin e_t_ aj_* > 1933) and reduced 
mortality as a result of endotoxic shock following cranial mesenteric 
arterial occlusion in dogs (Wessels, Gaffin & Brock-Utne, 1935) and 
rabbits (Zanotti & Gaffin, 1935). Current information shows that Anti-
LPS preparations function by three mechanisms: toxin neutralization, 
opsonization and complement mediated destruction of gram negative 
bacteria (Gaffin, Badsha & Vorster, 1935; Pudifin £t_. £l_. 1935; Wells 
et. al, 1936. Submitted). 
The results of this clinical trial show a reduction in hospitalization 
and mortality rate in Anti-LPS treated patients. It must be noted that 
wnen the Anti-LPS was administered intravenously, it was always diluted 
in several volumes of electrolyte solution and given slowly. On the 
other hand, subcutaneous injections were given at full strength. The 
same total dosage of 0.5 ml/kg (750yug/kg of LPS specific IgG) was 
utilized for both routes. No side effects were observed in any patient 
that received one or more injections of the Anti-LPS. This was in 
agreement with our previous clinical experience with the Anti-LPS. 
However, only three patients have received Anti-LPS again on a second 
occasion, more than 5 months from the time of original therapy, and all 
without side effects. Furthermore, it was observed that when a highly 
moribund animal received Anti-LPS by the intravenous route, recovery in 
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clinical signs was faster than by the subcutaneous route. 
It should be noted that this was not a double blind study and therefore 
open to subjective bias. However, similar results were obtained from 
participating veterinary surgeons in their own, unrelated, private 
practices. 
Recently, this Anti-LPS preparation was shown to be the most effective 
antibody preparation to treat a lethal model of abdominal sepsis 
(Shennib e_t aj_., 1935). When used in combination with antibiotics, 
Anti-LPS provided even longer survival. In summary, we conclude that the 
polyvalent, equine anti-endotoxin hyperimmune plasma can be of benefit 
when treating the clinical CPV patient and probably would advantageously 
affect the clinical course of many LPS mediated disorders. 
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MORTALITY RATES DURING THE ENTIRE STUDY PERIOD 
(n = 125) 
NUMBER DEATHS MORTALITY 
CONTROL DOGS 36 24 66.7% 
ANTI-LPS TREATED DOGS 8S 15 16.8% 
(p =<C 0,0005) 
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Circulating plasma endotoxin (LPS, lipopolysaccharide) concentrations 
were determined in fifty healthy dogs (25 of each sex) by means of the 
chromogenic substrate modification of the Limulus amoebocyte lysate 
assay. The mean value in 50 dogs was 0.053 - 0.004 ng/ml. In contrast, 
two groups of canine patients with hemorrhagic enteritis (Group 1, n = 
15; Group 2, n = 20) had significantly elevated plasma LPS 
concentrations upon admission (Group 1 = 0.216 - 0.024 ng/ml; . Group 2 = 
0.368-0.082 ng/ml; p ̂ 0.001). Both groups of hemorrhagic enteric 
dogs received conventional enteric therapy after being admitted to 
hospital. In addition, Group 2 dogs received a subcutaneous dose of 0.5 
ml/kg of polyvalent equine anti-endotoxin hyperimmune plasma (Anti-LPS) 
on admission, whilst Group 1 dogs received the same dosage of Anti-LPS 
24 hours after being admitted. Anti-LPS treatment significantly reduced 
the endotoxemia in both groups of hemorrhagic enteric patients. 
Circulating plasma LPS concentrations in Group 2 dogs declined rapidly 
to normal levels (0.058 ng/ml, p^O.001) after 24 hours. Group 1 dogs 
exhibited only a small reduction in plasma LPS concentrations after 24 
hours (0.179 ng/ml, p^0.05) following conventional therapy. When this 
group received Anti-LPS their plasma LPS concentrations were reduced to 
normal values 24 hours later (0.049 -0.006 ng/ml). 
An earlier and more accurate diagnosis of canine endotoxemia can be nade 
now that normal values of circulating plasma LPS concentrations have 
been established. Furthermore, this endotoxemia was rapidly reversed by 
using a commercial polyvalent equine Anti-LPS hyperimmune plasma. 
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INTRODUCTION 
Gram-negative bacteria and, hence, their endotoxins (lipopoly-
saccharides, LPS, pyrogens) are normally present in the intestines of 
healthy dogs . A wide variety of diseases and physical onslaughts can 
damage the intestinal defenses leading to a gram-negative bacteremia and 
endotoxemia " ' . Conventional antimicrobial chemotherapy may kill 
the parent gram-negative bacteria but these agents have no detrimental 
effect on LPS . Moreover, a rapid destruction of the parent bacteria, 
such as, by certain antibiotics, can cause a 2000 fold increase in 
plasma LPS concentrations . 
Endotoxemia is invariably diagnosed from the patient's history and 
symptomatology. Despite the advances made in diagnostic and treatment 
7-12 
regimens, the mortality rate of endotoxemia still remains high . The 
veterinarian would advance in scientific knowledge if the endotoxemia 
was accurately diagnosed, confirmed and successfully treated as it was 
developing. 
Confirmation of the diagnosed canine endotoxic patient can now be made 
by measuring the concentration of circulating plasma LPS. Recently an 
accurate, reliable and replicable test to determine plasma LPS was 
13 18 
reported ' This chromogenic substrate modification of the Limulus 
amoebocyte lysate assay can be performed in most properly equipped 
laboratories by competent technicians. With this test, it should be 
possible to make an earlier and more accurate diagnosis. However, in 
order to evaluate the clinical significance of any particular LPS 
concentration determined, a knowledge of the normal range of 
concentrations of circulating plasma LPS in healthy dogs must be 
established. To our knowledge such data has not been recorded in a 
Page 4 
canine population. • 
If a patient's plasma LPS concentration is recognized to be elevated, 
then an earlier treatment could lead to a reduction in mortality rates 
and morbidity periods, especially if the recently reported anti-LPS 
hyperimmune equine plasma (Anti-LPS) is incorporated into the total 
14-1 7 
treatment regimen . Anti-LPS contains specific IgG's which bind to 
the circulating LPS in vivo ' , opsonize it, and at the same time can 
rapidly destroy a wide range of circulating gram-negative bacteria by 
19 means of complement activation . 
In this study we determined the circulating plasma LPS concentrations in 
the blood of 50 healthy dogs (25 of each sex). We compared these 
baseline values with the plasma LPS concentrations of hemorrhagic 
enteric patients and the efficacy of Anti-LPS treatment was evaluated. 
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MATERIALS AND METHODS 
The Subjects For Normal Determinations 
Dogs were taken by their owners to a veterinary hospital for primary 
vaccination or routine annual revaccination. Each dog was subjected to 
a routine physical examination and if found to be clinically normal and 
healthy, a blood sample was withdrawn prior to vaccination. The 
appropriate vaccines were then administered according to manufacturer's 
directions for use. Owners were contacted by telephone two weeks later 
and if they reported any unusual behavioural pattern, (e.g., vomiting, 
diarrhea, "skipped" meal) then the dog was eliminated from this survey. 
A selection of an equal number of males and females was made, (total 
number = 25 of each sex) without regard to age, breed or weight. 
The Blood Samples: 
Sterile procedures were strictly adhered to for blood collections in 
both healthy and sick dogs. Only sterile, pyrogen-free, equipment was 
utilized. 
The anterior, mid-radial, aspect of the right foreleg was clipped and 
sterilized with alcohol and povidone-iodine. A 3 ml disposable syringe 
was "wet" internally with a 5000 i.u./ml solution of heparin. Using 
this syringe, a 2 ml blood sample was withdrawn from the cephalic vein 
and immediately placed into a disposable plastic test tube which was 
centrifuged in a clinical centrifuge for 10 mins. This plasma was 
tranferred to another labelled test tube and then stored in the freezer 
compartment of a household refrigerator (approx. - H ° C ) . The time 
interval from withdrawal to being placed in the freezer was ne^er longer 
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than 20 minutes.- These samples were later delivered, in their frozen 
state, to a laboratory in the University of Natal Medical School, 
Physiology Department, where all LPS determinations were made by the 
same technician. 
Endotoxin Determinations 
The chromogenic substrate modification of the Limulus amebocyte lysate 
13 18 
(LAL) test, as previously described ' , was performed on each sample. 
Hemorrhagic Enteric Patients 
Thirty-five unselected, consecutive canine patients routinely admitted 
to a veterinary hospital, with the following signs were included in this 
study: 
a) Vomit or diarrhea or both, noticed by owner during 48 hour period 
prior to admission. 
b) No food taken during 24 hours prior to admission. 
c) Lethargy, 
d) Congested mucous membranes with increased capillary refill time and 
showing slight to moderate cyanosis. 
e) Slightly tense to tense abdomen, when palpated. 
f) Tachycardia. 
g) Presence of melana or blood on a rectal thermometer at initial 
examination. Rectal temperature not critical, although 33 of 35 
patients exhibited either a subnormal (n=ll) or above normal 
temperature. 
These admitted patients were randomly split into two groups which 
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received the following therapy: 
Group 1 (n = 15) received conventional enteric treatment upon admission 
which included gentamycin, prednisolone and routine supportive 
intravenous fluid treatment, as determined by the attending 
veterinarian. Twenty four hours after admission these patients then" 
received Anti-LPS (0.5 ml/kg,s.c.). Group 2 (n = 20) received similar 
enteric therapy but they also received, on admission Anti-LPS as above, 
with their conventional therapy. 
Blood samples for LPS determinations, were taken from both groups on 
admission and prior to any treatnent, and daily thereafter. 
Anti-endotoxin Hyperimmune Plasma. 
Polyvalent equine hyperimmune plasma was obtained by the plasmapheresis 
of suitably immunized healthy equines, and contained 1200/ug/ml of anti-
LPS precipitable IgG ("ATOXIN", ATOX Pharmaceutical Co. 14 Old Main 
Road, Gillitts 3500, South Africa). These specific antibodies were 
previously found to bind to LPS obtained from a wide range of gram-
negative bacteria, to opsonize the bacteria by polymorphonuclear 
20 
leukocytes , and by complement activation, destroy a wide range of 
19 
gram- negative bacteria within seconds to minutes . Furthermore, it 
reduced elevated plasma LPS levels within 5 - 1 0 minutes of i.v. 
administration in cats . 
STATISTICS 
Statistical analyses were carried out using the student "t" test or 
paired ":" test. 
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RESULTS 
Table 1 shows that, while there was a small difference in the mean 
concentrations of circulating plasma LPS, between healthy male and 
female dogs, this difference was not statistically significant (p^O.l). 
Therefore, all results were pooled to record a normal value for the 
concentration of circulating plasma LPS in dogs, of 0.053 - 0.004 ng/ml 
with a range of 0.000 to 0.101 ng/ml. 
Hemorrhagic enteritis in canines, irrespective of etiology, produced a 
significant elevation in the concentration of circulating plasma LPS 
(Group 1 dogs = 0.216 -0.024 ng/ml; Group 2 dogs = 0.368 - 0.082 
ng/ml; p ̂ 0.001) as shown in Figure 1. In Group 1 dogs, routine 
therapy alone slightly reduced the concentration of circulating plasma 
LPS (0.216 to 0.179 ng/ml, p^D.05). However, these LPS concentrations 
were still significantly higher than normal baseline values (p^O.OOl). 
When Anti-LPS was administered) to this group, the plasma LPS 
concentration returned to normal values of 0.049 -0.006 ng/ml, twenty 
four hours later. In Group 2 dogs, the plasma LPS concentration returned 
to normal values (0.058 ng/ml) twenty four hours after receiving Anti-
LPS therapy in conjunction with conventional therapy. 
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Discussion 
Until recently, the value of the conventional LAL gel test was treated 
with scepticism because of an insensitivity of the original qualitative 
21 
gelation test and false positive results . The recently reported 
chromogenic substrate modification of the LAL test,however, is both 
13 17 
reliable and replicable ' 
No significant difference in plasma LPS concentrations in the 50 healthy 
dogs was observed when analyzed by age, mass and sex groups. We 
therefore conclude that our findings should be considered the normal 
value for circulating plasma LPS concentrations in a healthy canine 
population. This value is 0.053 ng/ml, with a range of 0 to 0.10 ng/ml. 
Any value above 0.10 ng/ml should be regarded as abnormally high. 
It has been demonstrated that a single injection of 0.5 ng/kg LPS 
produces granulocytosis of 200-300% within 4 hours, without other 
22 
reactions in heaUhy adult human volunteers . A slightly higher dose of 
22 
0.8 ng/kg LPS can be pyrogenic while 3.0 ng/ml LPS appeared to cause 
death in shocked cats . It is generally accepted that LPS is 
responsible for most of the mortality and morbidity associated with 
23 
gram- negative bacteraemia . 
Normal canine gut flora consists of large amounts of gram-negative 
bacteria and hence endotoxins (LPS) which form an intergral part of the 
0 A 
outer cellular membrane of these bacteria . Circulating LPS is 
extremely toxic to host cells, it is both chemical and heat-stable, and 
its toxicity is not reduced by conventional chemotherapeutic 
c a o A 
agents ' ' . Provided that LPS remains in the intestinal lumen, no 
25 
life-threatening effects have been reported . The intact intestinal 
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wall acts as the primary defence mechanism which appears to be highly 
1 7 26 
dependent upon an adequate oxygenated blood supply ' 
Small amounts of gram-negative bacteria "leak" by unknown mechanisms, 
into the portal system, which are then transported to the liver. In the 
liver, these bacteria are rendered harmless, in part by specific 
c 27 
antibodies and the macrophage-phagocyte system ' . In the systemic 
circulation some gram-negative bacteria may be destroyed by host defence 
28 
mechanisms with the release of free LPS . This LPS may then be bound 
and neutralized by specific Anti-LPS antibodies if these antibodies are 
present in sufficient concentration^*. If this neutralization action is 
functioning weakly, then LPS may exert its toxic effects causing 
depression, fever, and anorexia for up to 2 weeks before it is excreted, 
30 
mainly in the feces . 
Rising concentrations of LPS above those normally present in circulating 
plasma may indicate that a clinically significant endotoxemia is 
developing. It is doubtful that a developing endotoxemia could be 
accurately diagnosed, on clinical grounds alone. If treatment was 
initiated at this early stage, in particular by incorporating Anti-LPS, 
then the often fatal consequences of an endotoxemia may well be reduced 
14-1 7 
or eliminated altogether 
Four dogs were eliminated from the study group of healthy dogs because 
they developed qastroenteritis or depression 1-2 days after vaccination. 
Although they appeared normal at the time of vaccination, all four had 
significantly elevated plasma LPS concentrations (mean = 0.300 ng/ml) 
compared to healthy dogs. While these numbers are small, it does suggest 
that it should be possible to detect developing endotoxemia by measuring 
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the circulating plasma LPS.concentration. 
Hemorrhagic enteritis" is a symptomatic disease of canines with many and 
varied etiology. Whatever the cause of hemorrhagic enteritis, an 
endotoxemia may develop because of the breakdown of the host's 
intestinal defence mechanisms. In clinical practice, priority must be 
given to saving a patient's life, without the absolute necessity of 
obtaining an etiological agent. In this series of hemorrhagic enteric 
canines the etiological agent was unconfirmed in most cases, yet all of 
the patients survived. 
We consider the normal plasma LPS concentration in healthy canines to be 
established for our laboratory and that hemorrhagic enteritis patients 
have elevated LPS concentrations which are easily recognizable. 
Futhermore, these elevated plasma LPS concentrations can be effectively 
reduced by using polyvalent equine Anti-LPS plasma. Patients with rising 
plasma LPS concentrations can now be recognised earlier and LPS specific 
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Table 1. CIRCULATING PLASMA LPS CONCENTRATION IN 
HEALTHY DOGS. 
Mean LPS 
cone. S.D. Range 
Number ng/ml. ng/ml. ng/ml. 
Males 25 0.046 0.025 0.000 - 0.097 
Females 25 0.060* 0.029 0.000 - 0.101 
Combined 50 0.053 0.029 0.000 - 0.101 
Males to females p 0.1 (not significant). 
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- LEGEND 
Figure 1. CIRCULATING PLASMA LPS CONCENTRATIONS IN DOGS 
Group 1. = Dogs which received Anti-LPS 48 hours after admission. 
Group 2. = Dogs which received Anti-LPS 24 hours after admission. 
Pre 1 and Pre = Sample taken on admission before any treatment 
was administered. 
i c c - jaii ipIS uan.cn £ t nuur S ar te f a u m i i i i u i i and uefu i e rtiunrj 
was administered. 
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Intestinal ischemia is known to produce endotoxemia. Twenty-two dogs 
were subjected to a cranial mesenteric arterial occlusion for three 
hours. Equine anti-endotoxin hyperimmune plasma (Anti-LPS) was 
administered to fifteen dogs. Fourteen of these fifteen Anti-LPS 
treated dogs recovered for a minimum period of tv/o weeks after the 
occlusion was released. Seven out of seven controls died within sixteen 
hours of the released occlusion. (p^p.001). Anti-LPS thus 
significantly reduced mortality in this experimental endotoxic shock 
model. This would indicate that Anti-LPS may be of considerable benefit 
in the therapy of other canine endotoxic mediated disorders. 
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INTRODUCTION 
Endotoxins (1 ipopolysaccharide, LPS, pyrogen) are highly toxic and 
extremely chemically stable breakdown products from the v/alls of gram 
negative bacteria ' . During bacteremia the concentration of LPS in 
plasma can increase during the active growth phase of bacterial 
(3) 
replication or after these bacteria are destroyed . Endotoxemia is 
now considered an important contributory factor towards the mortality 
and morbidity associated with septic and non-septic shock in man and 
animals . In man, the mortality associated with endotoxemia still 
remains at an unacceptable rate of 30-80% worldwide " . 
Antimicrobials have an important role in the therapy of gram negative 
. bacteremia but they do not decrease the potent toxic effects of the LPS. 
Thus, the LPS may persist in the circulation, producing toxic effects 
long after" the bacteria have been destroyed by antibiotics . A recent 
work iias shown that rapid destruction of E.coli by gentamycin may 
produce a 2000 fold increase in plasma LPS concentration . 
normally, large amounts of gram negative bacteria and, hence, LPS, are 
(12) 
present within the intestines of most animals . The intestinal wall 
acts as an effective barrier to prevent the entry of LPS into the blood 
circulation, but, in order to function as such, it requires an adequate 
oxygenated blood supply. Temporary occlusion of the cranial mesenteric 
artery in experimental animals is known to result in damage to the small 
intestinal mucosa, leading to endotoxemia, shock and death ' . 
Previous studies have shown that treatment with Anti-LPS hyperinmune 
equine plasma (Anti-LPS) can neutralize and opsonize LPS and lead to 
reduced mortalities in a variety of animal models exhibiting 
Page 3 
, ,. • (15-18) 
endotoxemia 
The object of this study was to evaluate the therapeutic value of Anti-
LPS in dogs when given prior to, during, and after a normally lethal 
three-hour cranial mesenteric artery occlusion insult. 
MATERIALS AND METHODS 
Twenty-two dogs were chosen as available. They were a mixture of males 
and panhysterectomized females, crossbreeds and pure breeds, ranging in 
age from one to ten years, from 15 to 35 kg mass. They were all 
clinically normal before the experiment and had been housed separately 
in the University's experimental animal colony for a minimum period of 
-two weeks prior to use in this study. All the dogs received the same 
* * 
diet of commercial dry cubes , canned meat and water ad lib. 
Anti-LP5 was obtained by suitably immunizing healthy horses" and 
collecting their plasma under sterile conditions by plasmapheresis. 
This plasna contained IgG antibodies capable of binding LPS prepared 
from a wide range of different gram negative bacteria, including E.coli, 
Salmonella spp., Proteus spp., Pseudomonas spp. and Klebsiella 
spp. ' . The concentration of LPS precipitable IgG in Anti-LPS was 
1500/<jg/m1. The plasma was bottled under sterile conditions and stored 
frozen at -20°C until used. 
"VITAGEIJ" and "CKOU" = Epol (Pty) Ltd., Johannesburg, South Africa. 
+ "ATOXii," ATOX Pharmaceutical Co., 14 Old Main Rd, Gillitts 3G00, 
South /.frica. 
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EXPERIMENTAL SURGERY The dogs were anesthetized with pentobarbital 
sodium (20 mg/kg: i.v.) An endotracheal tube was placed in position and 
the cuff inflated. The cephalic vein was catheterized to accept a drip 
administration set. Ventilation of the lungs was performed using a 
Starling pump with a tidal volume of 70 ml and at a rate of 12/nrin. A 
sterile, pyrogen free, catheter of appropriate size was inserted into 
each dog's bladder. The abdominal cavity was then entered through a 
linea alba incision using routine sterile surgical techniques. The 
cranial mesenteric artery was located, isolated and the loop of a 
Vesselclude (Neuromedics Inc., Texas) was loosely applied around this 
artery. The Vesselclude was exteriorized through a small lateral 
abdominal incision where preplaced sutures v/ere inserted for later 
closure. The. bladder was emptied jusT; before the cranial mesenteric 
ar,ery was occluded and this urine was discarded. During the occlusion 
period and up to the time the dogs were placed in recovery cages, the 
amount of urine produced was measured. This was done e^ery hour by 
applying a syringe to the end of'the catheter and draining the bladder. 
Following a short acclimatization period, the cranial mesenteric artery 
was occluded by pulling the handle of the Vesselclude which tightened 
the loop around it. Routine sterile surgical closure of the linea alba 
incision -./as performed. The lateral incision was kept moist and 
sterile. dinger's lactate was administered via the cephalic vein at a 
rate of approximately 45 drops/min. 
Three hours after the beginning of the occlusion period, the Vesselclude 
was released and withdrawn via the small lateral abdominal incision. 
The preplaced sutures were then knotted. At this stage all the dogs 
received an i.v. injection of tetracyline (20 mg/kg). The positive 
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pressure veniii lai-ion was gradually withdrawn until spontaneous 
respiration was adequate. Fluid therapy was discontinued and i.v. 
catheters were then removed. The dogs were transferred to a recovery 
kennel where they regained consciousness within 1 to 1-1/2 hours. 
CONTROL DOGS: 3even dogs constituted the control group and were not 
given Anti-LPS at any stage. However, their other treatments (surgical 
and medical) were identical to the treated dogs. 
TREATED DOGS: Fifteen dogs were divided into three groups, each of 
which received Anti-LPS (1.0 ml/kg) at different times. Group I 
received Anti-LPS subcutaneously within one minute of occlusion of the 
artery; Group II dogs were given Anti-LPS mixed with 350 ml Ringer's 
lactate solution during the three-hour occlusion period; Group III dogs 
were given Anti-LPS subcutaneously, within three minutes after release 
of the occlusion. - These treated dogs then received a 
subcutaneous injection of Anti-LPS (1.0 ml/kg) 24 hours post occlusion. 
STATISTICS: The Fisher exact probability test was used to examine 




Seven of seven (100%) control dogs died within 6 to 16 hours after the 
release of the cranial mesenteric artery occlusion. 
All these dogs exhibited hypothermia (35-38°C); extreme congestion of 
all mucous membranes with obvious cyanosis; passage of melenic stools 
giving way to frank blood within four to five hours and abdominal nuscle 
rigidity following palpation. Oliguria was evident (less than 1 ml of 
urine/kg/hour) and abdominal paracentesis revealed a bloody fluid. 
Postmortal examinations performed on the controls showed extreme 
hyperemia and cyanosis of the small intestine with obvious 
extravasation of the blood. Multiple pinpoint to large petechial 
hemorrhages were visible on the internal organs, including the heart. 
The lungs were edematous and ascites, averaging 500 ml of a bloody fluid 
was present in all controls. Their bladders contained on average, 2 ml 
of concentrated urine. In some controls gangrenous lesions were 
visible in parLs of the small intestine. In two dogs extreme 
hemorrhages of the pancreas were present with signs of autodigestion of 
the surrounding tissues. Hepatomegaly was obvious and the livers were 
friable. The kidneys were congested and swollen. In all seven 
controls, the adrenal cortexes showed hemorrhagic necrosis and mild to 
moderate splenomegally. N'o arterial thrombi were noted either at the 
occlusion site or at any other sites pertaining to the vascular system 
of the snail intestine. 
ANTI-LPS TREATED DOGS: 
As seen in Table 1, 5/5 each of group I and of group II survived and 4/5 
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of group III survived for more than 14 days. This one death occurred at 
72 hours after the release of the occlusion. On postmortem a 
streptococcal pancreatitis and peritonitis was evident. This infection 
may have been introduced at the time of surgery. 
All the dogs in the Anti-LPS treated group were eating and drinking 
normally at 24 hours post occlusion release, including the one which 
died. This latter dog stopped eating approximately 43 hours after the 
release of the occlusion, when the classical symptoms of acute 
pancreatitis commenced. No specific treatment was given for this 
pancreatitis. 
iio Anti-LPS treated dog was euthanased for postmortal examination as 
chey v/ere all clinically normal (except for the one above) two weeks 
after the release of the cranial mesenteric arterial occlusion. 
Hislopathology was not performed as the postmortem features of the 
control group were thought to comply with the findings of endotoxemia. 
In both control and Anti-LPS treated groups of dogs, the bladder output 
of urine showed a steady decrease during the occlusion period. After 
the occlusion was released, however, the bladder output almost ceased. 
Their catheters were removed when they were returned to their recovery 
kennel when measurements stopped. However, all Anti-LPS treated dogs 
were urinating normally 24 hours post occlusion release and continued to 
do so for the next two weeks. 
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DISCUSSION 
In veterinary practice a patient with intestinal vascular occlusion 
usually has a guarded prognosis despite the advances made in the 
surgical and medical approach to treatment . Research utilizing the 
cranial mesenteric arterial occlusion (CMAO) shock model has shown that 
death- occurs faster in those dogs that had the CMAO released than in 
(21) 
those in which this occlusion was not released . This is an 
important concept to remember when corrective surgery is to be performed 
on any patient with an abdominal vascular occlusion diagnosis. Recent 
evidence suggests that endotoxemia is a major cause of morbidity and 
mortality associated with gram negative bacteremia ' 
-The intestines of dogs always contain gram negative bacteria and hence 
(12) 
LPS in large amounts . Normally the intestinal defense mechanisms 
;iay allow snail amounts of these bacteria and LPS entry into the portal 
circulation. In the liver they are detoxified and opsonized by specific 
(13 23) 
antibodies and the monocyte-macrophage system ' . During septicemia 
the liver becomes overwhelmed and their bacteria and LPS enter the 
general circulation where they now exert their often fatal consequences. 
A variety of diseases and traumatic insults can produce endotoxemia 
which may then become part of the common pathway leading to shock and 
death. In this study the endotoxemia producing death of these dogs was 
brought on. by CMAO. Similarly, gastric dilation-volvulus with or 
without compromise of splenic vasculature, intestinal volvulus, 
diaphramatic hernia with hepatic, gastric, splenic or intestinal 
herniation into the thoracic cavity are all known to be associated with 
vascular occlusion or ischemia, high mortality and high morbidity rates. 
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."'.adioactively labelled LPS and viable grain negative bacteria placed in 
;he small intestine of dogs can be found in the systemic circulation 
within a few minutes of intestinal ischemia . Macroscopic lesions in 
the intestinal wall seen at postmortem have been well reported in both 
man and animals following intestinal ischemia ' . One would expect 
that the mucosal damage would be greatest during the ischemic period, 
but these and previous studies have shown that intestinal mucosal damage 
is greatest some time after reperfusion of the small intestine with 
'21 ) 
oxygenated bloodv . Other researchers have suggested that reperfusion 
wilh oxygenated blood leads to the formation of high levels of toxic 
tissue peroxides, which, in turn, form free radicals, thus damaging the 
intestinal barrier even more than that already caused by the 
(25) 
ischemia 
In earlier studies related to CMAO, pretreatment with antibiotics did 
(21) 
provide some protection . However, antimicrobial therapy should not 
be initiated in gram negative bacterial infections restricted to the 
intestines unless there is evidence for, or a grave likelihood of 
bacteremia, due to the development of increased bacterial resistance and 
adverse effects in specific organ systems ' . Antibiotics, except 
for polymyxin, do not alter the toxicity of the LPS and it has been 
shown that certain antibiotics are actually capable of producing a 2C00 
fold increase in the plasma LPS levels . The LPS can remain in 
circulation long after the bacteria that produced them have been 
destroyed. 
in principle, the host is capable of synthesizing specific antibodies 
against specific LPS. All too often, however, the patient dies before 
this immunological process is complete. Therefore a specific anti-
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endotoxin antibody-preparation would appear to be a logical therapeutic. 
i 
The Anti-LPS preparation used in this study contained IgGs which bind to 
LPS found in a wide range of gram negative bacteria. Some IgGs in 
Anti-LPS are highly cross reactive among various genera of bacteria; 
some are specific; some bind to the interior Lipid A region of the LPS 
while others bind to the outer "0" antigens on the LPS molecule. 
Furthermore, the presence of complement in plasma in addition to 
specific IgG, leads to the destruction of a wide variety of grain 
negative bacteria, including Klebsiella, Pseudomonas, E.coli and 
(23) 
Proteus, Salmonella, Shigella and Enterobacter . Thus Anti-LPS has 
a combined effect: it destroys gram negative bacteria and also 
' neutralizes the LPS released from these bacteria. 
LPS specific antibodies (Anti-LPS) were previously shown effective in 
reducing morbidity and mortality of LPS related disorders in 
(15) 
experimental animals and in clinical veterinary practice . This 
included septic abortion, peritonitis, Pseudomonas otitis externa, 
(29) 
septicemia and endotoxemia following canine parvovirus infection 
Anli-LPS appears to be a practical mixture for clinical and prophylactic 
use since it is broad spectrum in character, so that identification of 
Uie infecting bacteria or LPS is not necessary. 
In the studies reported here we found that Anti-LPS, irrespective of 
mode of administration and timing, reduced mortality in CMAO shock in 
dogs. This is in accordance with similar studies in rabbits using Anti-
LPS of equine origin, and endotoxic shock following prolonged hemorrhage 
in cats using human Anti-LPS . Hence Anti-LPS may be beneficially 
administered during intestinal vascular occlusion conditions or after 
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the surgical correction has been undertaken, an important consideration 
in clinical veterinary practice. Furthermore, Anti-LPS could be 
considered beneficial as a prophylaxis in animals undergoing abdominal 
surgery. Other studies in this laboratory showed that Anti-LPS 
administration could lower the concentration of plasma LPS to baseline 
(31) 
levels within five minutes in endotoxic cats . The possibility that 
Anti-LPS may reduce the morbidity and mortality following septic shock 
deserves further clinical assessment. 
Recently in an independent study this Anti-LPS successfully treated a 
lethal model of abdominal sepsis. It was found that Anti-LPS, in 
combination with selective antibiotic therapy, allowed further 
• -,(32-) 
prolongation or survival 
During the course of this and other studies, not a single side effect 
has been noted. However, time has not yet allowed for this Anti-LPS to 
be challenged after a long period has lapsed. The authors find that 
•.his Anli-LPS is safe and extremely beneficial in Lhe treatment of 
vascular ischemic endotoxic canine conditions. 
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A::TI-LPS TKEATIIENT OF DOGS IN CRANIAL 
TREATMENT" II 
CONTROLS 7 
Anf.i-LPS Group I 5 
Anti-LPS Group II 5 
Ani;i-LPS Group III 5 
TOTAL ANTI-LPS TREATED 15 
•• Group I received Anti-LPS s.c. 
Group II received Anti-LPS as a 
Group III received Anti-LPS s.c. 
+ Fisfier exac'. probability test. 
MESENTERIC ARTERY OCCLUSION SHOCK 
DEATHS DEATHS SIGNIFICANCE* 
U) 
7 100 
0 0 p 0,005 
0 0 p 0,005 
1 20 p 0,05 
1 6,7 p 0,001 
at initiation of ischei.iia 
3-hour drip during ischemic perioa 
after release of occlusion 
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